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Preface 
This thesis is presented as a ‘Research Paper Style Thesis’ in accordance with submission 
guidance provided by the London School of Hygiene and Tropical Medicine. Four of the 
chapters comprise papers that have been published or are prepared for submission to peer-
reviewed journals. These are highlighted in italics in the Table of Contents. In view of the 
differing requirements of the journals in which the work has been published there is by 
necessity some repetition of material and variation in the formatting of these chapters. 
Publication details and acknowledgement of co- author contributions are included on the 
individual cover sheets for each paper. The remainder of the thesis is comprised of ‘linking 
material’ and includes an introduction to the overall research project. 
 
All material within this thesis was written by Stephanie Migchelsen.
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Abstract 
Trachoma causes blindness as a result of repeated ocular infection with Chlamydia trachomatis (Ct). 
International efforts are focused on eliminating trachoma as a public health problem by 2020; the 
World Health Organisation’s (WHO) and the Global Alliance for the Elimination of Trachoma by 2020 
(GET2020) (1) recommend the SAFE strategy (Surgery to treat trichiasis, Antibiotics to treat infection 
with Ct, Facial cleanliness and Environmental change to reduce transmission) (2). Current 
implementation guidelines for the A, F and E aspects of the strategy are based on the prevalence of 
trachomatous inflammation-follicular (TF) in children aged 1-9 years. Antibiotics are administered as 
azithromycin mass drug administration (MDA) to all residents of districts wherein the prevalence of 
TF in 1-9 year old children is greater than 10% (3). 
As we approach the global elimination of trachoma, the prevalence of TF in children will decline 
towards the elimination threshold of 5%, and with it, the positive predictive value of TF. This may 
result in inappropriate, continued administration of antibiotics, which is a mis-use of valuable 
financial and person resources, as well as raising concerns about antimicrobial stewardship. 
Once the prevalence of TF in children aged 1-9 years is below 5%, re-emergence must be monitored. 
The WHO recommends a ‘pre-validation’ survey to determine if re-emergence has occurred (4). The 
2014 Technical Consultation on Trachoma Surveillance (4) recommended exploring the district-level 
prevalence of TF, the district-level prevalence of conjunctival infection with Ct and the district-level 
prevalence of antibodies against Ct, to determine an appropriate measure, or combination of 
measures, for deciding when to stop MDA.  
Numerous methods exist for detecting antibodies against Ct antigens (5–9). Specimens may be 
collected by venepuncture or from fingerprick, stored as whole blood, serum or dried blood spots on 
filter paper, and assayed using enzyme-linked immunosorbent assays (ELISA), lateral flow assays 
(LFA), or multiplex bead assay (MBA); of theses, MBA allows for the testing for antibodies against 
numerous antigens from endemic infections, but the required instrumentation and reagents are 
more cost-intensive. Historically, serology for Ct fell out of favour due to the high cross-reaction with 
antigens from C pneumoniae, however, with the advent of new proteomic tools and assays with 
greater reported sensitivity and specificity, serology has re-emerged as a potential tool for 
monitoring the prevalence of antibody-inducing chlamydial infection (4,10,11). 
Both ELISA and MBA assays present output as numerical data, which must be translated to a 
population seroprevalence value. Therefore, a method must be determined for dichotomising 
numerical data and setting a threshold between seropositive and seronegative samples. Receiver 
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Operating Characteristic (ROC) curves have previously been used, but these rely on appropriate 
reference standards. Alternate methods that rely solely on the data generated within a study, such 
as finite mixture modelling, may be more appropriate (12–15).  
Once seropositivity has been estimated, it is of interest to detect changes in the age-specific 
seroprevalence of a population. Catalytic models have previously been used to monitor changes in 
the prevalence of malaria (13,16–22) and this methodology can be applied to detect changes in 
transmission as a proxy for the force of infection (FOI) as well as to estimate seroconversion rates, 
and to a lesser extent, seroreversion rates (13,19).  
The simplicity of dichotomous seroprevalence estimates may provide lower resolution information 
than the quantitative antibody levels. Recent work uses quantitative antibody levels to measure 
changes in transmission (23). Ensemble machine learning can be used to produce characteristic age-
specific antibody curves that may reveal changes in population mean antibody levels that would 
otherwise be masked because changes occurred above or below the seropositivity threshold. 
There remain several areas to be elucidated. While antigens used in modern serological studies are 
considered specific for Ct, there is yet no way to distinguish between antibodies due to ocular 
infection or genital infection, making serological studies in anyone over the age of sexual debut a 
challenge. There is no standard reference for antibody levels, making a comparison between 
different studies challenging. The two most commonly used assays produce different output data: 
ELISAs measures optical density- the amount of light absorbed by the specimen- while MBAs detect 
fluorescence in an assayed specimen. An internal standard would allow for comparison between the 
two assays.  
This PhD research addresses several key questions about the use of serology and Ct-specific 
antibodies for monitoring the prevalence of trachoma. As more countries progress to eliminating 
trachoma as a public health problem by 2020, efforts will need to be increased to monitor and 
evaluate elimination efforts and to prevent re-emergence of the disease. Serological techniques may 
be ideal for such activities. 
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Glossary of abbreviations and terms 
95% CI 95% confidence interval 
active trachoma 
The condition of having either trachomatis inflammation- follicular 
(TF) and/or trachomatous inflammation- intense; see also ‘scarring 
trachoma’ 
alkalo Village chief in The Gambia 
aOR Adjusted odds ratio 
Catalytic model 
A means of modelling to describe mathematically the rate of change 
of a variable as a function of time. 
CDC Centers for Disease Control and Prevention 
CF complement fixation 
cHsp Chlamydial heat shock protein; see also ‘heat shock protein’ 
CO Corneal opacity; corneal scarring that blurs the pupil margin 
CoV  
Coefficient of variation; ratio of the standard deviation within a 
group of samples to the mean of the samples 
Cohen’s kappa A statistical measure of agreement between categorical items. 
Control 
Reduction of disease incidence, prevalence, morbidity, and/or 
mortality to a locally acceptable level as a result of deliberate 
efforts (WHO, 2015) 
Cp Chlamydia pneumoniae 
C. psittaci 
Species within the genus of Chlamydia, causes avian chlamydiosis 
and respiratory psittacosis in humans.  
CRD Clinical Research Department 
Ct Chlamydia trachomatis 
CT694 
Protein secreted by Ct involved in pathogenesis and the secretory 
process 
DBS Dried blood spot 
ddPCR droplet digital PCR 
DNA Deoxyribonucleic acid 
EA 
Enumeration area- census area, as defined by the Gambian 
government 
EB 
elementary body- nonreplicating infectious particles that are 
released when infected host cells rupture 
Elimination as a public 
health problem 
Achievement of measurable global targets set by WHO in relation to 
a specific disease; unless otherwise specified, in this work the term 
‘elimination’ refers to elimination as a public health problem 
Elimination of transmission 
Reduction to zero of the incidence of infection caused by a specific 
pathogen in a defined geographical area, with minimal risk of 
reintroduction, as a result of deliberate efforts (WHO, 2015) 
ELISA Enzyme-linked immunosorbent assay 
EM 
expectation-maximisation algorithm- iterative method to find 
maximum likelihood estimates of parameters in a statistical model 
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ESPEN 
Expanded Special Project for the Elimination of Neglected Tropical 
Diseases 
FoI 
Force of Infection; the rate at which susceptible individuals acquire 
an infectious disease 
FMM 
finite mixture model- probabilistic model for representing the 
presence of two or more subpopulations within the overall 
population 
GTMP Global Trachoma Mapping Project 
GUM Genito-urinary medicine; see also STI 
hotspot 
Defined as a community in a district with a prevalence of TF higher 
than 10% when all other surveyed communities are below 10%. 
Note that this is not an official WHO definition but has been used in 
a country-specific example in Lao PDR (Southisombath et al., 2016).  
HRP Horseradish peroxidase 
Hsp 
heat shock protein; protein produced by cells in response to 
stressful conditions 
hyperendemic 
A population in which the prevalence of active trachoma (TF and/or 
TI) in children aged 1–9 years old is >20%  (Wright & Taylor, 2005) 
hypoendemic 
A population in which the prevalence of active trachoma in children 
aged 1–9 years old is <10%  (Wright & Taylor, 2005) 
hysterosalpingogram radiologic procedure to investigate the fallopian tubes 
Ig Immunoglobulin; summarise types written about 
IIF indirect immunofluorescence 
ITD Infectious and Tropical Diseases 
ITI International Trachoma Initiative 
laparoscopy 
Keyhole surgery to examine and/or treat fallopian tubes, ovaries or 
uterus 
LFA lateral flow assay 
LGV lymphogranuloma venereum 
LRR Lower River Region 
LSHTM London School of Hygiene and Tropical Medicine 
MBA multiplex bead assay 
MDA mass drug administration of antibiotics 
Mesoendemic A population in which the prevalence of active trachoma 
MFI-bkgd 
Median fluorescent intensity minus background, unit of 
measurement for MBA results 
MIF micro-immunofluorescence 
MOMP 39 kilodalton immunodominant major outer membrane protein 
MRC Medical Research Council 
NAAT Nucleic acid amplification test 
NG Neisseria gonorrhoeae 
NTD neglected tropical disease 
ompA gene that encodes the major outer membrane protein (MOMP) 
OD450 Optical density of an ELISA measured at 450nm 
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OR Odds ratio 
ORF 
Open reading frame; part of an organism’s genetic code that can be 
translated to produce a protein 
PBS Phosphate-buffered saline 
PBSTw PBS with 0.3% v/v Tween 20 
PCR 
polymerase chain reaction; technique to make many copies of a 
specific DNA sequence 
PCT 
Preventive chemotherapy and transmission control focus on 
diseases for which a strategy exists as well as on tools and the 
availability of safe and effective drugs that make it feasible to 
implement large-scale preventive chemotherapy. 
peri-elimination 
A region or country in which trachoma is believed to have been 
eliminated as a public health problem but has not yet been 
validated. It is expected that the prevalence of TF in children aged 
1-9 years would be less than 5%.  
perihepatitis 
Inflammation of the coating of the liver, often caused by 
inflammation of the upper genital tract in women, commonly 
known as pelvic inflammatory disease (PID) 
PID Pelvic inflammatory disease 
Pgp3 plasmid gene product 3 
PPV positive predictive value 
R0 
basic reproduction number; the average number of infections that 
occur from an index case in a fully susceptible population 
RCM Reverse catalytic model 
ROC curve 
Receiver Operating Characteristic curve; a graphical plot to illustrate 
the diagnostic ability of a dichotomous classification system as its 
threshold is varied. 
SAFE surgery, antibiotics, facial cleanliness, environmental improvements 
scarring trachoma 
The condition of having scarring in the tarsal conjunctiva (TS) and/or 
trachomatous trichiasis (TT) and/or corneal opacity (CO) as a result 
of ocular infection with Ct; see also ‘active trachoma’ 
SCR 
seroconversion rate (λ); the yearly average rate by which 
seronegative (never infected) individuals become exposed to a 
disease and produce antibodies against that specific disease 
SD 
standard deviation; a measure to quantify the amount of variation 
within a set of values 
seroconversion 
The process by which specific antibody develops and becomes 
detectable in the blood by a serological assay; antibody levels fall 
above a threshold for positivity 
seroreversion 
The point at which antibody is produced at insignificant amounts 
and is too low to be detected; antibody levels fall below a threshold 
for positivity 
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serovar 
A distinct variation of subspecies within Ct classified based on cell 
surface antigens allowing for epidemiological classification. Ct 
serovars tend to show tropism for ocular or genital regions 
SRR 
seroreversion rate (δ); the annual mean rate by which seropositive 
individuals revert to a seronegative status in the absence of re-
infection 
STI sexually transmitted infection 
TF 
trachomatous inflammation–follicular; the presence of five or more 
follicles in the upper tarsal conjunctiva 
TFI tubal factor infertility 
TI 
trachomatous inflammation–intense; the pronounced inflammation 
and thickening of the upper tarsal conjunctiva to obscures the 
normal deep tarsal vessels 
TMB tetra-methylbenzidine 
TRA 
Trachoma rapid assessment-a rapid survey based on a convenience 
sample of communities where trachoma is likely to be present 
TS 
Trachomatous scarring; the presence of scarring in the tarsal 
conjunctiva 
TT 
Trachomatous trichiasis; at least one eyelash rubbing the surface of 
the eyeball 
TV Trichomonas vaginalis 
URR Upper River Region 
validation 
The process by which elimination of a disease as a public health 
problem is documented (WHO, 2015) 
VIP 
Visual Inflection Point-an estimation of the point of inflection of a 
curve based on visual, human examination 
WHO World Health Organization 
WIF whole cell inclusion immunofluorescence 
Youden’s J-index 
A statistic to capture the performance of a dichotomous diagnostic 
test. Measured J=sensitivity+specificity-1 
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Thesis Outline 
This thesis is composed of explanatory materials, data chapters based on published and submitted 
manuscripts and linking material to create a logical flow. Chapters highlighted in italics consist of 
papers that have been published or submitted for publication. The other chapters are linking 
material prepared for this thesis. 
Chapter 1 is an overview of the components of my PhD research and the components of this project. 
It outlines the scientific rationale for my research. 
Chapter 2 provides the history of serology for the investigation of Chlamydia trachomatis (Ct) 
infection, an overview of assays, antigens and immunoglobulins, before reviewing the studies 
performed to-date, looking at both those specific to ocular and genital Ct infection. 
Chapter 3 details the development of the Pgp3-specific ELISA used to analyse samples from The 
Gambia, Laos, Uganda and Kiribati. The ELISA has also been used by other researchers to analyse 
sample from serological studies in Ghana, Malawi and the Solomon Islands. 
Chapter 4 presents serological data from The Gambia, Uganda and Laos and methods in which 
thresholds for serological data can be set to separate seropositive samples from seronegative 
samples. Results suggest that methods relying only on the samples themselves, rather than external 
controls, produce more consistent results. This chapter also details the Pgp3-specific ELISA used to 
generate serological data. 
Chapter 5 uses a reversible catalytic model to estimate seroconversion and seroreversion rates in 
The Gambia. Evidence suggests an abrupt change in transmission occurred approximately 20 years 
prior to samples being collected, in addition to a more gradual decline in disease and infection as 
access to water, healthcare and education increased from 1986 to the current day. 
Chapter 6 examines age-standardised antibody acquisition models as an alternative method to 
dichotomised seropositive results. Results are compiled from seven serological studies from endemic 
and previously-endemic countries across a range of ages. Age-dependent antibodies level provide 
proof of changes between pre- and post-MDA in a population, the ability to distinguish between 
populations with on-going transmission and ones in which trachoma has been eliminated and, at 
population-level, can approximate when Ct infection is acquired, whether ocular or genital 
infections. 
Chapter 7 provides the final discussion and conclusion to the research presented in this thesis. 
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Chapter 1 Overview of PhD objectives  
1.1 Project Summary 
Trachoma is a form of chronic conjunctivitis caused by ocular infection with the obligate intracellular 
bacterium Chlamydia trachomatis (Ct). It is the world’s most common form of infectious and 
preventable blindness and affects people predominantly in the most remote and poorest areas of 
the world. The World Health Organization (WHO) estimates that 190 million people live in trachoma-
endemic regions; 21 million people have active trachoma, and 7.3 million people need surgery for 
trachomatous trichiasis. Trachoma has led to visual impairment in 1.9 million people of whom 1.2 
million are blind [1]. 
Diagnosis of trachoma is based on the presence of clinical signs. Active trachoma is characterised by 
trachomatous inflammation. Trachomatous inflammation- follicular (TF) is defined as the presence 
of five or more follicles, each at least 0.5mm in diameter in the central part of the upper tarsal 
conjunctiva [2]. Trachomatous inflammation-intense (TI) indicates inflammation obscuring at least 
half the tarsal blood vessels [2]. Repeated infection over the course of a lifetime can lead to harmful 
sequelae known as scarring trachoma: trachomatous scarring (TS) in which scars are easily visible as 
white lines or bands in the tarsal conjunctiva; trachomatous trichiasis (TT) with at least one eyelash 
touching the surface of the eyeball; and corneal opacity (CO) when the repeated scratching of the 
eyeball leads to corneal scarring blurring the pupil margin and reducing visual acuity, leading 
ultimately to blindness [2].  
The WHO Roadmap proposed to eliminate trachoma as a public health problem by 2020 [3]. 
Elimination as a public health problem is related to both infection and disease, defined by 
measurable targets set by the WHO; continued actions are required to maintain targets and advance 
the interruption of transmission. Validation is the process of documenting the elimination of a 
disease as a public health problem [4]. The operational thresholds for the elimination of trachoma as 
a public health problem are defined as: (i) a prevalence of trachomatous trichiasis (TT) “unknown to 
the health system” of < 1 case per 1000 total population; and (ii) a prevalence of trachomatous 
inflammation-follicular (TF) in children aged 1–9 years of < 5%, in each formerly endemic district [5]. 
Elimination of trachoma as a public health problem is based on the SAFE strategy: Surgery for 
trichiasis, Antibiotics to reduce infection, Facial cleanliness to reduce transmission and 
Environmental improvement. The SAFE strategy comprises both preventive chemotherapy and 
transmission control (PCT) as well as hygiene and environmental management. Antibiotics in the 
form of azithromycin (and tetracycline eye ointment when contra-indicated) are distributed to all 
24 
 
members of communities wherein the prevalence of TF is greater than 10% in children aged 1-9 
years [6]. Substantial international effort has gone into the elimination of trachoma as a public 
health problem, with the Global Trachoma Mapping Project collecting data from 2.6 million people 
across 29 countries, to determine the prevalence of trachoma in these countries and their 
requirement for the elements of the SAFE strategy [7]. 
With the leadership of the WHO, the global effort to eliminate trachoma as a public health problem 
has seen significant success, with several countries declared as having met the elimination targets: 
as of October 2018, Cambodia, China, Gambia, Ghana, Islamic Republic of Iran, Iraq, Lao People’s 
Democratic Republic, Mexico, Morocco, Myanmar, Nepal and Oman had reported achieving 
elimination goals [1,8,9]. 
As efforts to eliminate blinding trachoma as a public health problem are increased to meet the 2020 
deadline [10], experts have agreed to explore the correlation between clinical signs, infection and 
antibodies, and how these can be used to advise programmatic decisions regarding the 
implementation, continuation and eventual cessation of  MDA of antibiotics [11]. Studies monitoring 
elimination efforts have previously measured the prevalence of disease [12–17], however there are 
concerns that surveys based on clinical signs in post-MDA communities may lead to ongoing 
interventions that are unnecessary and inappropriate: active trachoma (the presence of TF and/or 
TI) often persists after infection has cleared, these clinical signs may be overcalled (due to the 
challenge of standardised training) [18] or that follicular diseases may have different aetiology [19]. 
In post-MDA communities, the positive predictive value (PPV) of clinical signs is diminished [20]. 
Finally, there is no biological significance to the 5% TF prevalence as set by the WHO for either 
stopping MDA or predicting the recrudescence of active trachoma [21]. 
Surveillance efforts have also used PCR to estimate the prevalence of ocular Ct infection [22–26], 
however monitoring active ocular Ct infection is expensive with one test for infection estimated to 
cost $8-16 (US Dollars) per test [21] and no thresholds for the prevalence of ocular Ct infection have 
been suggested by the WHO. 
In 2014, the Technical Consultation on Trachoma Surveillance made recommendations to explore 
alternative indicators on which to base the decision to stop MDA; these include the district-level 
prevalence of antibodies to C. trachomatis-derived antigens [11].A change in the prevalence of 
seropositivity in a community may demonstrate when the level of Ct circulating in a community has 
reached a level low enough to prevent recrudescence of infection and disease. 
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Serological assays for Ct-specific antibodies have existed for many years and the historical context is 
provided in detail in Chapter 2 of this thesis. In brief, early assays were non-specific and often cross-
reacted with antibodies against C. pneumoniae (Cp) [27,28]. Additionally, concerns about the 
sensitivity and specificity of previous assays have been raised [29–31]. Advances in protein 
expression and purification techniques and the development of multiplex technology has led to the 
development improved assays [32–34], although in resource-poor settings, a less technologically-
dependent assay may be preferable. 
The research conducted as part of this thesis aims to explore serology as a means of monitoring 
intervention activities. This thesis first reviews the historical use of serology for detection antibodies 
against Ct infection and summarises the use of Ct-specific serological assays at a population level to 
measure the prevalence of antibodies resulting from ocular and genital infections. The development 
of a Pgp3-specifid ELISA is presented in Chapter 3 along with methods to set seropositivity 
thresholds in Chapter 4. Using age-standardised seroprevalence, the seroconversion and 
seroreversion rates were modelled under different epidemiological settings in Chapter 5. Finally, in 
Chapter 6, antibody acquisition models were used to compare datasets from countries where 
trachoma has been eliminated as a public health problem to those where transmission is on-going 
and further, where the prevalence of genital Ct infection is likely contributing to the prevalence of 
Ct-specific antibodies in the population. The final chapter summarises the work completed for this 
thesis and addresses the epidemiological implications of this research and suggests future research. 
 
1.2 Aims and Objectives 
1.2.1 Aim 
The aim of this research was to measure antibodies against Ct, using a Pgp3-specific ELISA, and use 
the age-specific seroprevalence as an alternative means of measuring the prevalence of ocular Ct 
infection. 
1.2.2 Specific Objectives 
1. Collect demographic and clinical information and fingerprick blood samples to investigate 
the epidemiology of trachoma and the age profiles of antibodies against Pgp3 in Lower and 
Upper River Regions of The Gambia 
2. Develop a Pgp3-specific ELISA to measure antibodies against Ct using fingerprick dried blood 
spots (DBS) 
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3. Determine appropriate cut-off thresholds to distinguish between seropositive and 
seronegative individuals in populations from The Gambia, Lao PDR and Uganda. 
4. Use seroprevalence data to estimate changes in transmission in The Gambia and estimate 
seroconversion and seroreversion rates. 
5. Use antibody level data as an alternative to seroprevalence data to measure changes in Ct 
transmission 
1.3 Hypotheses 
1. Antibodies against Pgp3 can be measured using a sensitive and specific ELISA. 
2. Internally-calibrated thresholding methods are an appropriate means of determining 
seropositivity thresholds. 
3. Serology can be used to infer changes in the incidence of trachoma. 
4. Antibody levels, rather than seropositivity, can be used to measure changes in disease 
transmission. 
 
1.4 Study sites 
This thesis includes data from seven countries: The Gambia, Lao People's Democratic Republic 
(Laos), Uganda, Nepal, Tanzania, Solomon Islands and Kiribati (Figure 1). Samples from The Gambia 
comprise the primary dataset. The datasets include countries multiple rounds of MDA have taken 
place: The Gambia, Laos, Uganda, Nepal and Tanzania. Of these, Nepal and Laos have been certified 
by the WHO as having eliminated trachoma as a public health problem, while The Gambia is 
preparing their dossier for elimination. The region from which the Tanzanian data were generated 
was shown to have no ocular Ct infection in 2002 [35]. In comparison, Kiribati was shown to have 
high levels of active trachoma and ocular Ct infection [36] and the Solomon Islands has moderate 
levels of active trachoma in children aged 1-9 years old, high prevalence of genital Ct infection 
[37,38] but low levels of ocular Ct infection [19]. Further information is detailed below.  
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Figure 1.1. Map produced by the WHO showing the status of elimination of trachoma as a public 
health problem, 2018. Research sites marked as red stars. From left to right, these are: The Gambia, 
Uganda, Tanzania, Nepal, Laos, Solomon Islands, Kiribati. Modified from [39]. 
Samples from Laos and Uganda were collected by collaborators at the International Trachoma 
Initiative (ITI) as part of the Trachoma Alternative Indicators Study [21]. At the time of sample 
collection, these countries were considered to be peri-elimination, that is the prevalence of TF in 
children aged 1-9 years would be less than 5%, but elimination as a public health problem has not 
yet been validated. Little has been published about the prevalence of trachoma in Uganda [40,41], 
however two regions were considered highly endemic for trachoma and received three years (2010-
2012) of the A, F and E components of the SAFE strategy, although no data is publicly available. DBS 
were collected as part of a trachoma impact assessment survey [42].  
A trachoma rapid assessment (TRA) was conducted in five provinces in Laos (Oudomxay, Luang 
Prabang, Vientiane, Salavan, and Sekong) in 2000, finding overall that 14.8% of children examined 
had active trachoma [43]. A population-based prevalence study was undertaken from November 
2013-August 2014 to examine 21,566 children aged 1–9 years, and 15,052 adults aged ≥15 years 
[43]. Three ‘hotspots’ were identified, where the prevalence of TF in children aged 1-9 years was 
above 10%. These three regions, one each in Attapu, Houaphan and Phôngsali, along with 
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surrounding villages were further surveyed and DBS collected during the extra survey round 
comprise part of this thesis [42].  
The DBS from The Gambia, Uganda and Laos were assayed for antibodies against Pgp3 by the author 
of this thesis, who also conducted all serological analyses of these samples. These samples are 
described in detail in Chapter 4. 
Additional serological datasets were requested and received from collaborators to compare the data 
from peri-elimination countries to (i) other countries or regions where trachoma has been validated 
as having been eliminated or where there is strong evidence to suggest that infection, transmission 
and disease have been eliminated, or (ii) where trachoma remains an ongoing public health 
problem. 
Two regions in which trachoma has been ‘eliminated’ were also included: Nepal was validated as 
having eliminated trachoma in 2018 [44], while studies have shown that ocular Ct infection in 
Rombo district, Tanzania, was eliminated in 2005 [35]. These samples were assayed using a multiplex 
bead assay (MBA) and primary analyses completed by collaborators at the Centers for Disease 
Control and Prevention, USA (CDC) [45,46]. Secondary analyses of antibody levels were completed 
by the author of this thesis. 
Two regions where chlamydial infections remain an ongoing health problem were included for 
comparison: populations in the Solomon Islands have high prevalence of genital Ct and antibodies 
against Ct but low prevalence of conjunctival scarring (TT) [47,48] while a recent study showed a 
high prevalence of disease, ocular Ct infection and antibodies against Ct in Kiribati [36]. The author 
of this thesis assayed the samples from Kiribati and conducted all serological analyses as well as 
secondary analyses of the data from the Solomon Islands.  
Additional data from the Solomon Islands were provided by Dr Robert Butcher of LSHTM [48], data 
from Nepal were provided by Dr Diana Martin of the CDC [45], data from Kiribati were provided Dr 
Anthony Solomon from the WHO [36], data from Tanzania by Drs Martin and Solomon [46].  
1.4.1 The Gambia 
The Gambia is the smallest mainland country in Africa. It is situated in West Africa, surrounded by 
Senegal except for its coastline on the Atlantic Ocean. The country stretches over 400 km inland, 
with the River Gambia dividing the country into two nearly equal halves. The 2013 National Census 
estimated the population to be 1.9 million, with women comprising 51% of the total population [49]. 
Due to a high fertility rate (5.4 births per woman), the population structure is skewed toward young 
people: 42% of the population is under 15 years and about 22% are between 15 and 24 years of age. 
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The Gambia has a typical Sahelian climate, with a short rainy season from June to October, and a 
longer dry season the rest of the year. 
The country became a sovereign republic in 1965, following more than two centuries of colonial 
British rule [50]. Administratively, The Gambia is divided into eight administrative areas: Banjul (the 
seat of the government), Kanifing, Brikama, Mansa Konko (formerly Lower River Region), Kerewan 
(formerly North Bank), Kuntaur, Janjabureh (both formerly Central River Division) and Basse 
(formerly Upper River Region). To align with previously published works, in this thesis the author has 
chosen to refer to Mansa Konko and Basse by their historical names of Lower River Region (LRR) and 
Upper River Region (URR), respectively (Figure 2). For census purposes, The Gambia is divided into 
Enumeration Areas (EA), which cover a settlement, a cluster of small settlements or part of a large 
settlement; one EA generally covers 600-800 residents [51]; this is equivalent to a ‘district’ as 
described by the Global Trachoma Mapping Project (GTMP) [7].  
 
 
Figure 1.2. Map of The Gambia, showing current administrative areas, with the historical names 
provided for the two primary study districts included. Map courtesy of Wikipedia user Acntx [52].  
Trachoma is associated with poverty and low access to water and sanitation services [53]. In The 
Gambia access to water has increased greatly, with nearly 11% of rural populations having a source 
of drinking water on premises and 67.2% less than 30 minutes round-trip to access drinking water 
[50]. Despite these improvements in water and sanitation, nearly two-thirds of rural population does 
not have access to improved toilet facilities, as defined by the WHO and United Nations Children’s 
Fund (UNICEF.)  Less than 13% of rural households have electricity and only 26% of rural households 
used soap and water for handwashing [54].  
1.4.2 Trachoma in The Gambia 
For many years trachoma was endemic in The Gambia. In 1986 a population-based national survey 
of blindness, low vision and eye disease was undertaken and found there to be a prevalence rate of 
blindness of 0.7%, of which trachomatous corneal opacity was responsible for 17% [55]. With only 
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one eye clinic and one ophthalmologist at the time, the Gambian National Eye Care Programme 
(NECP) was integrated into the national health services as primary health care, with support from 
Sight Savers International. Ophthalmic nurses are integrated into community health services and 
cover a population of approximately 50,000. They are overseen by senior ophthalmic medical 
assistants, trained in cataract surgery [56]. A second national survey in 1996 showed that the 
prevalence rate of blindness had decreased to 0.4% while the prevalence of active trachoma – based 
on the WHO classifications of TF or TI –  in children aged 0-14 years dropped from 10.73% to 4.81% 
[57,58]. Additional NECP activities have trained health care workers in primary eye care, recognition 
and treatment of conjunctivitis, and surgery for trichiasis, as well as community outreach activities 
like school screening and face-washing [58]. Further, the NECP has developed a network of nyateros 
(Friends of the Eye), who are non-health professionals, selected by their own communities, who 
have been trained in good eye health practices to promote within their communities [26]. 
 Subsequent interventions run by the National Eye Health Programme (NEHP) included the mass 
drug administration (MDA) of azithromycin in over 20 districts across the country between 2007 and 
2010. The Partnership for the Rapid Elimination of Trachoma (PRET) [59] was embedded within the 
NEHP and measured the prevalence of disease and ocular Ct infection in children in four district 
where MDA had been administered, including LRR, but not URR. 
 
1.4.3 PhD Fieldwork and Samples  
Primary fieldwork for this PhD research was conducted in Upper and Lower River Regions (URR and 
LRR, respectively) of The Gambia. URR is situated at the far east of the country, while LRR is located 
more centrally. I collected data and DBS over a three-month period from February to April 2014. The 
author assayed these DBS using a Pgp3-specific ELISA developed in collaboration with the CDC [42] 
and analysed all data. 
Samples were also collected from Laos [43] and Uganda as part of the Trachoma Alternative 
Indicators Study [21]. These populations are further detailed in Chapter 4 [42]. The author assayed 
these samples using the Pgp3-specific ELISA and analysed all data. 
Additional samples from Kiribati were provided for ELISA testing and analysis. These samples were 
collected as part of The Global Trachoma Mapping Project [7] undertaken on Kiritimati Island, in the 
far east of Kiribati, in the South Pacific [36]. Samples were collected from children 1-9 years old. The 
author of this thesis assayed these DBS with the Pgp3-specific ELISA and analysed the serological 
data. 
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Additional data came from the Solomon Islands, where DBS were collected from participants of all 
ages in participating villages in the provinces of Temotu and Rennell & Bellona as part of the 
Solomon Islands National Trachoma Elimination Program [48]. These samples were assayed using 
the same ELISA protocol as the samples above. The author performed secondary analysis of the 
serological data. 
Data were also supplied for pre- and post- MDA populations in Nepal [45] and a post-MDA 
population in Rombo, Tanzania [46]. In both populations, samples were collected from participants 
of all ages. These samples were run on a Luminex assay at the CDC. The author performed secondary 
analysis of the serological data. 
1.5 Study components 
This PhD consists of five main components: 
1. Literature review of uses of serology for monitoring Ct infection at the population-level  
(Chapter 2) 
2. Development of a Pgp3-specific ELISA (Chapter 3) 
3. Assessment of methods for determining thresholds between seropositive and 
seronegative populations (Chapter 4) 
4. Estimation of changes in transmission rates in The Gambia using reverse catalytic 
modelling (Chapter 5) 
5. Use of novel statistical methods to estimate age-dependent antibody levels as an 
alternative to seroprevalence (Chapter 6) 
1.5.1 Literature Review 
Historically, serology was commonly used as a diagnostic tool for genital chlamydial infections, 
however serology has been displaced as a diagnostic tool by more sensitive and specific methods 
based on nucleic acid amplification tests (NAATs), like polymerase chain reaction (PCR). 
Meanwhile improvements in protein expression and purification have made serological assays more 
sensitive and specific for detecting antibodies which have developed as a result of previous 
chlamydial infection. The author conducted a systematic literature search in June 2016, which was 
updated in April 2018. The author outlined the antigens used, antibodies detected, methods of 
detection and summarised the current literature based on the public health applications of Ct 
serology; this includes studies of ocular and genital Ct infections. 
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1.5.2 Development of a Pgp3 ELISA 
The author developed a Pgp3-specific ELISA with colleagues at the CDC. This was based on the 
existing MBA which has been previously published [33]. The author showed the ELISA to be sensitive 
and specific with reproducible results. 
1.5.3 Assessment of threshold methods 
The earlier development of a Pgp3-specific MBA relied on references standards to set a threshold for 
positivity using a Receiver Operator Characteristic (ROC) curve. The ‘known negative’ samples were 
de-linked serum samples from a population of 122 children from the United States, while the ‘known 
positives’ were DBS from 11 children, residing in a region in Tanzania which had undergone three 
rounds of MDA, from whom ocular swabs were PCR-positive for ocular Ct infection. Of these 
samples, three ‘known negatives’ were positive for antibodies against Pgp3, while one ‘known 
positive’ was negative for antibodies against Pgp3. This highlights issues in selecting appropriate 
reference standards. Therefore, the author explored other internally-calibrated methods (using data 
generated during the study) such as finite mixture modelling (FMM) and expectation-maximisation 
algorithms (EM) to establish positivity thresholds between seropositive and seronegative samples 
and compared these to thresholds set using an ROC curve, separately maximising sensitivity and 
specificity and Youden’s J-index, which balances sensitivity and specificity [60]. These modelling 
techniques are detailed in Chapter 4. 
1.5.4 Estimation of changes in transmission rates 
Pgp3-specific serological data were used to produce a reverse catalytic model (RCM). RCM has been 
previously used in studies of malaria and neglected tropical diseases [61] to determine the impact of 
interventions on the force of infection (FoI). The author used RCM to estimate changes in 
seroconversion rate (SCR) and seroreversion rate (SRR) associated with a reduction in the prevalence 
of trachoma in The Gambia. This method may be of use in districts where the SAFE strategy has been 
implemented to show a change in the FoI, and to evaluate the effectiveness of the intervention 
activities; one would expect to see a decrease in the FoI following the intervention. 
1.5.5 Estimation of age-dependent antibody levels 
Serological surveys have relied on binary seropositive/seronegative data for estimates of prevalence. 
Rather than dichotomise the serological data to simple seropositive and seronegative, the author 
used a recently developed statistical package ‘tmleAb’ to estimate age-dependent antibody curves in 
seven countries. The author of this thesis compared pre- and post-MDA data across all ages, data 
from children in populations where trachoma has been eliminated to those with ongoing disease 
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and infection and data from all ages in a population with high levels of genital Ct infections to one 
with low levels of both ocular and genital Ct infections.  
 
1.6 Fieldwork Protocol 
In the Gambia a cross-sectional seroprevalence survey was conducted by the author, in which 20 EAs 
(10 each in LRR and URR) were selected for study using probability proportional to size. Households 
within these EAs were then randomly selected for participation. Demographic and clinical data, 
photographs of everted eyelids, and finger prick blood samples- in the form of DBS- were collected 
from all household members who consented to participate. ELISAs were used to test for anti-Pgp3 
antibodies. Seroprevalence curves were generated and compared to historical and current 
prevalence data.  
1.6.1 Sample Size Calculations 
Sample sizes were estimated based on a two-sided comparison of seroprevalence rates between the 
regions (surveillance Zones). If there had been significant transmission of ocular chlamydial infection 
in the last generation, it was anticipated that 80% of 40-year olds will have antibody, compared to a 
suggested 20% in settings where minimal no transmission had occurred. These are represented 
below as regions A and B.  
The rate for each region was first calculated from the following equation: 
P(a) = 1 − exp (−a), 
where P(a) is the age-specific seroprevalence (prevalence at age a), and   is the force of infection to 
be estimated. 
Table 1.1. Estimates of seroprevalence and seroconversion rate (Λ) in two regions of The Gambia  
Region Age Seroprevalence* Λ 
A   40 0.8 0.04 
B 40 0.2 0.0056 
*Estimates of seroprevalence (D. Mabey, personal communication) 
Using the ‘stpower’ with the ‘exponential’ function and 90% power for a two-tailed test (α=0.05) in 
Stata, the necessary sample size for comparison is 150 individuals from Region A and 810 individuals 
from Region B.  Accordingly, we collected samples from 20% more subjects than this, approximately 
1000 per region. With an average household size of 7.5 people in LRR (National Eye Health 
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Programme data) and 25 in URR (Grant Mackenzie, personal communication), we anticipated that 14 
households should be sampled from each of the selected EAs in LRR and 4 from each of the EAs 
selected in URR.  
These calculations assumed that the rate of seroconversion is relatively constant in the populations, 
that individuals, once seropositive, do not revert to seronegative and that there is no specific 
migration due to trachoma infection status [61]. 
1.6.2 Community Sensitisation 
Members of the trachoma field team at the MRC Unit- The Gambia sensitised villages and obtained 
community-consent from the village chiefs, known as alkalos. Household head lists were compiled 
with the assistance of each alkalo and a census conducted in sequential randomly selected 
households consenting to participate until their combined population exceeded the projected 
sample of 100 per EA by 50%. Team members and eye health nurses explained the study to each 
head of household, answered any questions and explained the written consent form. All residents of 
selected households were invited to participate. If a selected household chose not to participate, the 
next one on the list was approached.  
1.6.3 Inclusion and Exclusion Criteria 
Inclusion Criteria 
Resident in the selected village, a member of a selected household, willing to consent and 
participate; if younger than 17, a guardian must have been willing to provide consent. All residents 
of selected households were invited to participate. Assent was sought from participants aged 12-17. 
Exclusion criteria 
We invited all residents of selected households to participate. Age was not an exclusion factor. 
Participants were able to stop participating at any point during the process. Some selected 
households were ‘reserves’ and were not approached to participate if the projected sample size had 
been reached.  
 
1.6.4 Informed Consent 
Written (thumbprint or signature), informed consent was obtained from each adult participant and 
each participating child’s parent or guardian. Each participant was free to ask questions to the field 
team before providing consent and throughout the ocular examination and sample collection. 
Assent was sought from children ages 12-17. 
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1.6.5 Data and Sample Collection 
The survey in the Gambia was undertaken between February and April 2015. Individual-level data 
were collected by a local eye-health nurse, including gender, age (in years or as date of birth) and 
ethnic group. Facial cleanliness was observed by a trained trachoma grader before each eyelid was 
everted for grading and photography. Demographic information, facial cleanliness and trachoma 
grade were recorded on a standardised form by the author (Appendix 2). Forms were entered into a 
custom built EyeScores database [62] to link with photographs of everted eyelids. A fingerprick 
blood sample was collected onto filter paper by a second eye health nurse and allowed to dry for 
approximately 5 hours; each filter paper had six extensions, calibrated to absorb 10 μl of blood. All 
samples were placed in individual plastic bags, then stored with desiccant in larger sealed plastic 
bags. Samples were transferred to the MRC Unit-The Gambia where they were stored at -20°C. All 
samples were subsequently shipped to LSHTM for ELISA testing. 
1.7 Laboratory testing 
DBS were tested for IgG antibodies against Ct using a Pgp3-specific ELISA. A detailed protocol is 
provided in Chapter 3. In brief, DBS were eluted into 250 μL of phosphate-buffered saline (PBS) with 
2.5% w/v milk powder plus 0.3% v/v tween 20 (PBSTw-milk). Immunlon 2HB plates were coated 
overnight at 4°C with 50 ng/well glutathione S-transferase (GST)-tagged Pgp3 then blocked for 1 
hour with PBST the following day. Plates were incubated for 2 hours with 50 µL of elution mixture 
and incubated at room temperature with HRP-labelled mouse anti-human IgG for 1 hour. Plates 
were then incubated for ten minutes in the dark with tetra-methylbenzidine (TMB), stopped with 50 
μL 1N H2SO4 and optical density was read at 450 nm (OD450). Control sera with known ratios of Pgp3 
antibodies (1000 units, 500 units, 200 units, 50 units and negative control serum) and a blank 
consisting of PBSTw-milk were run on every plate. All specimens were normalised to the 200 unit 
control sera, which typically gave a reading of 1.0 OD450. 
1.8 Data Analysis Tools 
All statistical analyses were carried out using R software version 3.3.2 [63]. Details of specific 
analyses for each component of this thesis are highlighted in the individual data chapters following. 
In brief, Chapter 4 considers 4 methods of setting seropositivity thresholds. These include three 
internally calibrated methods, relying solely on data generated in the study to establish thresholds; 
these are then compared to the commonly ROC curve which has been frequently used in trachoma 
serological studies [18,33,46,64–67]. Using a ROC curve to set a threshold requires well-
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characterised positive and negative reference samples from the population of interest. Inter-
laboratory calibration is also required, ideally using the original reference specimens. 
Misclassification of the reference samples can result in an inappropriate threshold. 
The FoI for two populations in The Gambia was modelled in Chapter 5. This work involved estimating 
seroconversion and seroreversion rates based on catalytic models [68] and has previously been 
applied to both malaria [69–71] and Chagas disease [61]. 
Finally, an analysis using antibody acquisition models is presented in Chapter 6, in which changes in 
community antibody profiles are compared between pre-, peri- and post-elimination countries and 
between communities where genital chlamydia is highly prevalent to one where both ocular and 
genital chlamydia infection levels are low. 
1.9 Ethical Considerations 
This thesis was conducted in accordance with the Declaration of Helsinki. Ethical approval was 
obtained from The Gambia government/Medical Research Council (MRC) Joint Ethics Committee 
(SCC1408v2) and the London School of Hygiene and Tropical Medicine (references 6319, 6514, 8355, 
8918). For specimens not directly collected by the author, ethical approval was obtained from  
• Laos: the Ministry of Health of the Lao People’s Democratic Republic (No:48 NIOPH/NECHR),  
• Uganda: Ugandan Ministry of Health (VCD-IRC/053) 
• Tanzania: Centers for Disease Control and Prevention (USA), Kilimanjaro Christian Medical 
College (KCMC)/ Tumaini University, and the National Institute for Medical Research (TZ) 
[46] 
• Nepal: Children’s Hospital and Research Center Oakland (IRB number 2013-043) and by 
Nepal Netra Jhoti Sangh (Nepali Prevention of Blindness Program) [45]. 
• Kiribati: London School of Hygiene & Tropical Medicine (reference numbers 6319, 8355 and 
10136) and the Kiribati Ministry of Health and Medical Services (08/11/2015) [36] 
• Solomon Islands: London School of Hygiene & Tropical Medicine (LSHTM; 8402) and 
Solomon Islands National Health Research Ethics Committee (HRC15/03)  
1.10 Data Management 
  
Each participant was assigned a unique identifying number, which was used to link photographs and 
demographic, clinical and laboratory data. In The Gambia, all fieldwork information was collected on 
standardised forms, which were then double entered into a custom build database, EyeScores [62]. 
Data from the other sites were provided directly to the author from collaborators.  
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Summary 
The bacterium Chlamydia trachomatis (Ct) causes both genital and ocular infection. Clinical signs are 
used to diagnose trachoma, cause by ocular infection with Ct, while genital infection is diagnosed 
using nucleic acid amplification tests (NAATs) to detect the presence of chlamydial DNA. Serology 
has historically been used as a diagnostic tool for both ocular and genital infections, however this is 
not an appropriate diagnostic method. We summarised the historical context of chlamydia serology 
reviewing samples, testing methodology, antigens, immunoglobulins detected and methods of 
analyses. We reviewed published serological studies to provide an overview of the current landscape 
of Ct serology as it relates to public health. 
Methodology 
The author of this thesis performed a systematic literature search of online databases (PubMed, 
Cochrane, Lilacs, Scielo, Scopus and Web of Science) in June 2016, and updated it in April 2018, 
following PRISMA guidelines. Studies were limited to peer-reviewed Ct serology studies in the public 
health context, that is not for research or individual diagnostics purposes with the reported outcome 
being the prevalence of antibodies against Ct. The studies were heterogenous in terms of population 
studies, sample collected, assay and antigen used and method of determining positivity.   
Conclusion 
Overall, 24 studies were included: 9 trachoma-related studies and 15 studies of genital Ct infections. 
The diversity of studies prompted a review of the historical development of serological assays for Ct 
to provide a more thorough overview of the elements of Ct serology and its public health 
applications. Few head-to-head comparisons have been made comparing either commercial and in-
house assays to each other or comparing different antigens, assay types or threshold methods 
across platforms. A standardised set of reference standards should be produced to facilitate 
comparisons between assays and settings if serology is to become more widely accepted as a useful 
public health tool. 
 
In the subsequent chapters, the author will cover the development of a Pgp3-specific ELISA for 
detecting antibodies against Ct to be used to measure seroprevalence and antibody acquisition in 
populations where trachoma is or has been a public health problem. Data generated using this ELISA 
are used to estimate changes in the force of infection following public health interventions. 
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Serological tests for the surveillance of Chlamydia trachomatis infections: the history, 
development and review of their use in public health 
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2.1 Introduction 
Chlamydia trachomatis (Ct) is one of the most frequent causes of bacterial sexually transmitted 
infections (STI) [1], as well as being the leading infectious cause of blindness [2]. The species consists 
of a number of serovars. To some extent it is possible to link serovars to pathology and tropism, with 
types A, B, Ba and C having tropism to the eye and causing trachoma. The remaining serovars are 
generally found in the genital tract, with types D-K causing the classical genital chlamydial infection 
whilst types L1, L2 and L3 cause  a more severe form of disease known as lymphogranuloma 
venereum (LGV) [3].  
Genital infection with Ct is common worldwide but ocular infection is now predominantly limited to 
tropical developing countries [4]. Repeated or prolonged infections (both genital and ocular) lead to 
complications and pathological sequelae. Genital Ct infection can cause pelvic inflammatory disease 
(PID), with potential sequelae of tubal factor infertility (TFI), ectopic pregnancy, chronic pelvic pain 
and infertility in women[5–8]. In men, genital Ct infection can cause epididymitis, an inflammation of 
the epididymis which causes severe testicular pain [9,10]. There is also some evidence that current 
infection with Ct is linked to sperm DNA fragmentation and reduced fertility [11].  Babies born to 
infected women are at risk of ophthalmia neonatorum or bacterial pneumonia [12].  
Following ocular infection with Ct, raised follicles develop on the upper tarsal conjunctiva, known as 
trachomatous inflammation- follicular (TF). This is often followed by inflammatory thickening, called 
trachomatous inflammation- intense (TI). The long-term sequelae of this inflammation include 
scarring of the upper tarsal conjunctiva, leading to trichiasis, a condition where the eyelashes rub 
against the surface of the eye, which can lead to corneal opacity and blindness [13].  
Methods for understanding the burden of Ct in populations differ between ocular and genital 
chlamydia disease. The prevalence of trachoma is determined by the presence of clinical signs 
detected by everting the upper eyelid to examine the tarsal surface [14]. Cross-sectional prevalence 
studies are typically performed in endemic locations, with children aged 1-9 years in selected villages 
being examined. Studies have shown a disparity between the clinical signs and the presence of Ct 
infection, particularly in areas of low-endemicity or post-intervention communities, with clinical 
signs often persisting after infection has been treated [15,16]. The prevalence and incidence of Ct 
infection is challenging to measure as infections are often asymptomatic and self-clearing [17]. In the 
primary care context, nucleic acid amplification tests (NAATs) are used to test a variety of specimen 
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types, including urogenital, pharyngeal and rectal swabs, as well as urine specimens [18] and these 
tests are also amenable to use in population monitoring and prevalence surveys. Some previous 
studies have been based on patients attending sexual health clinics, which suffer from population 
selection bias, selecting those at higher risk of chlamydia[19,20] whereas studies based on 
representative sampling show lower prevalence [21–23].  
Unlike a clinical diagnosis based on signs and symptoms, or a molecular diagnosis based on genetic 
material, serological assays detect antibodies against specific antigens and are not commonly 
considered a diagnostic tool for current infection, either ocular or genital, as antibodies persist for a 
time once the infection has self-cleared or has been treated. Tests for infection and disease 
prevalence do not account for past exposure, nor do they measure the cumulative exposure to 
infection that lead to the sequelae that intervention and screening programmes for trachoma and 
genital Ct infection aim to minimise. Serology serves an altogether different purpose and is not a 
replacement for clinical or molecular diagnostic tools: NAATs are the recommended diagnostic tool 
for current infection [24,25]. The presence of antibodies can be used to indicate past exposure and 
changes in transmission [26,27] as well as indicating the development of severe pathology and 
scarring sequelae [28]. 
Historical reviews have focused on the use of Ct serology as a diagnostic test [29,30] but few recent 
works provide a detailed description of how these methods can be turned towards applications in 
programmatic surveillance for disease control [31]. A recent upsurge in interest in such applications 
has led us to review the use of anti-Chlamydial serological tests as tools for surveillance, drawing 
attention to particular studies in which serology has been used to measure the prevalence of anti-Ct 
antibodies in population-based samples. We present a historical context and examine some of the 
technical aspects of using serology. We show the challenges and opportunities of using serology to 
detect antibodies against Ct in the context of programmatic surveillance and disease control. 
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2.2   Technological platforms 
Serological testing for Chlamydia spp. has a history dating back almost a century, with early (c. 1935) 
technologies such as the Complement Fixation (CF) assay having been largely replaced by the 
microimmunofluorescence (MIF) test and Enzyme Linked Immunosorbent Assays (ELISA) in the 
1970s. Whilst ELISA remains a mainstay of serology in the 21st century, the technology has continued 
to evolve as the hardware has become more automated and the quality of the purified antibodies 
has increased over the years. In the last ten years it has become possible to adapt the principles of 
ELISA to highly multiplexed assays, using solid state micro-bead technology to simplify workflows 
and increase throughputs, whilst also improving precision and accuracy of measurement. Full 
proteomic analysis via microarray-based studies has also become both possible and affordable and 
has led to a paradigm shift in quantitative multi-antigen serological analysis. In this section we briefly 
introduce key studies that have used these technologies in Ct research. 
2.2.1 Complement fixation (CF) 
The first serological assay was published by Bedson in 1935 and was a complement fixation (CF) 
assay using a group-specific lipopolysaccharide (LPS) antigen [32]. CF was first used to diagnose 
cases of human psittacosis, caused by C. psittaci and LGV [32]. However, because it detected genus-
specific Chlamydia lipopolysaccharides, it had poor specificity due to cross-reactivity [33,34]. Conway 
et al. used CF to detect high titres of antibodies in women with a history of PID and tubal 
damage[35]. Yet, it was not specified if the PID was due only to Ct, as other genital infections, such 
as gonorrhoea and bacterial vaginosis can cause PID[36,37]. Serological evidence of Ct infection was 
also detected in pregnant or potentially fertile women. Thus, although a positive CF result was 
correlated with tubal damage, it was not diagnostic of the condition, as many women without tubal 
damage had serological evidence of chlamydial infection [35]. Similarly, Richmond and colleagues 
performed a study in which CF was used to demonstrate anti-Ct antibodies in patients with 
psittacosis and those attending venereal disease and family planning clinics [38]. (Figure 2.1) 
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Figure 2.1 Schematic representation of Complement Fixation. If the patient's serum contains 
antibodies against the antigen of interest (lipopolysaccharide), they will bind to the antigen to form 
antigen-antibody complexes. The complement proteins will react with these complexes and be 
depleted. Thus, when the antibody-coated erythrocytes are added, there will be no complement left 
in the serum. However, if no antibodies against the antigen of interest are present, the complement 
will not be depleted and it will react with the antibody-coated erythrocytes, lysing the erythrocytes 
and spilling their contents into the solution, thereby turning the solution pink. 
 
2.2.2 Microimmunofluorescence (MIF) 
In 1970, Wang and Grayston developed the microimmunofluorescence (MIF) test to serotype strains 
of C. trachomatis [39], having already raised a range of type-specific polyclonal antibodies, which 
allowed for serotyping of many of the serovars [40] using elementary bodies (EB). EBs are non-
replicating infectious chlamydial particles that are released when an infected host cell ruptures [41]. 
Serovar-specific EBs are fixed onto glass slides as distinct dots and an immunoreaction is detected if 
a clinical specimen contains antibodies against the antigen. The reaction is visualised with a 
secondary antibody labelled with fluorescein isothiocyanate (Figure 2.2). The use of a specific 
secondary antibody allows the identification of antibody isotypes (commonly IgG, IgA or IgM). Both 
CF and MIF allow for serial dilutions to determine end-point titre of a specimen. Wang and 
colleagues also demonstrated serovar-specific IgM and IgG in serum and tears [42], as well as 
correlating the presence of IgM with infection [43]. It should be noted that the MIF is a labour-
intensive in-house method, with modifications common [44,45], therefore results are variable in 
terms of both quality and performance [30]. For many years, MIF was considered the only specific 
and sensitive serologic assay for any of the Chlamydia spp. [29,46], however, both its sensitivity and 
specificity have been questioned [47–49]. Peeling and collaborators  demonstrated the inter-
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laboratory variability of the assay, which makes the comparison of published data from different labs 
challenging and underlines a need for standardised serological tests [50].  
 
Figure 2.2. Schematic representation of the microimmunofluorescence (MIF) assay. Chlamydial 
elementary bodies (EB) are fixed onto a glass slide, a clinical specimen is applied. If anti-EB 
antibodies are present, an immunoreaction can be detected by applying a secondary antibody 
labelled with fluorescein isothiocyanate. 
 
2.2.3 ELISA  
Enzyme-linked immunosorbent assays (ELISA) were developed with advances in diagnostic 
technology, such as antibody purification techniques. They were easier to perform than MIF, more 
objective [51] and large batches of samples could be processed simultaneously using 96-well plates. 
In brief, antigen is coated to the bottom of the wells, sample is applied, whereupon specific 
antibodies will bind to the antigen. A conjugated secondary antibody is applied and detected using a 
fluorescing substrate (Figure 2.3). 
Numerous ELISAs for the diagnosis of chlamydial infections were introduced in the 1980s [52–55]. 
These ELISAs commonly used elementary bodies (EBs) as antigen [56]. These ELISAs were genus-
specific, rather than species-specific and were unable to distinguish between antibodies for Ct and 
Chlamydia pneumoniae (Cp), a common human respiratory pathogen [16]. An appropriate screening 
test for chlamydial seroprevalence must be able to distinguish between species. With the advent of 
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protein recombination techniques, new ELISAs have been developed providing greater reported 
sensitivity and specificity against MIF and CF [57,58]. Although most are indirect ELISAs, a double-
antigen “sandwich” ELISA has also been developed and shows increased sensitivity when compared 
to some commercial indirect ELISAs [59,60]. 
An assay that detects antibodies to non-species-specific antigens could lead to over-estimation of 
the prevalence of Ct infections. In trachoma-endemic populations, this may lead to prolonged 
elimination activities and excessive use of antibiotics. 
 
 
Figure 2.3. Schematic representation of the indirect enzyme linked-immunosorbent assay (ELISA). 
Immunogenic chlamydial proteins (antigens) are coated to the bottom of wells, a clinical specimen is 
applied and antibodies specific to the antigen will bind. The immunoreaction can be detected by a 
secondary antibody conjugated with a fluorescein conjugate. 
 
2.2.4 Multiplex bead assay (MBA) 
An antigen-based multiplex bead assay (MBA) has been recently developed and allows for the 
identification of antibodies against multiple antigens [61]. Fluorescent microspheres are conjugated 
to antigens (Figure 2.4), and the varying spectral addresses of the labelled beads allow for up to 100 
bead-antigen combinations to be used in a single assay well [62]. Following a workshop by the World 
Health Organization (WHO), experts in neglected tropical diseases (NTDs) concluded that antibody-
based MBAs offered the greatest prospect of simultaneous monitoring of elimination efforts for 
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several NTDs, for instance trachoma, lymphatic filariasis, schistosomiasis, onchocerciasis, and soil-
transmitted helminth infections [63]. The multiplex nature of the assay allows for dozens of antigens 
to be included, evidence of infection with several organisms to be obtained and for each sample to 
be assayed with several antigens. Previous studies using the MBA have used beads conjugated with 
plasmid gene product 3 (Pgp3) and CT694 (see Antigen selection, below), two immunogenic proteins 
produced by Ct, to monitor the changes in seroprevalence in trachoma-endemic populations at 
baseline and six months or one year after a single round of mass drug administration (MDA) [64,65], 
as a measure of the transmission intensity [26,66] and as a proxy for the force of infection (FoI) using 
seroconversion rates [27]. These studies have shown that in a programme-monitoring capacity, 
serological studies are a reasonable proxy for infection or clinical signs, particularly in areas of low-
endemicity or post-MDA communities.  
 
Figure 2.4. Schematic representation of the multiplex bead assay. Antigens are coated to 
fluorescent microspheres (beads) to which specific antibodies in clinical specimens will bind. A 
secondary antibody-conjugate is then applied and visualised by reading light emitted when the 
beads are excited using laser technology. 
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2.2.5 Proteomics 
Advances in recombinant techniques and proteomics have led to refinements in serological 
techniques. This, in turn, has led to an exploration of potential immunological targets using whole 
genome scale proteomic arrays, with several immunogenic antigens being identified. The 
development of synthetic and recombinant protein methods allowed for improved ELISAs, using 
more Ct-specific antigens- such as the major outer membrane protein (MOMP), heat shock proteins 
(hsp), Pgp3 and CT694.  
By assaying the peptides expressed by the open reading frames (ORF) of the chlamydial genome and 
plasmid, researchers have been able to identify antigens that elicit an immune response in infection-
positive women as well as pathogenic antigens that are specific to different scarring pathologies. 
Wang et al. performed a whole genome-scale proteome array of Ct serovar D: they expressed 
peptides encoded by the genome and plasmid and assayed them using a microarray against sera 
from Ct-infection positive women, with sera from infection-negative women as controls [67]. Of 
these proteins, 27 were recognised by ≥50% of the sera and were thus designated immunodominant 
antigens. These included antigens localised in the membrane, like MOMP, OmcB, and PmpD; 
proteins in the inclusion membrane, as well as proteins secreted into the host cell cytosol, such as 
Pgp3 [68]. The same whole genome array was used to profile antibody responses in individuals with 
and without trichiasis in The Gambia [69]. This study identified ten immunodominant antigens, 
including Pgp3, and CT694. Four additional antigens were associated with the trichiasis phenotype, 
producing a reaction only, or more strongly, in individuals with trichiasis compared to the controls 
who had no trichiasis. Another genome-wide study by Rodgers and colleagues was conducted using 
samples from women with laparoscopy-confirmed TFI and infertile women without TFI [70]. Many 
antigens elicited antibody responses in both groups, however 10 antigens were uniquely identified 
to elicit a response in TFI patients (100% specificity). Of these, two antigens (CT443 and CT381) had a 
sensitivity of 67.7% against clinically-diagnosed TFI, suggesting that they may prove to be useful 
biomarkers in the differential diagnosis of TFI. As such, serological assays based on these antigens 
may prove a less invasive tool than hysterosalpingogram or laparoscopy for diagnosing tubal 
pathology [71]. From the studies above, it is clear that the usefulness of serology as a tool depends 
on the careful selection of antigen(s) and also on the particular disease phenotype that is to be 
diagnosed. 
 
2.2.6 Summary of Diagnostic Platforms 
The use of a multiplex assay allows for the detection of antibodies against multiple antigens. This can 
be used to detect co-morbid diseases in integrated surveys, as has previously been demonstrated for 
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yaws and trachoma [72] and for a panel of infections endemic to Haiti, including lymphatic filariasis, 
giardiasis, toxoplasmosis, measles and malaria, as well as filarial antigens [62]. This type of multi-
antigen panel has been recommended by experts as the ultimate goal in NTD control and 
elimination [63]. Multi-antigen panels could also be used for detecting biological markers of upper 
genital tract infection and disease sequelae if they were to be used for monitoring the sequelae of 
genital Ct infections and estimating the risk of infertility. It is likely that a panel of antigens will be 
more informative than a single antigen assay, as suggested by microarray studies [69,70,73]. MBA 
platforms are more expensive than an ELISA plate reader, which may put them out of reach for 
public health programmes in low- and middle-income countries, in which case, the alternative may 
be to use a single-antigen ELISA assay. Both the MBA and ELISA are more objective and less labour-
intensive than MIF and can be automated or semi-automated. 
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2.3 Isotype selection 
The isotype of an antibody is determined by the heavy chains and although five isotypes exist in 
humans, three are of primary interest: IgM, IgA and IgG. These isotypes emerge at different times 
and will persist for varying lengths of time following infection (Figure 2.5). 
 
Figure 2.5 Pattern of antibody kinetics following infection with Ct. IgM is the first antibody to 
appear and this response is short-lived. IgA and IgG appear following the infection and persist 
longer. 
 
In serological assays, serum antibodies are bound to fixed antigens, which are then detected using a 
tagged secondary, anti-human antibody. Any serum antibodies specific for the fixed antigen will bind 
to it; these are then detected using anti-human antibodies specific for one of the three isotypes of 
interest. Thus the selection of secondary antibody is critical in detecting the antibodies that form the 
immune response.  
 
2.3.1 Immunoglobulin M (IgM) 
IgM is the first antibody produced in response to an initial exposure to an antigen. Following primary 
chlamydial infection, IgM titres increase within two-four weeks and are lost within two-six months 
[46,74,75]. Although the presence of anti-Ct IgM has been found in the sera of patients with 
suspected or proven Ct infection [76], its production is short-lived and only a small proportion of 
people infected by Ct have been shown to have IgM antibodies against Ct [77]. In a study by 
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Treharne et al., of the 35 women who were culture-positive for genital Ct infection, only 49% had 
detectable levels of IgM [45]. Because chlamydial infection is often asymptomatic, patients may not 
present until their levels of IgM have dropped below detectable levels [77]. Similarly, in patients 
with trachoma, Rahi et al. demonstrated that anti-chlamydial IgM correlates with clinical 
inflammation but elevated levels of IgM were rare, and in patients with severe trachoma no IgM was 
detected [78].For this reason, IgM is not a practical immunoglobulin to measure in serological 
assays. 
 
2.3.2 Immunoglobulin A (IgA) 
Immunoglobulin A (IgA) is induced by the presence of microbes and is produced by plasma cells [79]. 
It is the principal immunoglobulin of mucosal membranes, binding to polymeric receptors expressed 
by mucosal epithelial cells[80]. It is common in areas such as the urogenital tract and epithelium of 
the conjunctiva, both areas for which Ct exhibits tropism.  
Goodhew and colleagues used the MBA to measure the IgG and IgA immune responses to Pgp3 and 
CT694 in serum from children living in a trachoma-endemic region in Tanzania [64]. Fewer children 
had IgA responses than IgG responses, a difference more pronounced in older children; the 
measured levels of antibody were also lower which was expected, considering the lower levels of IgA 
in serum. Levels of IgA in the serum are related to total antigen dose, so the lower seroprevalence of 
IgA may indicate a lower infectious load [64]. In a study by Ghaem-Maghami and colleagues 
involving 113 patients from a genitourinary medicine (GUM) clinic, the IgA response was more 
prominent in patients with uncomplicated genital Ct infections compared to the groups with 
complications. Cervical IgA levels measured were 30-50 times higher than the levels in serum at 
baseline and both cervical and serum levels of IgA were higher than IgG levels [81]. The authors 
suggested that mucosal IgA may be indicative of recent infection, consistent with the plasma cells 
that are attracted to the site of infection, as shown in a study by Crowley-Nowick and colleagues 
[82]. Theoretically, IgA levels may provide evidence of a recent or ongoing infection [83]; however, 
due  to the low levels of IgA present in the blood, it seems unlikely that future serological assays will 
be targeted to detect it. If more accurate assays were developed using mucus or tears, an IgA-
specific assay may be worth revisiting. 
2.3.3 Immunoglobulin G (IgG) 
IgG is the most common type of antibody found in sera and represent approximately 75% of serum 
antibodies in humans[84]. IgG is produced by plasma B cells as part of the humoral immune 
response. Upon infection, IgG levels rise within six weeks and usually decrease slowly [85], making 
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them an ideal indicator of past infection; both trachoma and genital chlamydia studies suggest that 
IgG persists for months and possibly years after infection [64,86,87]. Numerous studies have used 
the presence of anti-Ct IgG as a proxy measure for the transmission of Ct infection in population-
based studies [27,59,92–101,60,102,103,64,66,72,88–91] as well as using it as a tool to estimate the 
proportion of disease sequelae attributable to Ct infection [104–110]. 
 
2.3.4 Summary of Isotype Selection 
Both IgM and IgA are of limited value in serological assays: IgM persists for only a short time, while 
IgA is scarce in serum samples [111]. IgG is the most practical antibody for serological studies as it is 
the most common immunoglobulin in serum[84] and persists following clearance of the bacterium. 
Compared to the other immunoglobulins mentioned above, IgG is the most commonly studied 
antibody in the serological studies presented in this review. 
 
 
  
59 
 
2.4 Antigen selection 
The core functionality of any serological test is provided by highly specific and highly avid 
interactions between a purified antibody and its corresponding antigen. Bound antigen is used as 
the instrument to detect circulating antibodies. These antibodies, if detected, are evidence of either 
a current or prior immune response to a Ct infection. 
Human immune responses are highly heterogeneous at both individual- and population-level and 
the appropriate selection of antigens is therefore a crucial determinant of the value of the 
serological test. The ideal antigen choice is one or more peptides or proteins that can be shown to 
induce strong immune responses in the majority of persons exposed to infection and do not cross 
react with other infectious agents. In this section we describe and assess the use of various Ct 
antigens throughout the literature. 
 
2.4.1 MOMP 
The major outer membrane protein (MOMP) is a 39kDa protein encoded by ORF CT681 [112]. It has 
long been recognised as an immunodominant protein [113], and although there is considerable 
amino acid homology between proteins encoded by Ct and Cp, it appears that cross-reaction 
between Cp anti-MOMP antibodies and anti-Ct MOMP antibodies is rare [114,115]. A study by 
Närvänen et al. [116] used Ct-synthetic peptides derived from the variable domain of MOMP in an 
ELISA to detect antibodies against C. trachomatis. Samples from children with Cp antibodies 
determined by MIF did not show any reactivity in the ELISA [116]. However, at least one study has 
shown conflicting results [117]. Recombinant MOMP antigen has been used by Mygind and 
colleagues to detect anti-Ct antibodies with a reported sensitivity of 80% and specificity of 91% [118] 
when compared to the MIF. When used to detect anti-Ct IgG in sera collected from patients with 
acute Ct urogenital infection determined by NAAT and healthy blood donors, sensitivity was 61% and 
specificity 84% [119]. This suggests that MOMP is not immunoreactive in all participants or there 
was insufficient time between infection and testing to detect MOMP-specific IgG, which typically 
increases six weeks-post infection [85]. An additional study by Morré  et al. compared three MOMP-
specific ELISAs against MIF [120]. Sera from 149 women were analysed for anti-Ct IgG and IgA. 
Cervical screens were PCR-tested with 43 women positive for Ct DNA, and 106 women were PCR-
negative. For all four assays, the overall seroprevalence rate was 40% for IgG and 7% for IgA. In 
infection-positive women, the IgG seroprevalence rates were two to three times higher than 
infection-negative women. Not all PCR-positive women were seropositive (74% sensitivity), nor were 
all PCR-negative women seronegative (75% specificity). An additional study by Miettinen and 
colleagues looked at the presence of MOMP-specific IgG and IgA in women with acute PID [113]. 
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When compared to culture, IgG antibodies had 53% sensitivity and 89% specificity. The authors note 
that anti-MOMP IgG was frequently detected in women with PID who were not culture-positive for 
Ct and among apparently healthy controls, most likely reflecting previous Ct infections. Similar 
results were seen in studies with patients with TFI and subfertility [118,121].  These studies highlight 
that infection is not an appropriate reference standard for a serological assay. 
  
2.4.2 Heat shock protein (hsp) 
Heat shock proteins are a family of highly-conserved proteins common to both prokaryotes and 
eukaryotes; bacterial hsps are highly immunogenic targets in humans [122].They are produced by 
cells in response to stressful conditions, such as changes in temperature or exposure to UV light. 
Three chlamydial hsps (chsp) have been studied. Chsp70 has been identified as an in-vitro target of 
neutralising antibodies [123–125] whilst chsp10 and chsp60 (which are co-expressed) [126] both 
have important roles in eliciting the host immune response [101,127]. These chsps are highly 
conserved in chlamydial species with greater than 95% within-genus protein-level homology [122]. 
They also have approximately 60% amino acid homology with hsps from other bacterial species and 
approximately 50% homology with human hsps [122]. Numerous studies have shown a relationship 
between serum IgG antibody response to hsp60 and the development of scarring sequelae following 
genital Ct infection [101,125,128–132]. A similar, albeit more limited, response is seen in cases of 
trachomatous scarring, with the presence of chsp-specific serum IgG associated with conjunctival 
scarring in a study of 296 children and adults in The Gambia by Peeling and colleagues [28]. In a 
study by Patten et al., IgA against chsp60 was significantly correlated with acute chlamydial 
infection, whilst anti-chsp60 IgG was significantly correlated with confirmed PID [133]. 
 
2.4.3 CT694 
CT694 is a small protein of approximately 40 kDa [112]. It is membrane-localised [134] and thought 
to play a role in host cell invasion or subversion of the immune system [135]. During early infection 
of the host cell, CT694 is secreted by the type III secretion system [136]. Early studies found that 
cross reactivity between antibodies against Ct and Cp lead to high rates of false positivity [137–139]. 
Although there are no known homologous sequences in the genomes of chlamydial species [136], 
some epitopes of CT694 may be structurally homologous to epitopes of other Gram-negative 
bacteria [30]. An MBA specific for CT694 and Pgp3 against C. trachomatis antigens has been 
developed by Goodhew et al., and used in numerous trachoma-endemic and previously-endemic 
areas [27,62,64,66,99,100]. CT694 has not been used in any single-antigen assays to-date as it may 
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produce variable results over time [64]. CT694 shows similar levels of sensitivity (91%) and specificity 
(98%) as Pgp3 when compared to PCR used as a reference standard. In post-MDA communities, and 
at an individual level, CT694 antibody response correlated well with both clinic signs of infection and 
PCR positivity [99]. In an additional study that measured antibodies against CT694 in children aged 1 
– 9 years of age at baseline and 6-months post-treatment, antibody levels decreased but none of the 
children reverted to seronegative status [64]. 
 
2.4.4 Pgp3 
Plasmid gene product 3 (Pgp3) is encoded by the Ct plasmid, which is not present in Cp, making the 
antibody response specific to Ct [140]. The Pgp3 antigen is recognised by specific IgG [141] and is 
thought to be the most immunodominant antigen encoded by the Ct [67]. Pgp3 has been used in 
numerous serological assays for both ocular [72,98,99,103,142] and genital Ct infection 
[57,102,143,144] as a proxy measure for the impact of intervention and screening programmes. 
Both commercial and in-house Pgp3-specific ELISAs have been developed, with varying sensitivity 
and specificity against MIF, clinical disease and infection as measured by PCR, depending on the 
population used to characterise the assays [57,103,143]. A Pgp3-specific in-house ELISA developed 
by Wills et al. was evaluated against three commercial ELISAs for IgG against MOMP and one MIF 
assay for IgG and IgM against EBs [57]. The sensitivity and specificity were determined using sera 
from both female and male GUM clinic-attendees who were diagnosed with Ct infection at least one 
month prior to serum collection as known positives (n=356) and archival sera from children which 
tested negative for Ct antibodies by MIF (n=740). The in-house Pgp3 assay was shown to have 
greater sensitivity (57.9% overall; 71.5% in women, 39.4% in men) than the other assays, and equal 
specificity (97.6% compared to 99%, 97.2% and 96% specificity of the three commercial assays). This 
assay has subsequently been used in several population-based studies in England, looking at the 
impact of the national chlamydia screening programme [102,144]. The authors have further 
developed the indirect ELISA to produce a double-antigen “sandwich” ELISA, with greater reported 
sensitivity (82.9% in women, 54.4% in men) [60]. 
A separate Pgp3-specific ELISA has been developed and used by Migchelsen and collaborators to 
measure seroprevalence in a trachoma context [103]. The authors also used the ELISA to determine 
the seroprevalence of Pgp3-specific antibodies in people of all ages in The Gambia [26]. One 
complication arising from this study is that, in populations where trachoma and genital Ct infection 
co-exist, it is not possible to distinguish between Pgp3-specific antibodies that result from ocular or 
genital infection[26]. A lateral flow assay has also been developed to detect Pgp3-specific antibodies 
and reports 96% sensitivity and 100% specificity with serum and 81.5% sensitivity and 100% 
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specificity for whole blood, when compared to the multiplex bead assay previously mentioned [142], 
although these results are not universal [145]. 
 
2.4.5 Novel Antigens 
Researchers continue to search for novel biomarkers of chlamydial infection and its scarring 
sequelae. Transcriptional and proteomic experiments have shown that several chlamydial proteins 
are differentially expressed and may be of diagnostic value in serology [70,146–148]. Two such 
proteins, TroA and HtrA, have recently been studied as biomarkers of Ct infection. TroA, encoded by 
CT067, is used in the iron-transport system and is present in infected cells, but less so in EBs [149]. 
HtrA, encoded by CT823, is required for bacterial replication [150] and increases during later 
developmental stages [151]. These recombinant proteins were used as antigens in ELISAs with sera 
from women with upper genital tract symptoms, patients from sexually transmitted infection (STI) 
clinics, blood donors and sexually inexperienced girls with sera being tested for IgG and IgA. IgA was 
infrequently detected in all patient groups. IgG against both TroA and HtrA was commonly detected 
in patients with perihepatitis caused by PID and in STI clinic-attendees. Absorbance measured for 
each antigen was low among blood donors and sexually-inexperienced girls, while absorbance was 
higher in patients with NAAT-confirmed infection or MIF-positive serology results. The authors 
suggest that TroA and HtrA antibodies appear following acute Ct infection, with the strongest 
response detected in upper genital tract infections and when there was evidence of previous or 
repeated exposure. Differential reactivity to TroA and HtrA, when combined with analyses of the 
antibodies mentioned above, may be of diagnostic value for reproductive tract complications. 
2.4.6 Summary 
Many of the assays used in serological surveys are based on the antibody response to one or two 
antigens, rather than detecting antibodies against a panel of antigens. A recent microarray  study 
showed that in adults with trachomatous scarring, antibodies could be detected against a diverse 
array of antigens, with eight antigens being associated with scarring [73], three of which were 
concordant with a prior analysis of the microarray [69]. ELISAs using the three concordant antigens 
were conducted for further analysis and, in an independent case-control study, two of these were 
not associated with scarring in adults. Pgp3 was used as a positive control and antibody responses 
against Pgp3 were strongly correlated between the microarray and ELISA. Recent research in the 
field of malaria has shown the value of multi-antigen panels, allowing researchers to determine 
whether or not an individual has been infected [152], how recently [153], and their immunity to re-
infection with Plasmodium falciparum [154]. Translating this technology to chlamydial antigens may 
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allow researchers to determine time since infection, number of infections, likelihood of sequelae, or 
perhaps even if antibodies were due to ocular or genital infection. 
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2.5 Data analysis and interpretation 
Population-based surveys have typically required an estimate of seroprevalence based on the 
proportion of seropositive and seronegative samples. Few of the current assays present a simple 
binary response, rather they are based on interpreting continuous quantitative data, and assigning it 
as positive or negative, based on some established cut-off threshold. It has been shown that the 
proportion considered seropositive can vary substantially depending on how the threshold is set, 
particularly if based on reference standards or “known positives” and “known negatives” [103,155]. 
A simple estimate of seroprevalence may be programmatically practical, but a greater understanding 
of the (FoI) as a proxy for incidence of infection in a population may be gained from using higher-
resolution methods, such as antibody acquisition models; analytical techniques are being explored 
to measure changes in seroprevalence without setting a threshold or using the quantitative data 
[156,157]. 
 
2.5.1 Methods for determination of thresholds 
Thresholds allow the continuous immunofluorescence values produced by an ELISA or MBA to be 
simplified to a binary or categorical variable. Establishing such thresholds, however, is not 
straightforward and several methods exist [103]. Mathematical methods can be used to determine 
threshold values from the distribution of continuous measurements. Internally calibrated 
approaches (i.e. using only data generated during the study), such as finite mixture modelling [155], 
expectation-maximisation algorithm [158] or even simply visually determining a threshold between 
positive and negatives [103] do not require externally calibrated samples- “known positives” and 
“known negatives” and have been shown to be reproducible and consistent [103,155,159–162]. 
Migchelsen et al. used four analytical methods to establish a threshold between seropositive and 
seronegative samples: three were internal reference threshold methods and the fourth was an ROC 
curve based on externally collected samples which was used to generate three thresholds based on 
varying levels of sensitivity and specificity [103]. The authors showed that the method selected for 
threshold specification can greatly affect the population prevalence estimates that are derived, 
making any comparison between studies more challenging. More traditional threshold methods 
require external references, making them subject to reference standard misclassification if the 
reference has been incorrectly classified using infection data [163,164]. 
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2.5.2 Finite Mixture Modelling (FMM) 
Techniques such as FMM can be used without reference standards to find a threshold between 
seropositive and seronegative samples[165]. In its simplest form, FMM sets two Gaussian 
distributions, a narrow one representing the assumed seronegative samples and a second broader 
one representing the assumed seropositive samples (Figure 2.6). Although the threshold is 
commonly defined as the mean of the seronegative samples plus three standard deviations (SD) 
[155,162,166], this can be made more specific by increasing the threshold to the mean plus four SD 
[26] or more sensitive by reducing the threshold to the mean plus two SD. Additionally, FMM does 
not require any reference standards, as the selection of the threshold depends only on the particular 
samples studied, making it an ideal method for setting a threshold in trachoma-endemic countries, 
where obtaining appropriate reference samples may be challenging [26,72,103]. Furthermore, this 
method could be used to identify patients from distinct populations such as ‘never infected’, 
‘vaccine-immunised’, and ‘infected’ [159]. FMM has recently been used to identify the number of 
component titre distributions in patients with laparoscopically-confirmed TFI or controls which  was 
then used to estimate the proportion of TFI attributable to genital Ct infection [167]. 
 
 
Figure 2.6. Finite mixture modelling composed of two individual Gaussian curves. X-axis measures 
optical density of ELISA results, while the Y-axis measures proportion of a sampled population. The 
blue line represents the narrow sub-population of assumed seronegative samples, while the pink 
line represents the wider sub-population of assumed seropositive samples. 
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2.5.3 ROC curves 
Receiver Operating Characteristics (ROC) curves have commonly been used to set thresholds in 
serology studies [57,99,112,143,168]. These curves plot assay sensitivity against one minus assay 
specificity for different threshold values of an assay [169], demonstrating the trade-off between the 
two characteristics. ROC curves allow for thresholds maximising  sensitivity, specificity or Youden’s J-
index, which balances sensitivity and specificity [170]. When test results with a high value are 
labelled as positive, increasing the threshold increases specificity whilst decreasing sensitivity, and 
vice versa for decreasing the threshold. The sensitivity and specificity displayed in the ROC curve rely 
on the accuracy of the reference assay and standards, highlighting concerns regarding reference 
standard misclassification [163]. Thresholds for Ct serology in trachoma studies have commonly 
been set using ROC curves; however, these have been based on a single set of reference standards 
from Tanzania [99]. The appropriateness of those standards for thresholds for sample sets from 
other countries appears weak, and potentially underestimates the seroprevalence [100]. 
 
2.5.4 Reference standards 
Finding an appropriate gold standard test for serology remains a challenge as does finding 
appropriate reference samples. Samples from patients with NAAT-confirmed infection, have 
previously been used to define “known positive” samples [57,99,143]; however, infection positivity 
is not an appropriate reference as patients may not yet have seroconverted or the infection 
detected was insufficient to induce antibody production [57]. Other serological techniques may also 
present challenges for confirming positivity. Western blotting and whole cell inclusion 
immunofluorescence (WIF) have been used to confirm negative samples but use of these techniques 
assumes their accuracy. WIF detects genus- and species-specific antigens potentially over-estimating 
the sensitivity of the assay [171], whilst western blots may not be an effective means of detecting 
antibodies against Pgp3 as antibody recognition is dependent on the native, trimeric conformation 
of the antibody; the gel electrophoresis step causes the trimeric Pgp3 to denature to a monomeric 
protein [172]. “Known positives” based on disease status may also be problematic, as some Ct-
associated outcomes, particularly those associated with the reproductive tract, are difficult to 
confirm due to invasive diagnostics [105] or may have more than one aetiology- for example PID 
may be due to genital infection with either Ct or Neisseria gonorrhoeae (NG). [35]. Similarly, serum 
samples from children or from non-trachoma endemic countries may be inappropriate for an assay 
designed for use with adults or in another country as non-specific antibodies arising from unrelated, 
prior infection, may result in different background ‘noise’ levels [173]. 
 
67 
 
2.5.5 Quantitative antibody levels 
New methods are being explored to use the quantitative serology data, rather than simply reducing 
it to a binary or categorical variable. In low transmission settings, these categorical outcomes may 
provide lower resolution information than quantitative levels [157]. Robust estimates of Ct 
transmission are required for the strategic planning, implementation and evaluation of 
interventions. Quantitative measures of antibodies may be better able to detect changes in high 
transmission areas and smaller and short-term trends in low-transmission populations 
[156,166,174]. 
 
2.5.6 Summary of analysis and interpretation of serological assays 
The current methods of determining known references are less than ideal, reflecting the challenges 
in selecting a ‘gold standard’ reference. Clinical signs and infection status are inappropriate 
reference standards and comparator serological assays must be carefully selected, taking into 
account their known limitations, which may exclude their use as gold standards for determining 
thresholds. Internally calibrated methods remove the need to use reference standards, and set 
thresholds specific to the samples being tested, eliminating the need to source standards specific to 
the population being studied. Finally, more robust analysis can be performed by using the 
quantitative data, providing a sensitive measure of transmission changes.  
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2.6 Serology used in population-based surveys 
The following section highlights some of the population-based studies using serological techniques 
to measure antibodies to Ct. Monitoring the prevalence of anti-Ct antibodies over time has strong 
potential as a surveillance tool in post-elimination settings as well as a tool to monitor and evaluate 
programme effectiveness [27,97,98]. It may also provide an understanding of what additional 
methods must be undertaken in regions where trachoma has not successfully been eliminated, 
despite MDA and other interventions[175]. Population-based serology studies are being explored as 
an alternative measure of prevalence of genital Ct infection, by providing a measure of age-specific 
cumulative incidence. Due to the often asymptomatic nature of urogenital chlamydia, ascertaining 
the prevalence of infection depends on the population tested [176]. Surveillance is commonly based 
on case reporting alone with no reporting on numbers of patients tested. Even when a testing 
denominator is known, positivity does not equal prevalence because the population tested has a 
different inherent risk than the general population [177]. 
In the first half of this section, we track the use of serology as a potential monitoring tool for 
trachoma programmes, whilst in the second half, we highlight serology’s use in population-based 
studies of genital Ct infection. 
A systematic literature search of online databases (PubMed, Cochrane, Lilacs, Scielo, Scopus and 
Web of Science) was conducted in June 2016, and updated in April 2018, following PRISMA 
guidelines [178] (Figure 2.7). The literature search used the following keywords: trachoma; 
Chlamydia trachomatis; chlamydia; prevalence; serology; epidemiology; diagnostics; genital; and 
ocular. The search was limited to peer-reviewed Chlamydia trachomatis serology papers published in 
English, French, Spanish and Dutch. The reference lists of retrieved articles were hand-searched to 
identify other studies that may have qualified for inclusion in the review. Studies were eligible for 
inclusion if they used population-based sampling, including if the participants were drawn from a 
sub-national geographic region of the country. No age limits were set on the population, as 
trachoma studies most commonly involve children, while genital chlamydia studies typically involve 
teenagers and adults. Participants must have provided a blood sample for analysis. No intervention 
or comparison groups were relevant to the inclusion criteria in this review. The outcome was the 
prevalence of antibodies against Ct, defined as the positive result of a serological assay by the study 
investigators. Studies were excluded if they were case-control studies or if samples were collected 
from patients at an STI or sexual health clinic or ophthalmology clinic (Figure 2.7) 
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Figure 2.7. Flow chart of publications identified and excluded for this review. 
2.6.1 Ocular Ct infection 
The following studies show the advance of serological techniques and their use from a simple measure of 
seroprevalence to proxy indicators of the transmission and FoI. We have included the demographic information and 
seroprevalence of each study in Table 2.1. 
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Table 2.1. Summary of ocular Ct studies 
Study Location Population (n) Sample Assay Antigen Immunoglobulin Reference standards Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Seropositivity 
(95% CI) 
Goodhew et 
al., 2012 [99] 
Tanzania Children aged 
1-9 years old 
from 4 
villages, post 
MDA (3 
rounds) 
(n=160) 
dried 
blood 
spots 
(DBS) 
in-house 
multiplex 
bead 
assay 
(MBA) 
Pgp3 IgG Ct-infection PCR-positive 
samples from Tanzanian 
children (n=11); assumed-
negative serum samples from 
US children (n=122) 
90.9% (62.2-
98.4); 10 of 
the 11 PCR 
positive DBS 
were also 
considered 
positive by 
MBA 
97.5% (93.0-
99.2); three 
assumed-
negative 
samples 
were 
positive for 
antibodies 
against Pgp3 
49.4% (41.7-
57.1) 
CT694 90.9% (62.2-
98.4); as 
above 
98.4% (94.2-
99.6); two 
assumed-
negative 
samples 
were 
positive for 
antibodies 
against 
CT694 
46.3% (38.7-
54.0) 
Goodhew et 
al., 2014 [64] 
Tanzania Children aged 
1-6 years old, 
baseline and 
DBS; 
swabs 
collected 
MBA Pgp3 IgG-baseline As in [99] 96.1% (87.0-
98.9); 49/51 
PCR-positive 
not possible 
to calculate 
from the 
63.9% (57.2-
70.2) for any 
IgG response 
71 
 
after one 
round MDA 
(n=208 tested 
for IgG at 
baseline; 
n=184 tested 
for IgA) 
for PCR 
test of 
infection 
IgG-post MDA samples 
tested positive 
for IgA 
antibody 
against Pgp3 
data 
provided 
no 
seroreversion 
IgA- baseline Ct-infection PCR-positive 
samples from Tanzanian 
children (n=10); assumed-
negative serum samples from 
US children (n=122) 
96.0% (86.5-
98.9); 48/50 
PCR-positive 
samples 
tested positive 
for IgA 
antibody 
against Pgp3 
53.2% (46.6-
60.1) for any 
IgA response 
IgA- post MDA no 
seroreversion 
CT694 IgG-baseline As in [99] 96.1% (87.0-
98.9); 49/51 
PCR-positive 
samples 
tested positive 
for IgA 
antibody 
against CT694 
no 
seroreversion 
IgG-post MDA no 
seroreversion 
IgA- baseline As for Pgp3-specific IgA 92.0% (81.2-
97.0); 46/50 
PCR-positive 
samples 
tested positive 
for IgA 
no 
seroreversion 
IgA- post MDA no 
seroreversion 
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antibody 
against CT694 
Martin et al., 
2015 [66] 
Tanzania Children aged 
1-6 years old 
from one 
village in a 
hyperendemic 
setting 
(n=208); 
children aged 
1-9 years old 
in 8 villages in 
a 
mesoendemic 
setting 
(n=987) and 
hypoendemic 
setting 
(n=680)  
DBS; 
swabs 
collected 
for PCR 
test of 
infection 
MBA Pgp3 IgG As in [99] Not described Not 
described 
Hyperendemic: 
62.0% (55.4-
68.6); 
Mesoendemic: 
32.7% (30.0-
36.0)  
Hypoendemic: 
21.2% (17.7-
24.6) 
CT694 Hyperendemic: 
61.5% (54.9-
68.1); 
Mesoendemic: 
34.0% (31.0-
37.0) 
Hypoendemic: 
18.4% (15.1-
21.7) 
Martin et al., 
2015 [27] 
Tanzania Participants of 
all ages in a 
community 
where 
trachoma was 
eliminated in 
2005 (n=571) 
DBS; 
swabs 
collected 
for PCR 
test of 
infection 
MBA Pgp3 IgG As in [99] Not described Not 
described 
33.8% (30.0-
37.8) 
seropositive 
against at least 
one antigen 
CT694 
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Pant et al., 
2016 [100] 
Nepal Children aged 
1-9 years old 
from 3 post-
MDA 
communities 
(n=68) 
DBS; 
swabs 
collected 
for PCR 
test of 
infection 
MBA Pgp3 IgG As in [99] Not described Not 
described 
1.50% (0.04-
7.9) 
CT694 0% (0-5.3) 
Zambrano et 
al., 2016 [98] 
Nepal Children aged 
1-4 and 9 
years from 15 
clusters across 
two districts 
(n=794) 
DBS; 
swabs 
collected 
for PCR 
test of 
infection 
MBA Pgp3 IgG As in [99] Not described Not 
described 
2.40% (1.5-3.7) 
Cocks et al., 
2016 [72] 
Fiji Children aged 
1-14 years in 
30 randomly-
selected 
villages in 
Western 
District 
(n=593) 
DBS; test 
for 
antibodie
s against 
Ct and 
Trepone
ma 
pallidum 
ELISA Pgp3 IgG Threshold set using finite 
mixture modelling; no 
reference standards required 
Not described Not 
described 
20.9% 17.8-
24.6) 
West et al., 
2018 [65] 
Kongwa, 
Tanzania 
Children aged 
1-9 years in 52 
communities 
enrolled in a 
clinical trial of 
surveillance 
studies; MDA 
DBS; 
swabs 
collected 
for PCR 
test of 
infection 
MBA Pgp3 IgG- baseline As in [99] 
 
As in [99] As in [99] 31.1% (29.1-
33.1) 
IgG- one year 
follow-up 
36.8% (34.8-
38.9) 
74 
 
completed 
2013 (n=2111) 
Butcher et al., 
2018 [189] 
Temotu 
and 
Rennell 
& 
Bellona, 
Solomon 
Islands 
Participants of 
all ages in 
villages that 
had received 
MDA six 
months prior 
(n=1,511); 
DBS collected 
from 1,499 
participants 
DBS; 
swabs 
collected 
for 
ddPCR 
test of 
infection 
ELISA Pgp3 IgG Threshold set using finite 
mixture modelling; no 
reference standards required 
Not described Not 
described 
42.2% (39.8-
44.8) 
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The first modern study by Goodhew et al., from Tanzania, described the prevalence of antibodies 
against Pgp3 and CT694 in dried blood spots (DBS) collected from children aged 1-9 years (n=160) 
from four villages that had received three rounds of azithromycin as part of an MDA campaign [99] 
(Table 2.1). Clinical signs were recorded, and conjunctival swabs were collected to test for infection 
using PCR. The level of antibodies against Pgp3 and CT694 were measured using an in-house MBA. 
The thresholds for seropositivity were set using ROC curves, determined using delinked serum 
samples from children from the United States as negative controls and dried blood spots from Ct-
infection PCR positive children from Tanzania as positive controls. Samples from Haitian children 
were also included as negative controls. The median fluorescence intensity minus background (MFI-
Bkgd) values for Pgp3- and CT694-antibodies measured in Tanzanian samples were higher than those 
from both the Haitian and American samples. The seroprevalence of antibodies against both Pgp3 
and CT694 was higher than the prevalence of either clinical signs or PCR positivity, with prevalence 
of antibodies against both antigens increasing with age. Older children were more likely to be 
seropositive but infection-negative and clinically-negative, suggesting past exposure with antibodies 
persisting after infection had been cleared, whilst most children under 3 years of age who were 
seropositive were also infection-positive or had clinical signs of trachoma.  Six children who had 
signs of trachoma failed to exhibit an antibody response to either Pgp3 or CT694, which may suggest 
that these children failed to develop an immune response to Ct infection or that the assay is not as 
sensitive as stated, when compared to clinical signs; it may also suggest that the grader mis-graded 
TF in these children, or that the follicles were of a different aetiology. At the community-level, 
villages with higher prevalence of trachoma also had higher prevalence of seropositivity for both 
Pgp3 and CT694.  
The second study, also from Tanzania and by Goodhew and colleagues, examined the change in 
antibody levels from baseline to six months after a round of MDA [64] (Table 2.1). Children aged 1-6 
years old (n=173) provided DBS at both baseline and 6 months post-MDA, in addition to undergoing 
a clinical examination and providing an eye swab for infection testing. Both IgG and IgA against Pgp3 
and CT694 were measured, as in [99].  At baseline, 47% of children were clinically positive for TF/TI, 
25% of children were infection-positive, IgG seroprevalence was 64% and IgA seroprevalence was 
53%. Both IgG and IgA against Ct-antigens increased with age. Data showed that although the levels 
of immunoglobulin (both IgG and IgA) decreased post-MDA, in no case did antibody levels decrease 
to a level where the sample would be considered negative. The mean decline in IgA antibody levels 
for antibody-positive children was greatest in the youngest children for both Pgp3 and CT694. No 
specific data were presented for IgG levels declining. The authors summarised that IgG may decline 
less significantly due to repeated Ct exposures, which induce memory B cells or plasma cells, as part 
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of the humoral immune response [179] whereas IgA immune response are shorter-lived particularly 
after mucosal infection with other organisms [79]. This would suggest that IgA is not a suitable target 
antibody for detection as it has a shorter duration than IgG. All IgA-positive samples were also IgG-
positive. However, of the samples positive for IgG against either antigen, 21% were seronegative for 
IgA against both antigens, 19% were seronegative for anti-Pgp3 IgA and 33% were seronegative for 
anti-CT694 IgA.  
An additional study, by Martin et al., in the same region of Tanzania used serological data from 
hyper-, meso-, and hypoendemic settings [180] to calculate the basic reproduction rate (R0) for each 
level of endemicity [66] (Table 2.2). Dried blood spots were collected from children aged 1-9 years 
(n=1208) and tested for antibodies against Pgp3 and CT694 using MBA. The R0 was calculated for 
each antigen in each endemicity assuming a constant (FoI) over age, which the authors caution may 
only hold true for young children, rather than the whole population (Table 2.1). When compared to 
R0 values calculated using maximum likelihood estimation [31], the values presented in Table 2.2 are 
much higher. 
Table 2.2. Calculated R0 in communities with three levels of endemicity in Tanzania, including 95% 
confidence interval (95% CI). Modified from [66].  
 R0 Pgp3 (95%CI) R0 CT694 (95% CI) 
Hyperendemic 29.4 (21.1-37.7) 28.3 (19.9-36.8) 
Mesoendemic 8.1 (6.3-10.0) 7.8 (6.9-9.6) 
Hypoendemic 2.8 (2.1-3.6) 2.8 (1.6-4.0) 
 
Age-specific seroprevalence appears to be a reasonable proxy for disease in determining 
transmission rates for trachoma in these communities. The higher R0 values seen in hyperendemic 
communities reflect a greater slope of the age seroprevalence curve and the prevalence of clinical 
signs. This study is a useful proof-of-concept that age-specific seroprevalence levels can be used as a 
proxy measure of the transmission of ocular Ct infection; it may be possible to use serology as an 
indicator of exposure. The authors caution that further studies are needed at district level, which is 
the functional unit for programmatic purposes, as well as studies with larger sample sizes, 
particularly for children at the youngest ages. 
A third Tanzanian study [27] took place in a community where ocular chlamydial infection was 
eliminated with MDA of azithromycin between 2000 and 2002; elimination was confirmed in 2005 
[181] (Table 2.1). The authors highlighted some of the challenges associated with ‘traditional’ 
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trachoma survey including inter-observer standardisation [16,180,182] and the likelihood that 
follicular conjunctivitis may be caused by non-chlamydial bacteria, particularly in post-MDA settings 
[183]. In this study, the authors use the age-specific seroprevalence of antibodies against Pgp3 and 
CT694 to model the FoI before and after MDA. All residents were invited to undergo eye 
examinations and had an ocular swab collected for PCR infection testing. DBS were collected from all 
participants (n=571), which were then tested for antibodies against Pgp3 and CT694 using the MBA. 
The overall prevalence of TF/TI was 4.6% (6.5% in 1-9-year olds) whilst 21.5% of the participants had 
signs of scarring trachoma. Seropositivity increased with age, such that by 40 years of age over 90% 
of participants were positive for antibodies to at least one antigen and 60% were positive for 
antibodies to both. Of 200 participants aged 1-9 years, only 3.5% had positive responses to one 
antigen. No infection was detected. Seroconversion rates (SCR) were modelled using a simple 
reversible catalytic model using maximum likelihood methods and the best fit was provided with a 
change in the FoI 10-15 years prior, which is consistent with MDA having occurred between 2000 
and 2002. The authors note that children born post-MDA have virtually no antibody response to 
Pgp3 or CT694, strongly suggesting a lack of Ct transmission, supported by the lack of clinical signs 
and infection. With regards to the few young children who have detectable levels of antibodies 
(3.5%), the authors suggest that these may be children who have acquired ocular or respiratory Ct-
infection at birth from a mother with genital Ct infection but also that the previously determined 
specificity of the assay is 96-98% and thus these may be false positives. The authors acknowledged 
that their study represents only one community with a small sample size and suggest that additional 
studies be done in other post-MDA regions before their findings can be generalised. An additional 
limitation of the study was the lack of pre-MDA serology data. These data would assist in 
determining antibody longevity and how titres change due to repeated exposure. However, as the 
scale of trachoma-intervention programmes has rapidly increased in recent years, few endemic-
populations are likely to have collected pre-MDA serological data; this should be considered for 
future intervention activities. 
 
A trachoma study by Pant and collaborators examined the seroprevalence of anti-Ct antibodies from 
68 children aged 1-9 years in three post-MDA communities in Nepal [100] (Table 2.1). Following 
three rounds of MDA in 2008-2010, the prevalence of TF remained relatively high in Achham district, 
and an additional round of MDA was carried out in 2014. The three villages were selected on their 
accessibility and convenience. In these three communities, participating children had their eyes 
examined for clinical signs of trachoma, an ocular swab was collected for NAAT and DBS collected. 
No clinical disease was detected, nor was any infection detected using PCR. Only one sample tested 
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positive for antibodies against Pgp3; none were positive for antibodies against CT694. Although it 
would not be surprising to see a low level of prevalence in these three communities, knowing that 
the prevalence of TF was above 5% as recently as two years before the study, and that serology 
measures cumulative exposure to Ct infection, it seems that unlikely that only 1 child would have 
antibodies against Ct.  No mention is made of the specificity of the assay. One possible explanation 
for this possible under-estimation of seroprevalence may be the threshold set for seropositivity. This 
threshold was set against ‘negative’ American serum samples and ‘positive’ Tanzanian DBS (outlined 
in [99]). If the baseline antibody level of the Tanzanian samples is greater than the baseline level of 
Nepalese samples – as seen in the original MBA study looking at data from Haiti and the USA – the 
Tanzanian threshold may not be appropriate for the Achham samples and positive samples may 
have been misclassified [184], highlighting the need for population-specific thresholds. The authors 
noted that the sample size is very small and thus the results should not be generalised but failed to 
address any concerns about sensitivity or specificity. 
 
A second, larger study [98] was conducted in Nepal by Zambrano and colleagues who looked at the 
prevalence of TF, infection and anti-Ct antibodies in children. They used the new WHO guidelines 
which recommend a population-based prevalence survey at least 2 years post-MDA measuring both 
TF and TT [185] (Table 2.1). The study took place in two districts which were at least two years post-
MDA. In low prevalence settings, the specificity of TF diagnosis is decreased, due to potential mis-
grading and the fact that follicular disease may have different aetiology [98]. It is thought that 
additional data, for example a test for infection or a test for antibodies against Ct, may provide 
additional evidence of elimination [185]. A random sampling of 15 clusters in two districts was 
selected in which 50 children aged 1 – 9 years had their eyes examined (n=2021). Selected children 
aged 1 – 4 and 9 years (n=794) had ocular swabs collected for infection testing and DBS collected for 
anti-Pgp3 IgG testing using the in-house MBA [99]. The prevalence of TF in surveyed children in both 
districts was ≤0.2%. Only one case of infection was detected. The data from this study suggest there 
was no ongoing transmission of ocular Ct infection in the two districts, with the low age-specific 
distribution suggesting the absence of exposure to Ct. The prevalence of anti-Ct antibodies was <5% 
and is similar to levels seen in a Tanzanian community where there was no infection and only low 
levels of trachoma (6.5% in 1-9 year olds) [27]. This study adds to the evidence for using serology as 
additional evidence of elimination. 
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A recent study in the South Pacific by Cocks and colleagues showed the potential for integrating 
surveys for NTDs; in particular yaws and trachoma, both of which are endemic in the region [72] 
(Table 2.1). A population-based survey was conducted in the Western Division of Fiji to measure the 
prevalence of yaws (infection with Treponema pallidum subsp. pertenue) and trachoma. A total of 30 
villages were selected randomly based on probability proportional to size, then 30 households in 
each village were selected. All children aged 1 – 14 years (n=607) in the selected households were 
invited to participate. Each child was examined for signs of yaws, and 593 children had a DBS 
collected to test for antibodies against T. pallidum and Ct. Samples were tested using the T. pallidum 
particle agglutination test and a Pgp3 ELISA [103] to detect antibodies against T. pallidum and Ct, 
respectively. No children were found to have yaws, nor were any children positive for antibodies 
against T. pallidum. Although children were not examined for signs of trachoma in this survey, a 
previous study found there to be a low prevalence (2.8%) of active trachoma in Western Division 
[186]. The current study found a seroprevalence of 20.9% in surveyed children. There was only a 
moderate increase in seropositivity with age, and many 1-year old children were already 
seropositive, suggesting that seroprevalence may reflect transmission in the birth canal. In such a 
situation, it would be useful to compare serological results with the prevalence of genital Ct 
infection as it has been previously noted that the prevalence of genital Ct-infections is high in Fiji 
[187]. This study shows that trachoma and yaws are not significant health problems in the region 
studied, though further studies are required to determine the prevalence of genital chlamydia. 
 
To measure the longevity of the immune response, West et al. collected DBS from children aged 1 – 
9 years in 52 communities in the Kongwa district of Tanzania [65] at two time points (Table 2.1). 
Kongwa was previously considered hyperendemic for trachoma, but following MDA, the prevalence 
of TF was <10% in 2013 [188]. At baseline, participating children had their eyes examined for signs of 
trachoma, swabs collected for infection testing and a DBS collected for antibody testing. One year 
later, additional DBS were collected; a total of 2,111 children had DBS at both time points. At 
baseline, the prevalence of TF was 5.2%, the prevalence of ocular Ct infection was 4.6% and 31.1% of 
children had antibodies against Pgp3, as measured using MBA. One year later, seroprevalence had 
increased to 36.8%. Of the children positive at baseline, 42 seroreverted to negative after one year, 
while of those negative at baseline, 143 seroconverted to positive. At baseline, the seroreverters had 
lower average MFI-Bkgd measurements than those who were remained positive at follow-up; at 
follow-up the seroreverters had significantly higher MFI-Bkgd measurements than those who were 
seronegative at both time points. Those who were seronegative at both time points were more likely 
to be 1- 3 years old, while those who were seropositive at both time points were more likely to be 
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aged 7-9 years, suggesting some stability in seropositivity for at least one year in low-prevalence 
communities. The authors suggested that the lack of age-specific increase in the prevalence of 
antibodies that is typically seen in low-endemic areas may be partially due to seroreversion rather 
than a lack of infection. 
 
Serology has been used in combination with ocular examination, photographic assessment and 
droplet digital PCR  to re-assess evidence of on-going  transmission of ocular Ct in two provinces 
(Temotu and Rennell & Bellona) in the Solomon Islands [189] (Table 2.1). An initial population-based 
prevalence survey found the prevalence of TF to be 26.1% in children 1-9 years old, although the 
prevalence of ocular Ct infection was very low (1.3% in 1-9 year olds) as was TI (0.2% in 1-9 year 
olds) and TT (0.1% in participants ≥15 years old) [190]; this was dissimilar what was seen in Kiribati, 
another South Pacific nation considered endemic for trachoma [191], and led researchers to 
question the underlying biology of TF in the Solomon Islands. Villages which had undergone mapping 
at baseline were e-surveyed: participants of all ages underwent ocular examination, had 
photographs taken of the everted right tarsal conjunctiva and dried blood spots were collected. 
Children aged 1-9 years had swabs taken of the everted right tarsal. Six months post-MDA, the 
prevalence of TF was 14.2%, the prevalence of infection remained low (1.8%), both in 1-9-year-old 
children and seroprevalence was 42.2% overall. Upon further analysis, ELISA results showed that an 
equal proportion (~80%) of TF-positive and TF-negative children lacked antibodies against Pgp3, 
unlike in other countries, where greater seropositivity was seen in TF-positive children, suggesting 
that trachoma was likely not the cause of the follicles. Additionally, the greatest increase in 
seroprevalence was seen in 16-25-year olds, suggesting sexually-acquired genital Ct infections. The 
few cases of conjunctival scarring detected in children were not typical of trachomatous scarring and 
were detected in children without any antibodies against Pgp3. The combined results of this study 
suggest that while there may be some Ct infection, likely both genital chlamydia and a small amount 
of ocular chlamydia, most of the cases of TF are likely due to an infection other than Ct. This study 
assessed age-specific infection prevalence, seroprevalence and clinical results together across the 
full age range of the population to provide further clarity as to what may be causing TF in this 
population.  
Summary of Seroprevalence Studies for Ocular Chlamydia 
Although only a handful of trachoma serology studies have been published thus far, there is clear 
development of the technique and its potential to measure the impact of elimination programmes. 
The majority of studies published to-date has been conducted using an in-house MBA. Use of a MBA 
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allows the assay to be expanded to include antigens from numerous infections and diseases, which 
could be used to monitor seroprevalence across programmes [99]. However, it has been noted that 
the cost of such technology may prevent it from being adopted in trachoma-endemic countries [97]. 
Enzyme-linked immunoassays (ELISA) or lateral flow assays may offer a more practical solution, and 
feasibility is currently being explored [26,103,142,145]. The manner in which an appropriate 
threshold is set may also present a problem and is not exclusive to trachoma serology. There is a lack 
of an appropriate reference standard and experts have yet to agree as to what samples may 
constitute a true positive or a true negative reference, with regards to infection and disease history. 
Trachoma serological studies to-date have been led by the Centres for Disease Control and 
Prevention (CDC) and have predominantly used samples from Tanzanian populations. The original 
study shows that the measured median antibody levels can vary between populations, particularly 
between endemic and non-endemic populations. This should be taken into account when assays are 
used to measure seroprevalence in other populations as thresholds set for one population may over- 
or under-estimate the seroprevalence in different populations. Population-specific thresholds should 
be set using in-country samples rather than relying on non-endemic samples. 
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2.6.2 Genital Ct infection 
In the section below, we have chosen to focus on the unique features of each study, which highlight 
the development of serology and its interpretation in studies focusing on genital chlamydia 
infection. We have included the demographic information and seroprevalence of each study in Table 
2.3.  
Early chlamydial serological studies were primarily concerned with determining the rate of exposure 
to ‘chlamydial agents’ [88]. Early diagnostic studies used cell-culturing systems [192], which required 
significant technical skill and expertise. The development of a MIF assay with whole EBs as antigen 
[44,193] was lauded as being sensitive, simple and much faster than traditional culture methods. It 
was used by Treharne and colleagues in a survey of serum samples from healthy blood donors from 
London (UK) which were screened for anti-chlamydial IgG and IgM [88] (Table 2.3). The MIF 
previously developed [39,194] divided ‘subgroup A Chlamydia’ into 14 subgroups. The modified 
protocol measured antibodies against four subgroups of chlamydia: serotypes responsible for i) 
hyperendemic trachoma, ii)“paratrachoma” [infection with C. pneumoniae],  iii) LGV, and iv)  human 
chlamydia infections “arising from birds or other animals”[44] [infection with C. psittaci]. The 
authors suggest that MIF positivity in women may correspond better with cell culturing than in men; 
however, the authors rightly pointed out the insensitivity of cell culture systems used in isolating 
chlamydia.  
 
In a retrospective study in Helsinki, Puolakkainen et al. [89] used CF to screen serum samples from 
60,000 patients of all ages with suspected viral infections for antibodies against primarily viral 
antigens, but also included group-specific CF antigen from Ct, serovar D (Table 2.3). It is important to 
note that the CF test detects antibodies against both C. psittaci and Cp as well as C. trachomatis. The 
authors also noted that the sensitivity of the CF assay is very much dependent on antibody titre, 
such that Ct infections seldom elicit a sufficiently strong antigenic response. The authors concluded 
that many of the seropositive patients had symptoms matching psittacosis, rather than genital 
chlamydia. 
 
A study by Jonsson and colleagues in Sweden was conducted to assess the prevalence of Ct using 
culture and serology and their relationship with possible risk factors [90] (Table 2.3). The population-
based study included the complete 19-, 21-, 23- and 25-year old cohorts of women registered in the 
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catchment area of Ålidhem health centre in Sweden. Participating women (n=529) completed a self-
administered questionnaire and had cervical and urethral specimens collected for culturing. Cultures 
were considered positive if cytoplasmic inclusion bodies were detected. Sera were collected from 
participants and MIF was used to detect antibodies against Cp, C. psittaci, and Ct. Only 15 women 
(2.8%) were culture-positive for Ct-infection, nine (60%) were also seropositive for antibodies 
against Ct. Overall, 130 women (24.6%) were seropositive for IgG against Ct. Antibodies against Cp 
were detected in 207 women (39.1%). There was no statistically significant difference in the 
prevalence of women with antibodies against both Ct and Cp compared to those with antibodies 
against only Ct (Χ2=2.65, p-value=0.1034). Of those women who were aware of a previous Ct 
infection, 60% were seropositive, compared to 17% seropositivity in women who were unaware of 
previous Ct infection. Commenting on the fact that only 60% of women were aware of a previous 
infection or a current infection, the authors stated that the exact conditions required for 
seroconversion following infection are unknown; nor is it known how long a detectable antibody 
response persists. The authors also commented on the specificity of MIF, having tested samples 
against three Chlamydia species. The authors felt that MIF was able to distinguish between 
antibodies against Ct and Cp without cross-reacting. The authors also found that reported PID was 
correlated with Ct-seropositivity. These findings agree with other studies [195–199] and suggest a 
possible role for Ct antibodies in determining the aetiology of female infertility. 
 
As part of a study into the prevalence of sexually transmitted diseases in Tamil Nadu, India, a 
population-based, probability proportional to size cluster survey was undertaken [200] (Table 2.3). 
Households in three districts were selected, with adults, both men and women, between 15-45 years 
invited to participate. Urine and blood samples were collected for PCR and IgM ELISA testing, 
respectively. A total of 1,849 samples were collected: 1,066 from females and 783 males. Sera were 
tested using a commercial IgM ELISA [201] with an overall seroprevalence of 2.4%. The 
seroprevalence in women was significantly higher (3.3%) than seroprevalence in men (1.3%) (Χ2, 
p<0.05). PCR positivity was lower, with only 16 of the 1,444 urine samples testing positive. The 
authors did not compare the proportion of PCR-positives to those that are seropositive, stating only 
that for participants in which results from the two tests are not concordant, this may be because 
infection have been resolved in a ‘substantial portion’ of IgM positive cases, or that infection had 
ascended to the upper genital tract. However, IgM is not a suitable marker for infection as the 
conditions under which seroconversion occurs or for how long IgM antibodies persist remain 
unclear. 
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A simple seroprevalence study was undertaken by Satpathy et al. to determine the prevalence of 
serovar-specific antibodies against Chlamydia in healthy male blood donors (n=844) in Delhi, India 
[92] (Table 2.3). Sera from 844 male blood donors were assayed using MIF to detect antibodies 
against pooled EBs from Ct (serovars A-C, D-K, L1-L3), C. psittaci and Cp. The authors state that 
antibodies against Ct, Cp, C. psittaci and C. pecorum are highly cross-reactive, with 47% of samples 
positive for antibodies against Ct serotypes A-C cross-reacting, 14% of samples positive for 
antibodies against Cp cross-reacting and 33% of samples positive for antibodies against C. psittaci 
cross-reacting. With many adolescents being infected with Cp as respiratory infections, screening of 
normal sera showed high positivity for antibodies against Chlamydia species, especially Cp [56]. The 
authors admitted that the high level of cross-reactivity between serovars and species made 
interpreting results for individual antigen groups challenging.  
 
In Denmark, women requesting abortion are tested for the presence of Ct and treated if positive. 
Baczynska and collaborators took the opportunity to test women requesting abortion to determine 
the prevalence of Mycoplasma genitalium (MG), M. hominis and Ct using culture and PCR, as well as 
the prevalence of antibodies against these bacteria using a MOMP-specific commercial ELISA 
(Medac)  [93] (Table 2.3). Endocervical swabs were collected for culturing M. hominis, and PCR 
detection of M. hominis [202], M. genitalium [203] and Ct. The authors compared the prevalence of 
Ct infection with the historical prevalence of infection (8-10%) [204] and noted that the apparent 
increase in prevalence may have been due to a true rise in prevalence or the use of improved 
diagnostic techniques. There was poor correlation between the detection of bacteria and the 
presence of specific antibodies. The authors suggested that PCR-positive/serology-negative women 
may have been sampled before IgG antibodies could be produced, whilst PCR-negative/serology-
positive women are likely to have experienced previous infection.  
 
To establish the prevalence of anti-Ct IgM and IgA in pregnant women in Venezuela, De Freitas and 
colleagues collected serum samples from 84 pregnant women, aged 14-43 years, attending 
University Hospital “Antonio Patricio de Alcalá” in Cumaná, Estado Sucre [94] (Table 2.3). A 
commercial ELISA assay (Diagnostic Automation INC) was used to detect IgA and IgM antibodies 
against a proprietary “LGV type 2 broadly reacting antigen” [205]. The authors stated that IgM is 
indicative of active, current infection, whilst IgA is indicative of early infection or secondary 
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infection. However, no samples were collected for culturing or NAAT, to confirm infection. Most 
patients, including those with either IgM or IgA, were asymptomatic. The authors found the 
prevalence of both antibodies to be greater in younger women (≤24 years of age).  
 
A retrospective population-based cross-sectional survey was conducted in England by Horner et al., 
in which 4,732 serum samples were assayed with an in-house IgG-specific Pgp3 ELISA [102] (Table 
2.3). The purpose of the study was to determine how seroprevalence of anti-Pgp3 antibodies 
changed over time and with age. Unlinked residual sera submitted to laboratories in England for 
routine microbiological or biochemical investigations were tested; sera known to have been 
collected from GUM clinics were excluded. Sera were limited to those collected between 1993 and 
2010 from women aged 17-24 years. Samples were tested for anti-Pgp3 IgG. The overall 
seroprevalence was 17.5%. Seroprevalence increased with age and with time, between 1993 and 
2002. In more recent years, age-standardised seroprevalence decreased in 17-22 year olds although 
this was only statistically significant in 20-22 year olds; there was no consistent trend in 
seroprevalence for 23-24 years olds in this time period. This may suggest that exposure to antibody-
inducing infection may have declined in the latter years, potentially in response to public health 
activities promoting increased screening for Ct [206] and safer sexual health practices [207]. 
 
In response to rising rates of reported genital Ct infection in the Netherlands, van Aar and colleagues 
explored the prevalence of IgG against Ct in the general population in 1996 and 2007 using samples 
from large population-based serum banks (Table 2.3). This study covered a time when enhanced 
efforts were undertaken to reduce the prevalence of genital infection [95]. Samples were used from 
cross-sectional population-based serosurveillance and were tested for IgG against a synthetic 
peptide from the immunodominant region of MOMP using a commercial ELISA (Medac). When 
compared to MIF, the sensitivity and specificity were 71.4% and 97.3%, respectively. A total of 3,716 
samples were tested: 1,579 from 1996 and 1,597 from 2007. In women, the seroprevalence 
increased with age, but not in men. In the younger women (15–24 years), the seroprevalence 
increased over time; for the older age group (25–39 years), the seroprevalence decreased. The 
authors noted the difficulty in interpreting results over time, as it is not possible to determine the 
precise time span between often-asymptomatic Ct infection and testing. Based on their findings, the 
authors hypothesised that anti-Ct antibodies may persist longer in women than in men, which may 
be due to a stronger immune response in the upper genital tract, in agreement with previous results 
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from Geisler et al. [208]. 
 
Ishak et al. undertook a retrospective study of serum samples from 1710 individuals in Brazil to 
determine the seroprevalence of antibodies against Ct [96] (Table 2.3). Samples were randomly 
selected from previous investigations at the Virus Laboratory of the Universidade Federal do Pará, 
which was established to determine the frequency of infectious agents in the Brazilian population. 
The samples had been collected from both urban and rural populations, including patients with 
respiratory illnesses, myocardial infarctions, villagers of Afro-descendant communities and 
indigenous groups; no further demographic information such as age or gender was included. A 
commercial indirect immunofluorescence assay (IIF; BioMerieux) was used to detect IgG and IgM 
against Ct serotype L2. Positive IIF samples were then tested for specific IgG at a dilution of 1:512. 
Samples positive for IgG at 1:512 were tested for specific IgM. A portion of the samples was tested 
with MIF against Cp and the serovars of Ct, including A, B, Ba, and C (associated with ocular Ct 
infection); D, E, F, G, H, I, J and K (associated with genital infection); and L1, L2 and L3 (associated 
with lymphogranuloma venereum [67]. Samples that tested positive against more than one serovar 
were serially titrated as the serovar with the highest titre is assumed to have caused the most recent 
infection. The authors believed the prevalence of antibodies against serotype A (15/237, 6.3%), a 
strain associated with trachoma, is an indication of endemic trachoma in the Amazon region of 
Brazil, dating back several centuries [209] and that trachoma has spread to urban and other non-
urban populations, despite a lack of patients with conjunctivitis or any other ocular disease 
resembling trachoma. 
 
Woodhall and colleagues used anonymised sera from a nationally representative health survey to 
measure the impact of a national programme of opportunistic screening for Ct in England [59] (Table 
2.3). Serum samples were collected as part of the Health Survey for England [22], which is a 
nationally representative health and lifestyle survey. Sera from participants aged 16-44 were tested 
using two in-house assays—an indirect ELISA and a double antigen “sandwich” ELISA to detect Pgp3-
specific IgG [57]. They found lower seroprevalence in men possibly due to lower sensitivity, as 
previously noted in [57]. Seroprevalence increased with age, peaking in 30-34 year old women and in 
35-39 year old men. These results may be comparable to those in [60], as both studies used the 
same in-house Pgp3-specific ELISA; however, the populations represented in each study are 
different. 
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Using stored sera from a New Zealand birth cohort, an in-house double antigen (sandwich) Pgp3-
specific ELISA was used by Horner and collaborators to measure IgG levels in participants at ages 26, 
32 and 38 years [60] (Table 2.3). The authors developed a double-antigen ELISA and measured the 
sensitivity and specificity against a previously used indirect ELISA [57], with sensitivity being defined 
as the proportion of individuals with past infections identified as positive by the assay [210]. The 
sensitivity was found to be 82.9% in samples from women who were NAAT-positive for Ct-infection 
at least one month before sample collection and 42.6% in men. Specificity was determined using 
NAAT-negative paediatric sera and was 97.8%. The assay was used to test stored serum samples 
from a New Zealand birth cohort study that had also collected information on self-reported Ct 
infection and sexual behaviour [211]. The double-antigen ELISA identified 1.75 times more the 
number of self-reported Ct cases than the previous indirect ELISA. IgG against Pgp3 persisted in most 
men (83.8%) and women (96.5%) who did not report a subsequent Ct diagnosis. The authors 
highlight the relatively high seroprevalence in women and men who did not report ever having been 
diagnosed with Ct infection, indicating that many infections were either undiagnosed or unreported. 
These samples were re-analysed using a Pgp3-specific double-antigen sandwich ELISA by Righarts et 
al. [212], with increased sensitivity compared to the indirect ELISA [60] (Table 2.3). In both women 
and men, incidence rates increased up to age 26 years, then decreased; seroprevalence increased 
with age. Incidence of chlamydia, measured either through self-reported diagnosis or serology, 
increased with number of sexual partners. In multivariate analysis, higher education was protective 
in women, while same-sex contact was found to be protective in males. This analysis showed that by 
age 38 years, 38.1% of women and 16.7% of men had ever self-reported a chlamydia diagnosis. Of 
these self-reported diagnoses, 80.0% of women and 29.0% of men had seroconverted by this age, 
which may suggest that males are less likely to mount an immunological response to Ct infection and 
also support the noted gender differences in the sensitivity of the assay as previously identified in 
[60]. 
 
MIF serology has been used to characterise past exposure to genital Ct infection and its association 
with developing uterine fibroids [213] (Table 2.3). Ct infection can stimulate an inflammatory 
immune response, which may lead to tissue repair and regeneration potentially causing uterine 
fibrosis [214,215]. African- American women participating in a prospective cohort study of fibroid 
development underwent transvaginal ultrasound and provided self-reported data and serum 
samples. Serum samples were tested using MIF for antibodies against whole EBs; researchers found 
seropositivity of 57%. In this study, seropositive women were more likely to be less educated, 
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parous, more likely to have ever smoked, to be heavier alcohol drinkers, to have an increased 
number of sexual partners, to have been younger at first sexual encounter and to have used depot 
medroxyprogesterone acetate (Depo-provera) as a method of birth control. Both primary (odds 
ratio=0.68) and multivariate analysis, adjusting for age (adjusted odds ratio=0.80), showed an 
inverse association between Ct seropositivity and fibroid prevalence in this population of African-
American women. This is contrary to findings in previous studies [216,217]; however, these studies 
looked at older women. The authors suggest that bacterial infection can lead to regression of some 
tumour types [218] either by enhancing anti-tumour effects or by enhancing immune surveillance, 
particularly if infection coincided with fibroid progression. The authors suggest further research 
using animal models is required to elucidate the association between genital chlamydia infection 
and uterine fibrosis.  
Frisse and collaborators used serology to ascertain the validity of self-reported Ct infection in a study 
of 409 English- or Spanish-speaking women between the ages of 18-35 years in the United States of 
America who were stopping contraceptives to attempt pregnancy [219] (Table 2.3). At baseline, a 
questionnaire was completed, a clinical examination was performed, and samples were collected for 
NAAT testing of NG, Ct, Trichomonas vaginalis (TV) and MG; blood samples were collected for 
serological testing for antibodies against Ct, TV and MG. As part of the medical questionnaire, 
participants were asked if they had ever been diagnosed by a health care professional as having had 
genital chlamydia. Blood samples were assayed using the modified MIF protocol [220]. Participants 
with either a serologically-confirmed or self-reported genital chlamydia were more likely to be 
younger, parous, non-white, unmarried, of lower socio-economic or educational level, uninsured, 
current drug user and former user of implant or Depo-Provera for contraception. There was only 
moderate agreement between self-reported Ct infection and seropositivity: 26% of participants 
reported a history of Ct infection, whereas 36% of participants were seropositive for antibodies 
against Ct. When comparing reported Ct infection to serological positivity, sensitivity was 52.1%, 
while specificity of self-reported infection to serology was 87.8%. Self-reporting was not found to be 
a valid marker of previous Ct infection, with only a moderate level of agreement between self-report 
and serology (Cohen’s kappa=0.42, p<0.001). The authors emphasized the need for assays with high 
validity for clinical assessment. 
 
Summary of Seroprevalence Studies for Genital Chlamydia 
From the surveys listed in the above section, it is clear that serological techniques have advanced 
and become more sensitive and specific. Due to the array of assays and antigens used, as well as 
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antibodies detected, it is not possible to compare results between most of the studies. MOMP and 
Pgp3 were the most common antigens, with IgG being the most common antibody detected. ELISAs, 
either commercially available or in-house, appear to be the assay of choice in the most recent 
studies, as they are robust, objective and are relatively high-throughput and can be automated. No 
multi-antigen assays were used in the studies described here, though they are currently being 
explored both with Ct-specific antigens and with a panel of antigens for STIs (T. Waterboer, personal 
communication). Numerous studies noted that participants were seropositive while not being aware 
of any prior Ct infections [60,90,219], and when participants of both genders were included, 
seroprevalence was higher in women than in men [88,200,212], which may be a result of greater 
sensitivity of the assay in women than in men [60,144,212] or that women experience a stronger 
immune reaction than men [95,212].  These could be further investigated by looking directly at the 
antibody levels present in males and females, rather than only seropositivity.
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Table 2.3. Summary of genital Ct studies  
Study Location Population (n) Sample Assay Antigen Immunoglobulin Seropositivity 
Darougar et al., 
1980 [88] 
London, UK Healthy female 
(n=150) and male 
(n=150) blood donors 
Serum modified MIF whole EBs: Ct 
serovars D-K 
IgG- females 3.3% (1.4-7.6) 
IgG- males 0.67% (0.12-3.7) 
IgM- females 0.67% (0.12-3.7) 
IgM- males 0% (0-2.5) 
Puolakkainen et 
al. , 1987 [89] 
Helsinki, Finland Hospital patients of all 
ages with suspected 
viral infections 
(n=60,000) 
Serum CF Lipopolysacchari
de 
complement 0.70% (0.64-
0.77) 
Jonsson et al., 
1995 [90] 
Ålidhem, Sweden 19-, 21-, 23- and 25-
year old cohorts of 
women (n=529) 
Cervical and 
urethral 
samples for 
culturing; 
serum 
MIF whole EBs: Ct 
serovars D-K 
IgG 22.4% (19.2-
26.0) 
Satpathy el al, 
2001 [92] 
Delhi, India Healthy male blood 
donors (n=844) 
Serum MIF EBs- Ct serovars 
A-C 
IgG 4.0% (2.9-5.6) 
EBs-Ct serovars 
D-K 
8.5% (6,8-10.7) 
EBs- Ct serovars 
L1-L3 
not specified 
EBs- Cp 42.8% (39.5-
46.1) 
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Joyee et al., 
2004 [200] 
Tamil Nadu, India Females (n=1,066) 
and males (n=783) 
aged 15-45 years, for 
a major study on 
community 
prevalence of sexually 
transmitted diseases 
(n=1849) 
Urine 
samples for 
PCR, blood 
samples for 
serology 
ELISA Inactivated EB 
Ct antigen 
IgM-females 3.3% (2.4-4.5) 
IgM-males 1.3% (0.7-2.3) 
Baczynska et 
al., 2008 [93] 
Denmark Women requesting 
abortion (n=102, 100 
women tested for 
antibodies) 
Swabs to 
detect 
infection 
(PCR); serum 
ELISA MOMP IgG 10.0% (5.5-17.4) 
Horner et al., 
2013 [102] 
England Unlinked residual 
samples from women, 
from Public Health 
England’s Sero-
Epidemiology Unit 
collection; samples 
from 1993-2010 
(n=4,732) 
Residual sera 
submitted to 
laboratories 
in England 
for routine 
microbiologi
cal or 
biochemical 
investigation
s 
in-house ELISA Pgp3 IgG 17.5% (16.4-
18.6) 
de Freitas et al., 
2006 [94] 
Cumaná, Estado 
Sucre, Venezuela 
Pregnant women, 14-
43 years old attending 
Serum IgM 65.5% (54.8-
74.8) 
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University Hospital 
“Antonio Patricio de 
Alcalá” (n=84) 
Diagnostic 
Automation 
INC ELISA 
"LGV type 2 
broadly reacting 
antigen" [94] 
IgA 19.1% (12.1-
28.7) 
van Aar et al., 
2014 [95] 
Netherlands Men and women 15-
39 years old 
participating in two 
population-based 
studies in 1996 and 
2007; the 2007 study 
oversampled in 
migrants and low 
immunisation 
communities 
Serum Medac 
quantitative 
CT IgG ELISA 
synthetic 
peptide from 
MOMP 
IgG-men (1996) 5.2% (3.8-6.9) 
IgG-women 
(1996) 
11.1% (9.2-13.6) 
IgG- men (2007) 6.2% (4.7-8.2) 
IgG- women 
(2007) 
8.5% (6.8-10.6) 
Ishak et al., 
2015 [96] 
Amazon region of 
Brazil 
Blood samples of 
individuals from ten 
human population 
groups (n=1,710; 237 
tested with MIF) 
Blood immunofluore
scence assay 
(Biomerieux) 
"serotype L2 of 
Ct" 
IgG 50.2% (47.9-
52.6) 
MIF EB IgG 8.7% (6.9-10.9) 
EB IgM 2.6% (1.6-3.7) 
Woodhall et al., 
2016 [144] 
England Nationally-
representative, 
population-based 
Health Survey for 
Residual 
blood 
in-house 
ELISAs- 
indirect and 
confirmatory, 
Pgp3 IgG -women 
(2010/2012) 
24.4% (22.0-
27.1) 
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England- men 
(n=1,119) and women 
(n=1,402) aged 16-44 
2010-2012; samples 
from women aged 16-
44 who participated in 
previous years (1994-
2012) (n=3,361) 
sandwich 
ELISA 
IgG- men 
(2010/2012) 
13.9% (11.8-
16.2) 
Horner et al., 
2016 [60] 
Dunedin, NZ Male and female 
participants in the 
Dunedin 
Multidisciplinary 
Health and 
Development Study; 
samples collected at 
26, 32 and 38 years of 
age (n=1,307) 
Stored 
serum 
in-house 
sandwich 
ELISA 
Pgp3 IgG- females 24.1% (20.2-
28.5) 
IgG- males 10.7% (8.1-13.9) 
Righarts et al., 
2017 [212] 
Dunedin, NZ Male (n= 448) and 
female (n=440) 
participants in the 
Dunedin 
Multidisciplinary 
Health and 
Stored 
serum 
Double-
antigen 
sandwich 
ELISA 
Pgp3 IgG- females (38 
years) 
26.8% (22.7-
31.1) 
IgG- males (38 
years) 
13.1% (10.1-
16.6) 
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Development Study at 
age 38 
Moore et al., 
2017 [213] 
Detroit, USA African-American 
females, aged 23-34 
years, participating in 
the SELF study 
[221](n=1,587) 
Serum MIF Whole EBs IgG 57.2% (54.7-
59.6) 
Frisse et al., 
2017 [219] 
USA English- or Spanish-
speaking women, 
aged 16-35, 
discontinuing 
contraceptive, with 
male partners and no 
known fertility 
problems (n=409) 
Blood 
sample 
Modified MIF 
[220] 
Whole EBs “anti- human 
globulin” 
35.7% (31.2-
40.5) 
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2.7 Discussion 
Currently, several in-house and commercial assays exist for detecting antibodies against Ct. Although 
many commonly detect antibodies against Pgp3, assays are also available for detecting antibodies 
against MOMP and CT694. Assays also exist in a variety of forms: ELISAs, lateral flow assays and MBA 
to detect IgG, IgA and IgM. MIF is considered to have fallen out of favour and the summary above 
shows studies with conflicting results regarding cross-reactivity between Ct and Cp [90,92]. To-date, 
there has been little head-to-head comparison of the many assays, though this has been identified 
as a research priority [I. Toskin, personal communication]. There is a need for a head-to-head 
comparison of assays using a common set of serum standards to establish appropriate thresholds, 
sensitivity and specificity in a diverse array of patient groups, both for trachoma as well as genital 
chlamydia. The intended use of the assay will also dictate the required sensitivity and specificity. For 
example, assays with a higher threshold will likely be more specific and have a higher positive 
predictive value (PPV), which is desirable in post-intervention trachoma settings as over-estimating 
seropositivity may lead to continued, unnecessary, MDA efforts. However, a test used to screen for 
the sequelae of genital Ct infection may be more sensitive to effectively determine patients in need 
of further diagnostics. 
The setting and use of the assay should be considered. For example, a Pgp3-based ELISA may be 
suitable for serosurveillance of anti-Ct antibodies to determine the cumulative incidence of genital 
Ct infections or as a proxy measure of the FoI in trachoma studies, whereas a multiplexed assay 
detecting antibodies against several immunogenic antigens would be useful in determining the risk 
of scarring sequelae, either of the tarsal conjunctiva or of the upper genital tract. 
Some of these issues regarding assay selection are highlighted in Figure 2.8. 
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Figure 2.8. Factors to consider when selecting an assay to detect antibodies against C. trachomatis. 
Much work remains to define the role of serology in public health, but it is clear that it has many 
exciting and potential applications. Further research should be focused on standardising assays using 
well-characterised serum samples. It is likely that different assays will be required for different 
purposes: an assay with a high sensitivity may be most appropriate as a screening tool, whilst one 
with a higher specificity may be more useful for measuring the sequelae of Ct infection or for 
estimating seroprevalence thresholds in trachoma elimination settings. The identification of 
immunogenic peptides specific for different disease conditions must be explored and a collection of 
well-characterised sera from a variety of sources is essential for future assay development and 
comparison between assays. Collaboration between academic research groups and public health 
bodies will be required to achieve this. 
From a practical point of view, future work should focus on what is feasible in a programmatic 
context for population-based studies, although this may result in using less-robust methods, namely, 
a single-antigen ELISA rather than a multiplex assay and internally referenced thresholds rather than 
those based on ROC curves referring to infection testing. This may also result in estimates of 
seroprevalence based on binary positive/negative, but research should continue to explore the 
possibilities using the numerical output from assays and explore changes in antibody levels across 
ages and over time following initial Ct infection.  
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For identifying antigens indicative of scarring sequelae, the use of proteomics to identify additional 
antigens is necessary. Multiplexed assays are likely to be of more use than single antigen assays, and 
the additional cost more acceptable in this context. Appropriate reference samples will be 
challenging due to the multiple aetiologies associated with scarring of the upper genital tract in 
women, and the invasive nature of current diagnostic assays.  
The production of a target product profile would help to guide further assay developments or 
refinements, while the development of a serum bank would facilitate comparison between assays 
and standardise assay evaluation. It is now up to international leaders in serology and chlamydia 
research to press for action. 
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Chapter 3- Development of a Pgp3-specific ELISA to measure 
antibodies against Ct using fingerprick dried blood spots  
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Summary 
In this chapter, the author outlines the development of a Pgp3-specific ELISA. The intent of this assay 
was to detect antibodies against a highly immunogenic protein expressed by the Ct plasmid. The 
assay was developed in collaboration with colleagues at the CDC, who developed a multiplex bead 
assay; the current assay requires highly specialised instrumentation which is often not available in 
trachoma-endemic populations. It was therefore the intent that this assay will be used ‘on-site’. 
Indeed, this ELISA has been used in The Gambia, Ghana and Malawi, in addition to being used to test 
a large array of samples assayed at LSHTM.  
This ELISA is based on the same Pgp3 from Ct serovar D-UW-3/.Cx used in the MBA [1] and in a 
whole-genome scale proteome assay [2]. It relies on five reference serum standards, with known 
levels of antibodies, measured in arbitrary units (u). The quantity of secondary antibody (HRP-
conjugated mouse anti-human IgG) and the incubation time of TMB were optimised.  
Significant quality control was undertaken. Reference standards were tested in triplicate with the 
standard deviation and coefficients of variation produced for each plate. As expected, the highest 
(1000u) and lowest (0 u and 50 u) standards showed more variation than those which fell in the 
linear range of the assay; a plate was permitted to have no more than one standard with a 
coefficient of variation greater than 15%. Standards were tracked across assays and inter-plate 
variation was less than 15%. 
The ELISA developed here forms the basis for the serological analyses presented in Chapters 4, 5 and 
6.  
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3.1 Purpose 
To develop a Pgp3-specific indirect ELISA based on dried blood spots. 
Previous work using serological assays to measure antibodies against Ct in trachoma-endemic 
populations was performed using a multiplex bead assay (MBA) and measured antibodies against 
Pgp3 and CT694[1,3,4]. This assay was financially unviable for this thesis research thus with 
collaborators from the CDC, the protocol for a Pgp3-specific ELSA was optimised by the author [5]. 
Antigen was kindly provided by Prof Guangming Zhong and the author expressed and purified the 
protein while at the CDC in March 2013.  
3.2 Background 
A multiplex bead was developed by collaborators at the CDC. This assay measured antibodies against 
Pgp3 and CT694 [1]. Due to changes in funding sources, the required platform and reagents were 
deemed to be too expensive for this thesis research. Additionally, if serology is to be used 
programmatically as part of trachoma elimination programmes, protocols should be developed that 
can be used in country, rather than relying on testing by international institutes. Therefore, a Pgp3-
specific assay was developed that was affordable [5] and could be run on an ELISA plate reader, 
which are available in many labs in trachoma-endemic countries [6].  
3.3 Methods 
The Pgp3-specific ELISA is an indirect ELISA. A detailed description of the finalised ELISA protocol is 
provided in Chapter 4. This chapter outlines the optimisation steps that were undertaken by the 
author prior to testing samples from the field. 
In brief, Pgp3, a Ct-specific antigen, was coated to microtitre plates at known concentrations. Pgp3 
was kindly provided by Professor Guangming Zhong of the Department of Microbiology and 
Immunology, University of Texas Health Science Center at San Antonio [2]. Protein was expressed 
and purified by the author while at the CDC in March 2013. Serum, in the form of eluted blood spots, 
was incubated so that anti-Pgp3 antibodies present in the serum bound to the antigen. Serum was 
then removed from the plate by washing with PBS + 0.3% v/v Tween-20 (PBSTw). An optimised 
concentration of horseradish peroxidase (HRP)-labelled mouse anti-human IgG(Fc)-HRP (Southern 
Biotech, Birmingham, USA) was applied and plates were incubated for one hour. Plates were washed 
to remove unbound antibodies. Fifty microliters of 3,3’,5,5’-tetramethylbenzidine (TMB) (KPL, 
Gaithersburg, USA) were added and the mixture was incubated in the dark for an optimised amount 
of time at room temperature. The colorimetric reaction was stopped with 50 μL 1N H2SO4 and 
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optical density was read at 450 nm (OD450) on a Spectramax M3 plate reader (Molecular Devices, 
Wokingham UK). Figure 3.1 shows a schematic of the indirect ELISA set-up. 
 
Figure 3.1. Visual representation of ELISA set-up (modified from www.abnova.com) Pgp3 is bound 
to the surface, where is capture anti-Pgp3 IgG present in the eluted dried blood spots bound to the 
antigen. The sample was then incubated with a secondary antibody which is conjugated with HRP 
and then TMB was added to produce a colourimetric reaction. 
 
3.3.1 Standards 
The standards were provided by the CDC and were prepared using serum from a Haitian donor, 
which tested at 2.0 OD450. This serum has arbitrarily been assigned 1000 arbitrary units (u). The 
serum was diluted using a normal human serum from a blood bank donor; dilutions were made to 
500 u, 200 u, and 50 u, while the normal serum itself was assigned 0 arbitrary units. 
3.3.2 Optimisation of anti-IgG concentration 
Anti-IgG bound to the IgG present in serum/samples, while the conjugated HRP (horseradish 
peroxidase) acted as an enzyme to oxidize TMB, causing a colourimetric change as the solution 
became blue. 
The standard protocol was followed for the Pgp3 ELISA, with the concentration of anti-IgG-HRP 
changed. The standard concentration used was 1:1000 (5.5ul in 5.5ml PBSTw). The first column of 
the plate was incubated with the standard concentration, while each subsequent column was 
incubated with a decreasing serial dilution, down to 1:2048k (Figure 3.2). Standards 1000 u, 200 u, 0 
u and Blank (PBSTw with milk) were tested in duplicate at each anti-IgG concentration, as shown 
below. TMB was incubated for 9 minutes before the colorimetric reaction was stopped with 50 μL 
1N H2SO4d before being read on the plate reader. 
Pgp3 
Anti‐IgG, HRP‐conjugated 
Antibody (IgG) 
TMB 
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Figure 3.2. Microtitre plate layout for optimisation of HRP-conjugated anti-human IgG used in a 
Pgp3-specific ELISA. Known standards were tested in duplicate at each of 12 concentrations of anti-
IgG. 
Results are shown in Figure 3.3 and Table 3.1. 
 
Figure 3.3. Serial dilution of HRP-conjugated mouse anti-human IgG. The standard concentration of 
anti-IgG is 1:1000 in PBS-Tween. Each well had 50μl of anti-IgG dilution applied, before incubating at 
room temperature for one hour.  
 
Table 3.1 shows the ratios between standards. Looking at the ratios of the standards in the linear 
range (1:16k to 1:256k), the greatest difference between high and low is seen at 1:64k 
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Table 3.1. Ratio of OD values between standards measured to optimise the concentration of anti-
IgG 
    
 
1000 u/0 u 1000 u/200 u 200 u/0 u 
1:16k 1.74 1.14 1.52 
1:32k 2.13 1.28 1.62 
1:64k 2.00 1.24 1.61 
1:128k 1.93 1.23 1.57 
1:256k 1.84 1.21 1.52 
 
3.3.3 Optimisation of TMB incubation time 
As for the optimisation of anti-IgG concentration, the high-, mid-, and low- standards and blanks 
were tested in duplicate, at an anti-IgG concentration of 1:32k, while the incubation time increased 
from 4 to 15 minutes. 
 
Figure 3.4. Microtitre plate layout for optimisation of TMB incubation time used in a Pgp3-specific 
ELISA. Known standards were tested in duplicate at each of 12 lengths of time for incubation with 
TMB. 
 
Results are shown in Figure 3.5 and Table 3.2 
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Figure 3.5. Optimisation of TMB incubation time for Pgp3-specific ELISA. Standard protocol was for 
four minutes incubation with TMB, however the best ratios between standards were at 9 minutes 
incubation. 
 
Table 3.2 shows the ratios between standards. The highest ratios between standards occurred after 
9 minutes of incubation. 
Table 3.2. Ratio of OD450 values between standards measured to optimise the incubation time with 
TMB. 
Ratios 1000 u/200 u 200 u/0 u 1000 u/0 u 
4 mins 2.98 2.94 5.04 
5 mins 3.04 3.02 5.16 
6 mins 3.27 3.28 5.88 
7 mins 3.40 3.14 5.87 
8 mins 3.46 3.53 5.40 
9 mins 3.78 3.64 6.12 
10 mins 3.64 3.35 5.59 
11 mins 3.49 3.14 5.32 
12 mins 3.17 3.27 5.03 
13 mins 2.88 3.51 5.00 
14 mins 2.07 3.45 4.77 
15 mins 2.01 3.72 4.51 
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Based on the optimisation steps, the finalised protocol was to dilute anti-IgG to 1:32k and to 
incubate with TMB for 9 minutes. 
 
3.3.4 Quality Control 
The five serum controls (1000 u, 500 u, 200 u, 50 u, 0 u) were tested in triplicate and the mean 
values for each plate were tracked across each sample set and inter-plate variation was less than 
15% across all plates in each sample set tested. A plate was permitted to have no more than one 
control with>15% variation from the sample set mean for that control; if a plate had two or more 
controls with values more than 15% greater or lesser than the sample set mean, the plate was re-
run.  
Less than 5% of plates were re-run due to variation. Additionally, the standards were run in triplicate 
and the coefficient of variation was calculated; in all cases this was less than 10% as shown in Figure 
6. Coefficients of variation are less in the linear range of the standard curve; values that fall toward 
the top or bottom of the curve tend to have a higher amount of error because of both the assay’s 
and plate reader’s limits. 
 
 
Figure 3.6. Standard curve produced from 5 standards at arbitrary units (1000 u, 500 u, 200 u, 50 u 
and 0 u). Error bars denote the coefficient of variation of the OD450 values for each standard assayed 
in triplicate.  
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Summary 
In the previous chapter, the development of a Pgp3-specific ELISA was explained. In this chapter, the 
narrative focuses on appropriate means to set thresholds for positivity. 
Both ELISAs and multiplex bead assays (MBA) produce continuous numerical readings as output for 
samples tested; ELISA results are measured in optical density (OD), while MBA results are median 
fluorescence intensity minus background (MFI-bkgd). It is appealing to assign a classification 
(seropositive or seronegative) to each sample assayed. This is challenging however, as the range of 
output value in the seropositive and seronegative populations will overlap to a lesser or greater 
extent.  
In the following study, the author explored techniques of setting thresholds using data three sets of 
samples, each one from a population that was being assessed following trachoma prevalence 
surveys. 
Previous studies have relied on Receive Operator Characteristic (ROC) curves; however, this runs the 
risk of reference standard misclassification if the references are inappropriately selected. To reduce 
the risk of setting an inappropriate seropositivity threshold, the author explored possible solutions 
based solely on data generated during the study. The author included a method based on visual 
examination of the data, to demonstrate that the threshold based on human pattern recognition is 
consistent with those set by more complex modelling techniques such as finite mixture modelling 
and expectation-maximisation algorithm. All three of these methods established similar thresholds.  
In comparison, three thresholds were set using an ROC curve. Thresholds were set to maximise 
Youden’s J-index to balance sensitivity and specificity, the second and third were set for high 
sensitivity (minimum 80%) and high specificity (minimum 98%), respectively. The thresholds set 
using the ROC curve were higher than those set using internal calibration and therefore were more 
specific but had reduced sensitivity.  
Setting appropriate thresholds allows for the estimation of seroprevalence, a measure that can be 
easily understood. Furthermore, additional analyses, such as estimating changes in force of infection 
(FoI) over time depend on age-specific seroprevalence estimates. In a longitudinal context, however, 
the change in seroprevalence over time, from a survey prior to the commencement of MDA 
compared to a follow-up or monitoring survey may be of greater importance than the absolute 
seroprevalence. 
 
The subsequent chapter relies on the seroprevalence estimates established in this chapter to 
estimate changes in the FoI in two districts in The Gambia. 
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Abstract
Background
Efforts are underway to eliminate trachoma as a public health problem by 2020. Program-
matic guidelines are based on clinical signs that correlate poorly with Chlamydia trachomatis
(Ct) infection in post-treatment and low-endemicity settings. Age-specific seroprevalence
of anti Ct Pgp3 antibodies has been proposed as an alternative indicator of the need for
intervention. To standardise the use of these tools, it is necessary to develop an analytical
approach that performs reproducibly both within and between studies.
Methodology
Dried blood spots were collected in 2014 from children aged 1–9 years in Laos (n = 952) and
Uganda (n = 2700) and from people aged 1–90 years in The Gambia (n = 1868). Anti-Pgp3
antibodies were detected by ELISA. A number of visual and statistical analytical approaches
for defining serological status were compared.
Principal Findings
Seroprevalence was estimated at 11.3% (Laos), 13.4% (Uganda) and 29.3% (The Gambia)
by visual inspection of the inflection point. The expectation-maximisation algorithm esti-
mated seroprevalence at 10.4% (Laos), 24.3% (Uganda) and 29.3% (The Gambia). Finite
mixture model estimates were 15.6% (Laos), 17.1% (Uganda) and 26.2% (The Gambia).
Receiver operating characteristic (ROC) curve analysis using a threshold calibrated against
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external reference specimens estimated the seroprevalence at 6.7% (Laos), 6.8% (Uganda)
and 20.9% (The Gambia) when the threshold was set to optimise Youden’s J index. The
ROC curve analysis was found to estimate seroprevalence at lower levels than estimates
based on thresholds established using internal reference data. Thresholds defined
using internal reference threshold methods did not vary substantially between population
samples.
Conclusions
Internally calibrated approaches to threshold specification are reproducible and consistent
and thus have advantages over methods that require external calibrators. We propose that
future serological analyses in trachoma use a finite mixture model or expectation-maximisa-
tion algorithm as a means of setting the threshold for ELISA data. This will facilitate standar-
disation and harmonisation between studies and eliminate the need to establish and
maintain a global calibration standard.
Author Summary
Trachoma is caused by the bacterium Chlamydia trachomatis (Ct). Individuals who have
previously been infected with Ct carry specific antibodies in their blood. Recent studies
have suggested that these antibodies may be a good way to estimate the intensity of trans-
mission of this bacterium in a population. Among people who do have antibodies (seropo-
sitives) there is variation in the amount that is detectable in their blood. Some people have
such low levels that differentiating them from those who don’t have antibodies (seronega-
tives) is challenging. We used a new test for Ct antibodies on blood specimens from three
countries. Our test worked extremely well, giving reproducible results when we tested the
same samples multiple times. We compared four different methods for setting the posi-
tion of the threshold line between seronegatives and seropositives. The estimated trans-
mission intensity in each country varied depending on the threshold method used, but
two methods that used statistical modelling algorithms to define the two groups per-
formed consistently across all three countries’ samples. We recommend that future studies
should consider adopting the statistical modelling approaches, as they are objective tests
that require no reference material and allow for standardisation between studies.
Introduction
Trachoma is caused by ocular infection with the bacterium Chlamydia trachomatis (Ct) [1]. It
is the leading infectious cause of blindness worldwide [2]. The World Health Organization
(WHO) estimates that over 200 million people in 42 countries are at risk from trachoma blind-
ness [3], that 1.4 million people experience moderate to severe visual impairment because of
the disease and that of these, around 450,000 have been irreversibly blinded [4].
The most commonly used system for estimating the prevalence of trachoma uses the WHO
simplified grading system [5] of clinical signs of trachoma. These include trachomatous
inflammation—follicular (TF), trachomatous inflammation—intense (TI) and trachomatous
trichiasis (TT), which is the rubbing of the eyelashes against the globe of the eye. WHO guide-
lines recommend the SAFE strategy to combat trachoma: Surgery to treat trichiasis, annual
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mass-drug administration (MDA) of Antibiotics to treat Ct infection and Facial cleanliness
and Environmental improvement to reduce transmission. Implementation of the SAFE strat-
egy and cessation of MDA depends on the prevalence of TF in children aged 1–9 years. Con-
cerns have been raised about the appropriateness of having treatment guidelines based on
clinical signs such as TF and TI. In some low endemicity [6,7] and post-MDA settings [8,9],
both TF and TI correlate poorly with the prevalence of Ct infection and both clinical signs are
sometimes associated with bacteria other than Ct [10,11].
Tests for infection have been suggested as possible tools for trachoma control programmes.
Numerous nucleic acid-amplification tests (NAATs) have been developed, including the
adapted use of commercial kits originally designed for diagnosing genitourinary Ct infections
[12–16]. NAATs have been shown to be cost-effective in some settings [17] but concerns have
been raised that the per-sample cost of NAATs can be too much for national eye health pro-
grammes in countries where trachoma remains a problem [18]. The cost of specialist devices
and platforms for deploying NAATs can also be prohibitive.
Serology has been suggested as a possible alternative to clinical signs and infection testing,
as it indicates the cumulative exposure to Ct [19,20], with the potential to assess the impact of
intervention efforts [21]. By monitoring the exposure to Ct of the youngest age groups, born
after implementation of MDA, serology may prove useful for confirming that transmission
has been interrupted [22].
Serology has recently been used in several studies [19,20,22–24], three of which have taken
place in districts that have completed three or more rounds of MDA [22–24]. These studies
have used the multiplex bead array platform (Bio-rad, Hercules, California) to detect antibod-
ies against Pgp3 and CT694, antigens thought to be highly immunogenic [25]. Because this
platform is costly, technically complex and unlikely to be found in most laboratories in
resource-limited regions, alternative, simpler methods of antibody detection have been pro-
posed [22,26].
To make serological testing more widely accessible, the Pgp3/CT694 assay used in previous
studies [19,20,22–24] has been adapted for use in a simple Pgp3-specific enzyme-linked immu-
nosorbent assay (ELISA). Pgp3 is a Ct-specific 84kDa heterotrimeric protein [27] and is recog-
nised by specific IgG [28]. It is thought to be the most immunodominant of the proteins
encoded by the Ct plasmid that is unique to Ct [29].
ELISAs are routinely used to detect specific IgG in dried blood spots [30–34]. ELISA data,
measured as optical density (OD) is quantitative and continuous. It is desirable to be able to
assign a classification (seronegative, seropositive) to each sample, but this can be challenging
because the distributions of OD values in the negative and positive populations may overlap to
a greater or lesser extent [34]. The aim of this study was to determine the most appropriate
method for setting the threshold for positivity as well as to determine the usefulness of an anti-
Pgp3-specific ELISA for identifying communities in which the transmission of ocular Ct has
been interrupted. We tested dried blood spots collected as part of trachoma surveys in three
countries: Laos, Uganda and The Gambia. We evaluated the age-specific seroprevalence using
four methods and compared the resulting estimates of prevalence of seropositivity based on
six possible thresholds. We discuss the merits of the different methods in the context of pro-
grammes seeking to monitor the elimination of trachoma as a public health problem.
Methods and Materials
Ethics statement
This study was conducted in accordance with the Declaration of Helsinki. This study received
approval from the Ethics Committee of the London School of Hygiene & Tropical Medicine
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(LSHTM; references 6319, 6514, 8355, 8918), UK; the Ministry of Health of the Lao People’s
Democratic Republic (No:48 NIOPH/NECHR), Ugandan Ministry of Health (VCD-IRC/053)
and The Gambia government/Medical Research Council (MRC) Joint Ethics Committee
(SCC1408v2). In all countries, a local health official explained the study to each head of house-
hold, answered any questions and explained the written consent form before requesting their
agreement and signature. Written (thumbprint or signature) consent was obtained from each
participant or the parent or guardian of each child under 18 who participated; assent was
sought from children aged 12–17.
Clinical assessment
Trachoma graders were trained according to the Global Trachoma Mapping Project (GTMP)
protocols and were required to score a minimum kappa of 0.7 for the diagnosis of TF in an
inter-grader agreement test with 50 eyes of 50 children [35,36]. The samples in Laos were col-
lected in November 2014 as part of a follow-up study to the GTMP work completed there.
Three districts in three regions were selected based on baseline trachoma survey findings
that indicated potential ‘hot spots’ [37]. From these three regions, all children aged 1–9 in
selected villages were invited to participate. Trachoma elimination programmes have never
been undertaken in Laos. In Uganda, samples were collected as part of a trachoma impact sur-
vey in May 2014, following three years (2010–2012) of implementation of the A, F and E com-
ponents of the SAFE strategy in two regions (Pader and Agogo). Prior to MDA, trachoma was
considered highly endemic in these regions, although no data is publicly available. This study
was a population based prevalence survey, which used a two stage sampling strategy; villages
were selected with probability proportional to size, and households were randomly selected
within each selected village based on a household list produced by the village chief and local
health officials.
All children aged 1–9 years in the selected households were invited to participate. In The
Gambia, a population based prevalence survey using a two stage sampling strategy was under-
taken in February-March 2014; villages were selected with probability proportional to size, and
households were randomly selected within each selected village based on a household list pro-
duced by the village chief and local health officials. One region, Lower River Region (LRR) had
undergone three rounds of annual (2007–2009) MDA for trachoma, while the other, Upper
River Region (URR), has never had trachoma elimination activities because trachoma has not
been of a sufficiently high prevalence to justify implementation. All members of randomly
selected households were invited to participate, regardless of age.
After informed consent was obtained, a trachoma grader examined both eyes for signs of
trachoma using a binocular loupe (2.5×) and a torch. The grader changed gloves between each
participant to minimise the risk of carry-over contamination. Antibiotics were provided to
individuals with evidence of active trachoma and/or the affected household, according to each
country’s national policy.
Blood collection
Each participant had a finger-prick blood sample collected onto filter paper (Trop-Bio Pty,
Townsville, Australia), using a sterile single-use lancet (BD Microtrainer, Dublin, Ireland).
Each filter paper had six extensions, calibrated to absorb 10 μL of blood. Samples were air-
dried for approximately five hours and then stored in individual Whirl-Pak plastic bags
(Nasco, Modesto, California) with desiccant sachets (Whatman, Little Chalfont, UK) before
being stored at -20˚C.
All samples were shipped to LSHTM for testing.
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ELISA analysis of anti-Ct-Pgp3 antibodies
Dried blood spots (DBS) were tested for antibodies against Pgp3. One whole filter paper exten-
sion per sample was eluted in 250 μL PBS + 0.3% v/v Tween-20 (PBSTw) (Sigma-Aldrich, Dor-
set, UK)+ 5% w/v non-fat milk powder (PBSTw-milk) (AppliChem, Maryland Heights, USA)
overnight at 4˚C. Immulon 2HB 96-well plates (VWR International, Lutterworth, UK) were
coated with recombinant Pgp3 protein [19] overnight at 4˚C (25ng per well in 0.1M sodium
carbonate buffer, pH 9.6). Plates were washed with PBSTw to remove unbound protein,
blocked with 100 μL PBSTw for 1 hour at 4˚C and washed two times. Control sera with known
ratios of Pgp3 antibodies (1000 units, 500 units, 200 units, 50 units and negative control
serum) and a blank consisting of PBSTw-milk were run on every plate. All samples and con-
trols were tested in triplicate at a 1:50 dilution in PBSTw-milk. After 2 hours incubation on an
orbital shaker at room temperature, wells were washed 5 times and 50 μL of an HRP-labelled
mouse anti-human IgG(Fc)-HRP (Southern Biotech, Birmingham, USA) diluted 1:32,000 was
added. Plates were incubated for 1 hour on an orbital plate shaker at room temperature then
washed 5 times to remove unbound antibody. Fifty microliters of TMB (KPL, Gaithersburg,
USA) was added and the mixture was incubated in the dark for 9 minutes at room tempera-
ture. The reaction was stopped with 50 μL 1N H2SO4 and optical density was read at 450 nm
(OD450) on a Spectramax M3 plate reader (Molecular Devices, Wokingham UK). Readings
were corrected for background by subtracting the average absorbance of three blank wells con-
taining no serum, using Softmax Pro5 software (Molecular Devices, Wokingham UK).
Data analysis
Blanked OD450 values for samples and controls were normalised by dividing the mean of the
three wells against the mean of 200 unit control included on each plate. This was done for each
plate.
Data analysis for ELISA was performed separately and masked to the results of demo-
graphic and clinical information. Statistical analysis was carried out using R [38].
Defining seropositivity
We used four different methods for establishing a threshold for seropositivity: visual inspec-
tion of the inflection point (VIP), a finite mixture model (FMM) [39], the expectation-maximi-
sation algorithm (EM) [40] and an receiver operating characteristic (ROC) curve based on
previously-assayed dried blood spots from children in Tanzania [19]. There are as yet no
accepted guidelines as to what level of sensitivity or specificity is required of a serological test;
thus we referred to a previously published template [18] and established three possible thresh-
olds from the ROC curve: one maximising specificity, one with a sensitivity greater than 80%
[18] and one optimising the balance between sensitivity and specificity, by maximising You-
den’s J-index [41].
Visual inflection point (VIP)
We asked 12 arbitrarily selected non-laboratory staff and students at LSHTM to visually exam-
ine a simple plot of the sorted OD450 data curves and determine the inflection point for each
sample set. For this exercise, we defined the inflection point as the point on the data curve
where the curve changes from predominantly horizontal to predominantly vertical. The 12
values were then averaged to determine the threshold and standard deviations (SDs) were
calculated.
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Finite mixture model (FMM)
A finite mixture model [42] was used to classify the samples as seropositive or seronegative
based on normalised OD450 values. The data were fitted using maximum likelihood methods,
estimating the distribution parameters for each classification group (seropositive or seronega-
tive) as well as the proportion of samples in each category to fit the overall distribution of
results [34,43,44]. The threshold for seropositivity was then defined as the mean of the Gauss-
ian distribution of the seronegative population plus three SDs of the seronegative population
[44,45]. FMM was performed on each set of samples, based on country of origin.
Expectation-maximisation algorithm (EM)
The expectation-maximisation algorithm is similar to FMM in that it classifies samples based
on population parameters. It relies on the Bayesian information criterion to select an appropri-
ate model. EM is an iterative optimization method to estimate some unknown parameter [40],
in this case the threshold between seropositive and seronegative, given the number of clusters
and the normalised OD450 values. EM estimates where to set the threshold while maximising
the likelihood of each sample parameter [40]. Using the ‘mclust’ package in R, parameters
were set to specify a univariate model with equal variance between 2 clusters [46].
Receiver operating characteristics (ROC) Curve
Serum samples from 122 children from the United States and blood spots from 11 Ct-specific
PCR-positive children from Tanzania were used to make the original ROC curve [19]. A second
set of 124 Tanzanian dried blood spots were assayed using the multiplex bead array and dichot-
omised based on the original threshold. These samples were then re-tested with the ELISA and
the data from this assay were used to generate the ROC curve used in this manuscript. The R
package ‘Epi’ [47] was used to generate three different thresholds: the first of which maximises
Youden’s J-index to balance sensitivity and specificity [41], the second and third were set for
high sensitivity (minimum 80%) and high specificity (minimum 98%), respectively.
Statistical analysis
The prevalence of signs of trachoma and the exact binomial confidence intervals were calcu-
lated using the R ‘Stats’ package [38]. Due to the low prevalence of clinical signs, Fisher’s exact
test was used to test for association [48].
Seroprevalence in each population was calculated using each of six thresholds. We also
examined the relationship between the clinical data and serological data. Due to the low preva-
lence of clinical signs, data for clinical signs were pooled across all three studies.
Results
Clinical assessment
We recruited 978 Laotian children aged 1–9 years from the provinces of Attapu (n = 406),
Houaphan (n = 307) and Phoˆngsali (n = 239). Twenty-six participants had incomplete clinical
records and were excluded from further study. The proportions of the sample populations
who were male were 52.9%, 60.3% and 54.0% in Attapu, Houaphan and Phoˆngsali, respec-
tively. The median age was five years in all three provinces. Fifteen cases of TF were diagnosed
(1.6%, exact binomial CI = 0.9%-2.6%), 11 of which were bilateral cases (Table 1). No cases of
TI were observed. There was a higher prevalence of TF in Attapu (2.7%, 11/406) than in either
Houaphan (1.0%, 3/307) or Phoˆngsali (0.4%, 1/239), (p = 0.02) using Fisher’s exact test [49]
with the Simes-Bonferroni correction for multiple tests [50].
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2738 children aged 1–9 years were recruited in the Ugandan districts of Agogo (n = 1388,
49.7% male) and Pader (n = 1377, 50.4% male). 38 participants were missing complete clinical
data and were excluded from further study. The median age was five years in both districts. 93
cases of TF were diagnosed (3.4%, exact binomial CI = 2.8%-4.2%), 44 of which were bilateral.
Eight cases of TI were diagnosed (0.3%, exact binomial CI = 0.1%-0.6%) (Table 1). No other
clinical signs were assessed. The prevalence of TF was 3.2% in Agogo and 3.7% in Pader. There
was no significant difference between the estimated prevalence of TF in the two districts (TF:
Χ2 = 0.429, p = 0.5125; TI: Χ2 = 3.1566, p = 0.07562).
In the Gambia we recruited participants of all ages from the Lower River Region (LRR,
n = 1028, 41.9% male) and Upper River Region (URR, n = 840, 42.5% male). Ten participants
were excluded from the study because they either declined to provide a blood sample (n = 1)
or had incomplete clinical data (n = 9). The median age in LRR was 13 years (range: 1–88) and
11 years in URR (range: 1–90). Overall, 30 cases of TF were diagnosed (1.6%, exact binomial
CI = 1.1%-2.3%), 19 of which were bilateral (Table 1). There were 25 cases of TF in children
aged 1–9 years. Four cases of TI were observed (0.2%, exact binomial CI = 0.06%-0.6%), two of
which were in children aged 1–9 years. Examiners found 78 cases of TS (4.2%, exact binomial
CI = 3.3%-5.2%), eight cases of TT (0.4%, exact binomial CI = 0.2%-0.8%) and one case of CO
(0.05%, exact binomial CI = 0.001%-0.3%). There was a significant difference in TS prevalence
between the URR and LRR (Χ2 = 7.2435, p = 0.007116); the difference in TF prevalence was
non-significant (Χ2 = 0.1343, p = 0.714). The prevalence of TI, TT and CO in this population
was too low for meaningful statistical analysis.
Observed frequencies of clinical signs of trachoma in the various samples are summarised
in Table 1. A more detailed description, including prevalence by age and gender, is presented
in Supplementary S1, S2 and S3 Tables.
Serological analysis
The five serum controls were tested in triplicate and the mean values for each plate were
tracked across each sample set. The coefficient of variation was less than 10% in each of the
Table 1. Distribution of participants in three trachoma studies, including clinical signs.
Country Province N TF TI TS TT CO
Laos* 952 15 (1.6%) - - - -
Attapu 406 (42.6%) 11 (2.7%) - - - -
Houaphan 307 (32.2%) 3 (1.0%) - - - -
Phoˆngsali 239 (25.1%) 1 (0.4%) - - - -
Uganda* 2700 93 (3.4%) 8 (0.3%) - - -
Agogo 1353 (50.1%) 43 (3.2%) 1 (0.1%) - - -
Pader 1347 (49.9%) 50 (3.7%) 7 (0.5%) - - -
The Gambia* 1868 30 (1.6%) 4 (0.2%) 78 (4.2%) 8 (0.4%) 1 (0.1%)
All LRR 1028 (55.0%) 18 (1.8%) 4 (0.4%) 55 (5.4%) 7 (0.7%) 1 (0.1%)
URR 840 (45.0%) 12 (1.4%) 0 (0.0%) 23 (2.7%) 1 (0.1%) 0 (0.0%)
1–9 year olds LRR 383 (20.5%) 14 (3.7%) 2 (0.5%) 1 (0.3%) 0 (0.0%) 0 (0.0%)
URR 359 (19.2%) 11 (3.1%) 0 (0.0%) 6 (1.7%) 0 (0.0%) 0 (0.0%)
10 year olds LRR 645 (34.5%) 4 (0.6%) 2 (0.3%) 54 (8.45) 7 (1.1%) 1 (0.2%)
URR 481 (25.7%) 1 (0.2%) 0 (0.0%) 17 (2.6%) 1 (0.2%) 0 (0.0%)
‘*’ Age range in Laotian and Ugandan participants was 1–9 years; age range in all Gambian participants was 1–90 years; ‘-’ not assessed.
N = Normal; F = trachomatous inflammation, follicular; TI = trachomatous inflammation-intense; TS = trachomatous scarring; TT = trachomatous trichiasis;
CO = corneal opacity.LRR = Lower River Region; URR = Upper River Region.
doi:10.1371/journal.pntd.0005230.t001
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three replicates of each control specimen. Inter-plate variation of controls was less than 15%
across all plates in each sample set as shown in Table 2. A plate was permitted to have no more
than one control with>15% variation from the sample set mean for that control; if a plate had
two or more controls with values more than 15% greater or lesser than the sample set mean,
the plate was re-run. Less than 5% of plates were re-run due to this. Table 2 shows the mean
values and the accepted 15% range for the five controls.
The sample set for each country was tested separately. Each plate showed a large but nar-
rowly distributed proportion of low-OD specimens, with a smaller proportion of higher-OD
specimens. Fig 1 shows typical results from an ELISA plate. In all three sample sets, density
data peak around 0.25 OD450; this can be seen in centre panels B in Figs 2, 3 and 4.
Visual inflection point (VIP)
The leftmost panels of Figs 2A, 3A and 4A were shown to 12 people, each of whom was asked
to determine each graph’s point of inflection. The mean of the inflection points was calculated
for each sample set and the SD and range were calculated. For Laos, the mean threshold was
calculated to be 0.619 OD450 (SD = 8.2%, range 0.485–0.750); for Uganda the threshold was
calculated to be 0.641 OD450 (SD = 14.4%, range 0.410–0.795) and for The Gambia the thresh-
old was calculated to be 0.579 OD450 (SD = 7.3%, range 0.402–0.673). The sorted normalised
OD450 values are shown in Figs 2A, 3A and 4A (leftmost panels), alongside marginal density
distribution plots of the same values (centre panels) and boxplots (rightmost panels) showing
the range of the 12 threshold values that were selected by the volunteers.
Table 2. The mean OD450 value for the five controls sera used on the ELISA plates. Mean, SD and coefficient of variation for the five serum standards
run alongside the Ugandan samples across 24 plates. Data were similar for the standards run alongside the Laotian and Gambian samples.
Control serum Mean SD Coefficient of variation Upper limit (mean+15%) Lower limit (mean-15%)
1000u 2.01 OD450 0.13 OD450 6.47% 2.26 OD450 1.75 OD450
500u 1.74 OD450 0.13 OD450 7.38% 2.00 OD450 1.49 OD450
200u 1.11 OD450 0.10 OD450 9.46% 1.31 OD450 0.90 OD450
50u 0.63 OD450 0.06 OD450 9.45% 0.74 OD450 0.51 OD450
Negative control serum 0.28 OD450 0.02 OD450 8.51% 0.32 OD450 0.23 OD450
doi:10.1371/journal.pntd.0005230.t002
Fig 1. Typical results from an ELISA plate. Specimens are sorted by increasing OD values and are each
represented by a separate diamond. The mean values of the controls tested in triplicate are represented by
coloured horizontal lines.
doi:10.1371/journal.pntd.0005230.g001
Seropositivity Thresholds in Trachoma Studies
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005230 January 18, 2017 8 / 19
Finite mixture model (FMM)
A finite mixture model was tested on all three sample sets, setting the threshold at the mean of
the seronegative population plus three SDs [44,45]. The thresholds were set at 0.6963 OD450,
0.5537 OD450 and 0.6725 OD450 for Laos, Uganda and The Gambia, respectively. The FMMs
are shown in Figs 2B, 3B and 4B.
Fig 2. Threshold values for Laos (1–9 year olds) data. Panel A shows the threshold as determined by visual inflection point analysis by 12 volunteer
individuals. Volunteers had access only to the data presented in the leftmost panels, which shows sorted OD450 values. The second panel in A shows the
density of data points for the sample while the third panel in A shows a box and whisker plots with the range of threshold values that were selected by the
12 volunteers. The box shows the inter-quartile range for the values, with the thick horizontal line marking the median value. Whiskers show the upper
quartile plus 1.5x the range between the 1st and 3rd quartiles. Outliers are shown by an open circle. Panel B shows the thresholds set by the finite mixture
model and expectation-maximisation algorithm. Density plots of normalised OD values and thresholds, showing the FMM estimated distribution functions
of ‘seronegative’ specimens in red and ‘seropositive’ specimens in green. Vertical lines show the threshold values determined by the finite mixture model
(right-most line) and the expectation-maximisation algorithm (left-most lines). Panel C compares the threshold specifications by four different methods.
Scatterplots show the normalised and sorted OD450 values with horizontal lines marking the thresholds specified by VIP (OD450 = 0.619), EM (OD450 =
0.650), FMM (OD450 = 0.696), ROC curve maximising Youden’s J-index (OD450 = 0.870), ROC curve with sensitivity >80% (OD450 = 0.968) and ROC
curve with specificity>98% (OD450 = 1.951).
doi:10.1371/journal.pntd.0005230.g002
Fig 3. Threshold values for Uganda (1–9 year olds) data. Panel A shows the threshold as determined by visual inflection point analysis by 12
volunteer individuals, as detailed in Fig 2. Panel B shows the thresholds set by the finite mixture model and expectation-maximisation algorithm, as
described in Fig 2. Panel C compares the threshold specifications by four different methods. Scatterplots show the normalised and sorted OD450 values
with horizontal lines marking the thresholds specified by VIP (OD450 = 0.641), EM (OD450 = 0.450), FMM (OD450 = 0.554), ROC curve maximising
Youden’s J-index (OD450 = 0.870), ROC curve with sensitivity >80% (OD450 = 0.968) and ROC curve with specificity>98% (OD450 = 1.951).
doi:10.1371/journal.pntd.0005230.g003
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Expectation-maximisation algorithm (EM)
An EM model was fitted to all three sample sets, specifying parameters for a univariate model
with equal variance between 2 clusters [45]. The thresholds were set at 0.65 OD450, 0.45 OD450
and 0.57 OD450 for Laos, Uganda and The Gambia, respectively. The EM-derived threshold
selections are shown in Figs 2B, 3B and 4B.
ROC curve
Using the ROC curve to set a threshold optimising Youden’s J-index to balance specificity and
sensitivity resulted in a threshold at 0.870 OD450 (specificity 93.9%, sensitivity 91.4%). Setting
the threshold to ensure a minimum sensitivity of 80% resulted in a threshold at 0.965 OD450
(specificity 94.8%, sensitivity 89.4%). Setting the threshold for a minimum specificity of 98%
resulted in a threshold at 1.951 OD450 (specificity 98.28%, sensitivity 43.94%). Fig 5 shows the
ROC curve with the three thresholds identified.
Panels 2C, 3C and 4C show all six thresholds in relation to the normalised OD450 data in
each of the three populations. The internally calibrated methods (i.e., VIP, FMM and EM)
were reasonably conformant and appeared to favour threshold placements that were substan-
tially lower than those set by the ROC, which is calibrated with Tanzanian specimens, even
when a higher sensitivity (i.e., lower threshold value) test was specified in the ROC analysis. As
a consequence of this, the seroprevalence estimates that were determined by VIP, EM and
FMM were similar to one another, while the seroprevalence estimates set by any of the ROC
curve thresholds were much lower in all three populations (Table 3).
Seroprevalence for each sample set, using the six different thresholds were calculated, along
with 95% confidence intervals. As the threshold increases in value, fewer specimens are classi-
fied as being seropositive, decreasing the seroprevalence. The seroprevalence for each sample
set at each threshold is presented in Table 3. Seroprevalence for each country by sex, region
and age is provided in Supplementary S4, S5 and S6 Tables.
Table 4 presents the proportion of seropositive samples by clinical grade, as estimated by
each threshold specification. Due to the relatively low prevalence of all clinical signs, preva-
lence values for have been pooled.
Fig 4. Threshold values for Gambian (all ages) data. Panel A shows the threshold as determined by visual inflection point analysis by 12 volunteer
individuals, as detailed above in Fig 2. Panel B shows the thresholds set by the finite mixture model and expectation-maximisation algorithm, as
described in Fig 2. Panel C compares the threshold specifications by four different methods. Scatterplots show the normalised and sorted OD450 values
with horizontal lines marking the thresholds specified by VIP (OD450 = 0.570), EM (OD450 = 0.570), FMM (OD450 = 0.672), ROC curve maximising
Youden’s J-index (OD450 = 0.870), ROC curve with sensitivity >80% (OD450 = 0.968) and ROC curve with specificity>98% (OD450 = 1.951). Note that the
thresholds set by VIP and EM are identical (0.570 OD450) and overlap on the graph.
doi:10.1371/journal.pntd.0005230.g004
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Discussion
Several previous studies have used anti-Pgp3-specific ELISAs to test for genital chlamydial
infection [21,51–54] but only one [55] has used the method for the detection of antibodies
against ocular chlamydial infection. In this study, we used an ELISA test to detect IgG antibod-
ies specific to the Ct protein Pgp3 in studies with large sample sizes from three countries. To
Table 3. Seroprevalence by Country, as estimated using alternate threshold specification methods.
Threshold % (95% Confidence Interval)
VIP EM FMM ROC Youden’s
J-index
ROC Sensitivity
>80%
ROC
Specificity > 98%
N OD = 0.619 OD = 0.65 OD = 0.696 OD = 0.870 OD = 0.965 OD = 1.951
Laos (1–9 year olds) 952 11.3% (9.4–13.6) 10.4% (8.6–12.6) 15.6% (13.3–18.0) 6.7% (5.3–8.6) 6.3% (4.9–8.1) 1.1% (0.5–2.0)
OD = 0.641 OD = 0.45 OD = 0.5537
Uganda (1–9 year olds) 2700 13.4% (12.1–14.7) 24.3% (22.7–26.0) 17.1% (16.0–18.9) 6.8% (5.9–7.8) 5.3% (4.5–6.2) 0.3% (0.1–0.8)
OD = 0.57 OD = 0.57 OD = 0.672
The Gambia (all ages) 1868 29.3% (27.3–31.5) 29.3% (27.3–31.5) 26.2% (24.2–28.2) 20.9% (19.1–22.9) 18.9% (17.2–20.8) 3.3% (2.6–4.3)
Seroprevalence by Gender, Region and Age is provided in Supplementary S2 Table.
VIP = visual inflection point; EM = expectation-maximisation algorithm; FMM = finite mixture model; ROC = receiver-operating characteristic curve.
OD = optical density, measured at 450 nm.
doi:10.1371/journal.pntd.0005230.t003
Fig 5. Receiver Operating Characteristic (ROC) curve showing the relationship between sensitivity,
specificity and threshold values. Three different thresholds were specified to meet the requirements of: (A)
an assay (threshold = 0.870 OD450, specificity = 93.9%, sensitivity = 91.4%, PPV = 89.8%, NPV = 92.4%) with
balanced sensitivity and specificity (maximal Youden’s J value); (B) an assay (threshold = 0.965 OD450,
specificity 94.8%, sensitivity = 89.4%) with at least 80% sensitivity and (C) an assay (threshold = 1.951 OD450,
specificity = 98.3%, sensitivity = 43.9%, PPV = 66.7%, NPV = 95.0%) with at least 98% specificity.
doi:10.1371/journal.pntd.0005230.g005
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date, this is the largest study to measure antibodies to Ct in trachoma-endemic populations
and the first to look at populations from more than one country, including East Africa, West
Africa and Southeast Asia. We have shown that within and between runs there is a low coeffi-
cient of variation in the assay and that the bimodal data distribution of normalised OD450 val-
ues in those samples reflects that which would be expected in populations where a minority of
individuals are seropositive and where there is a broad range of antibody titres in the seroposi-
tive sub-population. This is best observed in the data from the Gambia (Fig 4), where we
included adults in the sample and where the more substantial seropositive sub-population can
be accounted for by both sexually transmitted Ct infection and the formerly high level of
endemicity of trachoma in the Gambia.
Clinical specimens without any Ct-specific IgG still have some degree of baseline reactivity
in ELISA tests because of non-specific binding of irrelevant antibodies. There is also sub-
stantial between-specimen variation in seropositives, which reflects natural variation in the
antibody titre. The potential for there being substantial overlap between the seronegative speci-
mens with high baselines and the seropositives with low anti-Pgp3 antibody titres means that
it can be difficult to differentiate between the two groups.
There is very little published information on the prevalence of trachoma in Laos and
Uganda [56], but on the evidence of our analysis, clinical signs of disease are rare and the levels
of seropositivity appear to be comparable to those in The Gambia, where elimination has been
declared. We have no data on the prevalence of Ct infection in the communities in Laos and
Uganda, nor is there any longitudinal data to monitor changes in antibody levels following
documented infection. Numerous studies have looked at the prevalence of ocular Ct infection
in The Gambia and shown it to be negligible [7,57,58]. All the populations we studied have
received MDA and we did not screen a population with higher prevalence levels. Further
research in meso- and hyper-endemic populations will be needed in order to assess the utility
of this method in other settings.
We have shown how the method that is selected for the statistical interpretation of ELISA
data (with particular regard to the method of threshold specification) can greatly change the
population prevalence estimates that are derived. Methods that indicate the use of a higher
threshold value are likely to be more specific and have a higher positive predictive value
Table 4. Proportion of participants with different phenotypes considered seropositive by each threshold.
No sign of trachoma according to the WHO simplified
system
Active trachoma Scarring trachoma
% (95% confidence interval) (TF and/or TI) (TS and/or TT and/or CO)
1–9 year-olds 10+ year-olds % (95%CI) % (95%CI)
N across all studies 4268 964 150 87
VIP* 11.1 (10.2–12.1) 42.8 (39.7–46.0) 9.3 (5.4–15.5) 70.1 (59.2–79.2)
EM* 17.1 (16.0–18.2) 42.8 (39.7–46.0) 12 (7.5–18.6) 70.1 (59.2–79.2)
FMM* 12.7 (11.8–13.8) 38.5 (35.4–41.6) 16.7 (11.3–23.8) 69 (58.0–78.2)
J-index 5.8 (5.1–6.5) 31.8 (28.9–34.9) 4 (1.6–8.9) 55.2 (44.2–65.7)
Sensitivity >80% 4.7 (4.1–5.4) 28.8 (26.0–31.8) 3.3 (1.2–8.0) 49.4 (38.6–60.2)
Specificity >98% 0.4 (0.2–0.7) 4.8 (3.6–6.4) 0 (0–3.1) 16.1 (9.4–25.9)
*Note that country-specific thresholds were used for VIP, EM and FMM.
TF = trachomatous inflammation, follicular; TI = trachomatous inflammation-intense; TS = trachomatous scarring; TT = trachomatous trichiasis;
CO = corneal opacity.
VIP = visual inflection point; EM = expectation-maximisation algorithm; FMM = finite mixture model.
doi:10.1371/journal.pntd.0005230.t004
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(PPV), but they do incur a penalty in the form of reduced sensitivity. In the context of post-
MDA trachoma control, a test with high PPV is more desirable as over-diagnosis might lead to
the inappropriate continuation of MDA interventions. Meanwhile a lower sensitivity test,
applied in a low prevalence setting such as the post-MDA population of the Gambia, is likely
to have a high negative predictive value (NPV) and the clinical impact of the false negative rate
is likely to be modest as long as the sensitivity does not fall too far. In our hands, the ROC anal-
ysis supported the use of higher thresholds than did the other methods. Unfortunately the ref-
erence material was not sampled from any natural population and so the estimated sensitivity
and specificity of the test based on ROC were unlikely to reflect the true performance in the
populations that were sampled in this study [59].
We explored three internally calibrated thresholding methods (i.e. using only data gener-
ated during the study), all of which specified thresholds at approximately the same OD450
value. This was true across sample sets from all three countries. It is perhaps unsurprising that
similar estimates emerged from FMM and EM, as there are methodological similarities in the
two approaches. At face value the VIP method might seem arbitrary and crude, but the human
brain can outperform computers in some aspects of pattern recognition and by obtaining a
threshold estimate that closely matches that of EM and FMM, our data indicate that the results of
a conditionally independent method (VIP) correlate closely with the computational approaches
and are able to successfully determine where the most obvious bimodal split in the data occurs.
What gives FMM and EM the edge over VIP is that they are more replicable and that the differ-
ent requirements for higher or lower specificity and sensitivity in different clinical settings can be
controlled by changing the number of SDs that the algorithm uses to determine the cut point.
For instance, an increasingly specific test could be implemented by setting the threshold at four,
five or six SDs of the negative population, rather than three SDs we used here. None of the popu-
lations that we surveyed would be expected (based on clinical signs) to have a high level of Ct
seropositivity and it may be that the data in Tables 3 and 4 (and Supplementary Data S4, S5 and
S6 Tables) reflect a high false positive rate, low positive predictive value. By adjusting the parame-
ters of the algorithms we might achieve a prevalence estimate that is more accurate, but without
any gold standard we can never truly assess how accurate our estimates are. In the Gambian data,
using respectively 4 or 5 SDs would have led to cut points at respectively OD = 0.81 and
OD = 0.95, values much closer to the cut-points recommended by the ROC analysis.
For programmatic purposes, the absolute value and accuracy of the prevalence estimate is
actually somewhat less important than the precision of that estimate and the longitudinal
change in repeat measures from the same population across the lifetime of the intervention
and monitoring programme. This is because the absolute estimate is clearly highly variable
given quite arbitrary choices made during data analysis, whilst percentage changes in popula-
tion seroprevalence across time (regardless of the actual number values) can be indicative of
the effectiveness of MDA. As long as the method is fixed and replicable, then both longitudinal
and between–population comparisons are appropriate and will have a fixed level of error, even
though the absolute accuracy will remain unknown. The real value of using an internally con-
trolled method such as FMM or EM is that it is possible to use an algorithmic approach that is
simple to apply to any data set and which requires no additional testing of external specimens
or controls. In this study, we generated a ROC curve based on specimens that had previously
been calibrated against the original reference standards described by Goodhew et al [19].
There is no gold standard for serological testing of chlamydia, and mis-classification in the ref-
erence standards is likely to have introduced error in the reference panel. Goodhew described
how one PCR-positive DBS tested negative for antibodies against Pgp3, while three samples
that were in the negative reference group tested positive for antibodies against Pgp3 [19]. As
these original reference standards were no longer available, we have had to rely on a second set
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of standards that were tested against the original standards. Problems relating to the ROC ref-
erence specimens could be solved by the establishment of a fully maintained and quality con-
trolled international standard, but this is unlikely to happen as it is would be very difficult to
identify a reliable source of large volumes of seropositive plasma.
FMM has been used in numerous serological studies [34,39,43,45,60–66] and we propose
that it, or the closely related EM, should be considered as the method of choice when perform-
ing data analysis for trachoma serology data. In trachoma control programmes, the SD param-
eter should be adjusted to favour high specificity and a larger number of SDs than used here
would seem appropriate. One attractive option would be to use data from a post-elimination
country (i.e. the Gambia) to subtract out the background positivity and by doing so calibrate
or normalise the test for use in populations where elimination has not yet been reached and
prevalence is unknown.
Variability and error are inherent to any diagnostic test and with every change in reference
standard and assay technique, variability and error increase over and above any variation that
may be inherent in a test due to inter- or intra- centre and user variation. Thus, we believe that
an alternate approach to assay design, reference selection and threshold specification should
be considered.
For all the sample sets included in this study, the density data peak around 0.25 OD450 (Figs
2A, 3A and 4A), suggesting that a comparison of seroprevalence levels between populations is
possible. Compared to ROC curves, internally-referenced thresholds inherently account for
differing background levels in each population. If not accounted for using the ROC curve, this
may result in an under- or over-estimation of seroprevalence. This will facilitate the program-
matic usage of seroprevalence levels set by the finite mixture model or expectation-maximisa-
tion algorithm if serology is to be adopted as an alternative monitoring method.
Conclusion
The ELISA assay presented in this paper is easy-to-use, affordable in terms of both reagents and
equipment required, and can potentially be deployed in low- and middle-income countries.
The unit cost per sample was less than £4.00; this includes all materials required for sample
collection and DBS testing, including reagents, ELISA plates and sterile gloves. Our results
show that the technological aspects of the assay are robust and that there is low variation both
between replicate samples and plates and between populations, making it possible to compare
seroprevalence levels between countries. Internally calibrated thresholding methods, such as the
finite mixture model or the expectation-maximisation algorithm are more appropriate than
thresholds set by a ROC curve, but for programmatic surveillance, they may require calibration
using data from countries where trachoma has been declared as having been eliminated.
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Supplementary Table 4.1: Prevalence of the clinical signs of trachoma for Laos, by 
Gender, Region and Age. 
 Prevalence of clinical signs (%) 
 N TF 
Overall 952 15 (1.6) 
Female 423 9 (2.1) 
Male 529 6 (1.1) 
Attapu 406 11 (2.7) 
Houaphan 307 3 (1.0) 
Phôngsali 239 1 (0.4) 
1 year old 78 2 (2.6) 
2 years old 105 3 (2.9) 
3 years old 101 5 (5.0) 
4 years old 127 0 
5 years old 114 1 (0.9) 
6 years old 100 2 (2.0) 
7 years old 100 1 (1.0) 
8 years old 99 0 
9 years old 128 1 (0.8) 
TF = trachomatous inflammation, follicular 
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Supplementary Table 4.2: Prevalence of the clinical signs of trachoma for Uganda, by 
Gender, Region and Age 
 Prevalence of clinical signs (%) 
 N TF TI 
Overall 2700 93 (3.4) 8 (0.3) 
Agogo 1353 43 (3.2) 1 (0.1) 
Pader 1347 50 (3.7) 7 (0.5) 
Female 1351 48 (3.6) 6 (0.4) 
Male 1349 45 (3.6) 2 (0.1) 
1 year old 242 11 (4.5) 2 (0.8) 
2 years old 353 17 (4.8) 0 
3 years old 358 16 (4.5) 3 (0.8) 
4 years old 336 14 (4.2) 1 (0.3) 
5 years old 329 12 (3.6) 1 (0.3) 
6 years old 333 8 (2.4) 0 
7 years old 264 6 (2.3) 1 (0.4) 
8 years old 235 3 (1.3) 0 
9 years old 250 6 (2.4) 0 
TF = trachomatous inflammation, follicular; TI = trachomatous inflammation-intense 
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Supplementary Table 4.3: Prevalence of the clinical signs of trachoma for The Gambia 
by Gender, Region and Age 
 Prevalence of clinical signs (%) 
 N TF TI TS TT CO 
Overall 1868 30 (1.6) 4 (0.2) 78 (4.2) 8 (0.4) 1 (0.1)  
LRR 1028 18 (1.8) 4 (0.4) 55 (5.4)  7 (0.7) 1 (0.1) 
URR 840 12 (1.4) 0 23 (2.7) 1 (0.1) 0 
Female 1080 10 (0.9) 3 (0.3) 52 (4.8) 5 (0.5) 1 (0.1) 
Male 788 20 (2.5) 1 (0.1) 26 (3.3) 3 (0.4) 0 
<1 year old 36 0 0 0 0 0 
1 year old 65 1 (1.5) 0 0 0 0 
2 years old 88 3 (3.4) 0 2 (2.3) 0 0 
3 years old 101 8 (7.9) 0 1 (1.0) 0 0 
4 years old 96 5 (5.2) 0 1 (1.0) 0 0 
5 years old 96 3 (3.1) 0 1 (1.0) 0 0 
6 years old 89 0 0 2 (2.2) 0 0 
7 years old 77 2 (2.6) 1 (1.3) 0 0 0 
8 years old 78 1 (1.3) 0 0 0 0 
9 years old 52 2 (3.8) 1 (1.9) 0 0 0 
10-19 412 4 (1.0) 1 (0.2) 2 (0.5) 0 0 
20-29 191 0 0 1 (0.5) 0 0 
30-39 152 1 (0.7) 1 (0.7) 5 (3.3) 0 0 
40-49 99 0 0 5 (5.1) 0 0 
50-59 95 0 0 15 (15.8) 2 (2.1) 0 
60+ 141 0 0 43 (30.5) 6 (4.3) 1 (0.7) 
1-9 year olds -LRR 383 14 (3.7) 2 (0.5) 1 (0.3) 0 0 
1-9 year olds -URR 359 11 (3.1) 0 6 (1.7) 0 0 
≥10 year olds-LRR 645 4 (0.6) 2 (0.3) 54 (8.45) 7 (1.1) 1 (0.2) 
≥10 year olds-URR 481 1 (0.2) 0 17 (2.6) 1 (0.2) 0 
TF = trachomatous inflammation, follicular; TI = trachomatous inflammation-intense; TS = 
trachomatous scarring; TT = trachomatous trichiasis; CO = corneal opacity 
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Supplementary Table 4.4: Seroprevalence for Laos by Gender, Region and Age, for each of six thresholds. 
Threshold, % (95% confidence interval) 
  VIP EM FMM ROC Youden’s J-
index 
ROC 
Sensitivity>80% 
ROC 
Specificity>98% 
 N OD=0.619 OD=0.650 OD=0.696 OD=0.870 OD=0.965 OD=1.951 
Overall 952 11.3% (9.4-13.6) 10.4% (8.6-12.6) 15.6% (13.3-18.0) 6.7% (5.3-8.6) 6.3% (4.9-8.1) 1.1% (0.5-2.0) 
Female 423 10.4% (7.7-13.8) 9.9% (7.3-13.3) 15.6% (12.3-19.5) 6.9% (4.7-9.8) 6.4% (4.3-9.3) 0.70% (0.2-2.2) 
Male 529 12.1% (9.5-15.3) 10.8% (8.3-13.8) 15.5% (12.6-18.9) 6.6% (4.7-9.2) 6.2% (4.4-8.7) 1.3% (0.6-2.8) 
Attapu 406 4.4% (2.7-7.0) 3.7% (2.2-6.2) 9.4% (6.8-12.7) 0.70% (0.2-2.3) 0.70% (0.19-2.3) 0 (0-1.1) 
Houaphan 307 21.5% (17.1-26.6) 20.5% (16.2-25.6) 24.1% (19.5-29.4) 16.0% (12.1-
20.7) 
15.0% (11.3-
19.6) 
2.3% (1.0-4.8) 
Phôngsali 239 10.0% (6.7-14.7) 8.8% (5.7-13.3) 15.1% (10.9-20.4) 5.0% (2.7-8.8) 4.6% (2.4-8.3) 1.3% (0.3-3.9) 
1 year old 78 10.2% (4.8-19.7) 10.2% (4.8-19.7) 10.2% (4.8-19.7) 9.0% (4.0-18.2) 9.0% (4.0-18.2) 2.6% (0.4-9.8) 
2 years 
old 
105 8.6% (4.2-16.1) 8.6% (4.2-16.1) 14.3% (8.5-22.7) 6.7% (3.0-13.7) 6.7% (3.0-13.7) 0 (0-4.3) 
3 years 
old 
101 9.9% (5.1-17.9) 8.9% (4.4-16.7) 12.9% (7.3-21.4) 6.9% (3.1-14.2) 6.9% (3.1-14.2) 2.0% (0.3-7.7) 
4 years 
old 
127 13.4% (8.2-20.8) 12.6% (7.6-19.9) 15.7% (10.1-23.5) 9.4% (5.2-16.3) 9.4% (5.2-16.3) 0.80% (0.04-5.0) 
5 years 
old 
114 6.1% (2.7-12.7) 4.4% (1.6-10.4) 8.8% (4.5-15.9) 2.6% (0.7-8.1) 2.6% (0.7-8.1) 0.90% (0.04-5.5) 
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6 years 
old 
100 12.0% (6.6-20.4) 11.0% (5.9-19.2) 18.0% (11.3-27.2) 6.0% (2.5-13.1) 6.0% (2.5-13.1) 3.0% (0.8-9.2) 
7 years 
old 
100 8.0% (3.8-15.6) 8.0% (3.8-15.6) 13.0% (7.4-21.6) 6.0% (2.5-13.1) 6.0% (2.5-13.1) 0 (0-4.6) 
8 years 
old 
99 15.2% (9.0-24.1) 12.1% (6.7-20.6) 24.2% (16.4-34.1) 8.1% (3.8-15.8) 7.1% (3.1-14.5) 1.0% (0.-6.3) 
9 years 
old 
128 17.2% (11.3-25.1) 16.4% (10.7-24.2) 21.1% (14.6-29.4) 6.35% (2.9-12.3) 3.9% (1.4-9.3) 0 (0-3.6) 
TF = trachomatous inflammation, follicular; TI = trachomatous inflammation-intense; TS = trachomatous scarring; TT = trachomatous trichiasis; CO = corneal 
opacity; VIP = visual inflection point; EM = expectation-maximisation algorithm; FMM = finite mixture model; OD = optical density, measured at 450 nm 
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Supplementary Table 4.5: Seroprevalence for Uganda by Gender, Region and Age, for each of six thresholds.  
Threshold, % (95% confidence interval) 
  VIP EM FMM ROC Youden’s J-
index 
ROC 
Sensitivity>80% 
ROC 
Specificity>98% 
 N OD=0.641 OD=0.450 OD=0.554 OD=0.870 OD=0.965 OD=1.951 
Overall 2700 13.4% (12.1- 4.7) 24.3% (22.7-26.0) 17.1% (16.0-18.9) 6.8% (5.9-7.8) 5.3% (4.5-6.2) 0.3% (0.1-0.8) 
Female 1351 13.3% (11.6-15.3) 23.8% (21.5-26.1) 17.2% (15.7-19.1) 6.2% (5.0-7.7) 5.0% (3.9-6.3) 0.3% (0.1-0.8) 
Male 1349 13.4% (11.7-15.4) 24.9% (22.6-27.3) 17.8% (15.8-20.0) 7.4% (6.1-9.0) 5.6% (4.5-7.0) 0.2% (0.1-0.7) 
Agogo 1353 12.6% (10.9-14.6) 23.3% (21.1-25.6) 15.9% (14.0-18.0) 6.0% (4.8-7.4) 4.9% (3.8-6.2) 0.3% (0.1-0.8) 
Pader 1347 14.1% (12.3-16.1) 25.4% (23.1-27.8) 18.9% (16.9-21.1) 7.7% (6.3-9.2) 5.7% (4.6-7.1) 0.2% (0.1-0.7) 
1 year old 247 2.4% (1.0-5.5) 7.3% (4.5-11.4) 3.6% (1.8-7.0) 1.6% (0.5-4.4) 0.8% (0.1-3.2) 0 (0-1.9) 
2 years 
old 365 5.5% (3.5-8.5) 10.7% (7.8-14.4) 7.9% (5.5-11.3) 3.8% (2.2-6.5) 3.8% (2.2-6.5) 0.3% (0-1.8) 
3 years 
old 367 7.1% (4.8-10.3) 18.3% (14.5-22.7) 10.6% (7.8-14.3) 3.5% (2.0-6.1) 2.2% (1.0-4.4) 0.3% (0-1.8) 
4 years 
old 349 11.5% (8.4-15.4) 22.1% (17.9-26.9) 15.2% (11.7-19.5) 4.9% (3.0-7.8) 4.0% (2.3-6.8) 0 (0-1.4) 
5 years 
old 331 15.7% (12.1-20.2) 27.2% (22.5-32.4) 18.4% (14.5-23.1) 8.2% (5.5-11.8) 6.6% (4.3-10.0) 0.6% (0.1-2.0) 
6 years 
old 344 18.3% (14.5-22.9) 31.1% (26.3-36.3) 23.5% (19.2-28.5) 8.1% (5.6-11.7) 6.4% (4.1-9.7) 0 (0-1.4) 
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7 years 
old 269 16.7% (12.6-21.9) 32.3% (26.9-38.3) 23.4% (18.6-29.0) 9.3% (6.2-13.6) 6.7% (4.1-10.5) 0 (0-1.8) 
8 years 
old 240 20.4% (15.6-26.2) 32.5% (26.7-38.9) 24.2% (19.0-30.2) 9.2% (6.0-13.7) 7.5% (4.6-11.8) 0.8% (0.1-3.3) 
9 years 
old 253 23.7% (18.7-29.5) 37.2% (31.2-43.4) 30.4% (24.9-36.6) 13.4% (9.6-18.4) 9.9% (6.6-14.4) 0.4% (0-2.5) 
TF = trachomatous inflammation, follicular; TI = trachomatous inflammation-intense; TS = trachomatous scarring; TT = trachomatous trichiasis; CO = corneal 
opacity; VIP = visual inflection point; EM = expectation-maximisation algorithm; FMM = finite mixture model; OD = optical density, measured at 450 nm 
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Supplementary Table 4.6: Seroprevalence for The Gambia by Gender, Region and Age, for each of six thresholds. 
Threshold, % (95% confidence interval) 
  VIP EM FMM ROC Youden’s J-
index 
ROC Sensitivity>80% ROC 
Specificity>98% 
 N OD=0.570 OD=0.570 OD=0.672 OD=0.870 OD=0.965 OD=1.951 
Overall 1868 29.3% (27.3-31.5) 29.3% (27.3-31.5) 26.2% (24.2-28.2) 20.9% (19.1-22.9) 18.9% (17.2-20.8) 3.3% (2.6-4.3) 
Female 1080 35.0% (32.2-37.9) 35.0% (32.2-37.9) 31.6% (28.8-34.5) 26.0% (23.4-28.8) 23.7% (21.2-26.4) 4.8% (3.7-6.3) 
Male 788 21.6% (18.8-24.6) 21.6% (18.8-24.6) 18.7% (16.1-21.7) 14.0% (11.7-16.6) 12.3% (10.1-14.9) 1.3% (0.7-2.4) 
LRR 1028 33.9% (31.0-36.8) 33.8% (31.0-36.8) 30.5% (27.7-33.4) 25.1% (22.5-27.9) 22.6% (20.1-25.2) 3.7% (2.7-5.1) 
URR 840 23.8% (21.0-26.9) 23.8% (21.0-26.9) 21.0% (18.3-23.9) 15.8% (13.5-18.5) 14.4% (12.1-17.0) 2.9% (1.9-4.3) 
<1 year 36 0 (0-12.0) 0 (0-12.0) 0 (0-12.0) 0 (0-12.0) 0 (0-12.0) 0 (0-12.0) 
1 year old 65 4.6% (1.2-13.8) 4.6% (1.2-13.8) 3.1% (0.5-11.6) 0 (0-6.9) 0 (0-6.9) 0 (0-6.9) 
2 years 
old 88 4.5% (1.5-11.9) 4.5% (1.5-11.9) 2.3% (0.4-8.7) 1.1% (0-7.1) 0 (0-5.2) 0 (0-5.2) 
3 years 
old 101 5.9% (2.4-13.0) 5.9% (2.4-13.0) 5.9% (2.4-13.0) 2.0% (0.3-7.7) 2.0% (0.3-7.7) 0 (0-4.6) 
4 years 
old 96 8.3% (3.9-16.2) 8.3% (3.9-16.2) 7.3% (3.2-14.90 4.2% (1.3-10.9) 4.2% (1.3-10.9) 0 (0-4.8) 
5 years 
old 96 8.3% (3.9-16.2) 8.3% (3.9-16.2) 6.3% (2.6-13.6) 3.1% (0.8-9.5) 3.1% (0.8-9.5) 0 (0-4.8) 
6 years 
old 89 5.60% (2.1-13.2) 5.6% (2.1-13.2) 4.5% (1.4-11.7) 4.5% (1.4-11.7) 3.4% (0.9-10.2) 0 (0-5.2) 
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7 years 
old 77 10.2% (4.9-20.0) 10.4% (4.9-20.0) 7.8% (3.2-16.8) 2.6% (0.5-9.9) 2.6% (0.5-9.9) 0 (0-5.9) 
8 years 
old 78 10.3% (4.8-19.7) 10.3% (4.8-19.7) 7.7% (3.2-16.6) 6.4% (2.4-15.0) 3.8% (1.0-11.6) 0 (0-5.8) 
9 years 
old 52 19.2% (10.1-33.0) 19.2% (10.1-33.0) 15.4% (7.3-28.6) 9.6% (3.6-21.8) 9.6% (3.6-21.8) 1.9% (0.1-11.6) 
10-19 412 21.4% (17.6-25.7) 21.4% (17.6-25.7) 15.5% (12.2-19.5) 11.1% (8.4-14.7) 9.7% (7.1-13.1) 1.7% (0.7-3.6) 
20-29 191 36.6% (29.9-43.9) 36.6% (29.9-43.9) 31.4% (25.0-38.6) 23.0% (17.4-29.8) 19.9% (14.6-26.4) 3.7% (1.6-7.7) 
30-39 152 53.9% (45.7-62.0) 53.9% (45.7-62.0) 52.0% (43.8-60.1) 46.1% (38.0-54.3) 44.1% (36.1-52.3) 5.9% (2.9-11.3) 
40-49 99 69.7% (59.5-78.3) 69.7% (59.5-78.3) 65.7% (55.4-74.7) 56.6% (46.2-66.4) 50.1% (40.3-60.1) 12.1% (6.7-20.6) 
50-59 95 74.7% (64.5-82.8) 74.7% (64.5-82.8) 72.6% (62.4-81.0) 62.1% (51.5-71.7) 55.8% (45.3-65.9) 8.4% (4.0-16.4) 
60+ 141 75.9% (67.8-82.5) 75.9% (67.8-82.5) 73.8% (65.6-80.6) 63.1% (54.5-71.0) 58.2% (49.5-66.3) 12.8% (7.9-19.7) 
TF = trachomatous inflammation, follicular; TI = trachomatous inflammation-intense; TS = trachomatous scarring; TT = trachomatous trichiasis; CO = corneal 
opacity; VIP = visual inflection point; EM = expectation-maximisation algorithm; FMM = finite mixture model; OD = optical density, measured at 450nm  
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Summary 
In the previous chapter, methods of setting thresholds to define seropositivity were explored. 
Thresholds set using finite mixture modelling (FMM) were selected going forward. 
In this chapter age-specific seroprevalence in two populations in The Gambia are used to estimate 
changes in the force of infection (FoI) and seroconversion and seroreversion rates. A population-
based cross-sectional survey was conducted in Lower River Region (LRR) and Upper River Region 
(URR). 
One population (LRR) received MDA because the prevalence of TF was greater than 10% in children 
aged 1-9 years old; the other population (URR) did not receive MDA because the prevalence of TF 
was not above the 10% threshold. In the current survey, both regions had less than 5% TF in children 
aged 1-9 years old. Seroprevalence was measured using antibodies against Pgp3. Seroprevalence 
was significantly different in the two regions: 26.2% in LRR and 17.1% in URR. Age-specific 
seroprevalence was used with reverse catalytic modelling to show a decrease in the transmission of 
Ct infection in both regions over 15 years ago. This change in the force of infection likely reflects a 
secular decline as access to healthcare, sanitation and water has increased over the past 30 years, as 
well as a previously unpublished mass drug campaign with topical tetracycline. Seroprevalence data 
was also used to estimate changes in seroconversion and seroreversion, which showed a reduction 
in seroconversion over time in both populations. 
The serological analysis support findings from clinical examination and test for infection but is 
confounded by the fact that the antibodies detected in this study are unable to distinguish between 
ocular and genital Ct infection, potentially confounding results as changes in seroconversion may be 
due to historical interventions against trachoma or may reflect more recent acquisition of genital Ct 
infection.  
This chapter demonstrates a potential use for serological data beyond simple estimates of 
population seroprevalence, showing how the age-specific prevalence of antibodies can be used to 
demonstrate past changes in the force of infection. In the subsequent chapter antibody levels, 
rather than seroprevalence data, is used to model changes in the force of infection over time and 
between populations. 
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Serology reflects a decline in the 
prevalence of trachoma in two 
regions of The Gambia
Stephanie J. Migchelsen  1, Nuno Sepúlveda1,2, Diana L. Martin3, Gretchen Cooley3, Sarah 
Gwyn4, Harry Pickering1, Hassan Joof5, Pateh Makalo5, Robin Bailey1, Sarah E. Burr1,5, David 
C. W. Mabey1, Anthony W. Solomon1 & Chrissy h. Roberts  1
Trachoma is caused by Chlamydia trachomatis (Ct). It is targeted for global elimination as a public health 
problem. In 2014, a population-based cross-sectional study was performed in two previously trachoma-
endemic areas of The Gambia. Participants of all ages from Lower River Region (LRR) (N = 1028) and 
Upper River Region (URR) (N = 840) underwent examination for trachoma and had blood collected 
for detection of antibodies against the Ct antigen Pgp3, by ELISA. Overall, 30 (1.6%) individuals had 
active trachoma; the prevalence in children aged 1–9 years was 3.4% (25/742) with no statistically 
significant difference in prevalence between the regions. There was a significant difference in overall 
seroprevalence by region: 26.2% in LRR and 17.1% in URR (p < 0.0001). In children 1–9 years old, 
seroprevalence was 4.4% in LRR and 3.9% in URR. Reversible catalytic models using information on 
age-specific seroprevalence demonstrated a decrease in the transmission of Ct infection in both regions, 
possibly reflecting the impact of improved access to water, health and sanitation as well as mass drug 
administration campaigns. Serological testing for antibodies to Ct antigens is potentially useful for 
trachoma programmes, but consideration should be given to the co-endemicity of sexually transmitted 
Ct infections.
Trachoma is caused by ocular infection with the obligate intracellular bacterium Chlamydia trachomatis (Ct). It 
is the leading infectious cause of blindness worldwide1. Infection is associated with clinical signs of inflammation 
in the conjunctiva, known as active trachoma; these include trachomatous inflammation—follicular (TF) and 
trachomatous inflammation—intense (TI). Many repeated episodes of active trachoma over years to decades can 
lead to trachomatous trichiasis (TT), which may lead to impaired vision. The World Health Organization (WHO) 
estimates that over 200 million people in 42 countries are at risk of blindness from trachoma2. In 2010, approxi-
mately 1.9 million people suffered from visual impairment or blindness due to trachoma1. The WHO Alliance for 
the Global Elimination of Trachoma by 2020 (GET2020) aims to eliminate trachoma as a public health problem 
by 20202 through the SAFE Strategy (Surgery, Antimicrobials, Facial cleanliness and Environmental improve-
ment). The WHO-endorsed strategy for global control is to reduce the population prevalence of TF to <5% in 
children aged 1–9 years and the prevalence of unmanaged TT to <0.2% in adults aged 15 years and above3. By 
2014, seven countries had reported having met these targets nationally4. The Gambia has been a hub for trachoma 
research for over 50 years and is on course to declare the elimination of trachoma as a public health problem by 
2020. Two National Surveys of Blindness and Low Vision in The Gambia demonstrated that there had been a 
nation-wide decrease in the prevalence of active trachoma and TT between 1986 and 20005,6. Specific elimination 
efforts, undertaken between 2007 and 2010 and run by the National Eye Health Programme (NEHP), included 
mass drug administration (MDA) of azithromycin in 23 districts across the country. The Partnership for the 
Rapid Elimination of Trachoma (PRET)7 was embedded within the national programme and measured the prev-
alence of Ct infection in children residing in four districts in which MDA had been administered. Deployment 
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of interventions and disease control measures across The Gambia was not even, with some districts receiving the 
full SAFE intervention and others receiving reduced (F & E components) or no specifically targeted interventions. 
It is important to be able to evaluate the effectiveness of these interventions and a significantly reduced or halted 
transmission of infection is a key indicator that elimination may have been achieved.
The current guidelines for post-intervention surveillance of Ct transmission intensity are based on the 
prevalence of TF in children aged 1–9 years. This is problematic because in the peri-elimination period and 
low-endemicity settings7,8 the correlation between the clinical signs of trachoma and the presence of ocular Ct 
infection is poor. This diminishment of the positive predictive value of clinical signs means that the false positive 
rate of TF screening is increased and the specificity of the clinical sign is negatively affected.
Reduced global endemicity also leads to the unmasking of diseases that resemble trachoma clinically but 
which have no clear link to Ct infections. We recently surveyed the western division of the Solomon Islands9, a 
population where TF was not found to be a highly specific indicator of ocular Ct infection. Around 26% of 1–9 
year olds living there had TF, but Ct infection was very scarce at just 1.3%. Using a serological tool we showed that 
53/66 (80%) of the cases of TF that we observed were in people who were serologically negative for prior Ct infec-
tion10. Clinical signs of trachoma were also a poor indicator for the need to deploy antimicrobials in Fiji, where 
the high prevalence of TT cases could be better explained by socio-epidemiological practices of eyelash depilation 
than by Ct infections11. The current WHO guidelines would recommend MDA in both Fiji and the Solomon 
Islands, but the evidence from more detailed surveys makes an argument against the likelihood that the use of 
antimicrobials would be effective. Situations such as this highlight the need to develop new tools that can sup-
port programmes to make informed decisions about how to use antimicrobials in trachoma control. Antibodies 
against Chlamydia trachomatis reflect cumulative exposure to Ct12,13 and it has been suggested that programmes 
could use some measure of seroprevalence as an alternative indicator of changes in transmission14,15. Previous 
work has investigated the use of age-specific seroprevalence for surveillance in the peri-16 and post-MDA set-
ting15,17,18. Serological techniques for the detection of antibodies against Ct have been used to study the epidemi-
ology of both urogenital and ocular Ct infections19,20. An enzyme-linked immunoassay (ELISA) which detects 
antibodies against Pgp3 (pCT03) has recently been used for analysis of samples collected from trachoma-endemic 
regions21,22. The Pgp3 molecule is an immunogenic Ct-specific protein that is encoded by the Ct plasmid and 
which is highly conserved at the genetic level among Ct isolates23.
In the current study we have used serological data from a Pgp3-specific ELISA to gain insight into the dynam-
ics of Ct transmission in two regions of The Gambia, one of which (the Lower River Region [LRR]) had received 
three annual rounds of MDA, whilst the other (the Upper River Region [URR]) had not. URR was not targeted 
for antimicrobial use because the TF prevalence had already dropped below the WHO threshold for elimination 
as a public health problem.
To explore the utility of serology as a tool for surveillance in trachoma elimination programmes, we have 
modelled the seroconversion rate (SCR) in URR and LRR under different epidemiological settings. The SCR is the 
yearly average rate by which seronegative individuals become seropositive because of disease exposure. SCR is a 
metric that acts as a surrogate measure for the underlying force of infection (FoI) and the age specific SCR can be 
used to model changes in FOI across time, potentially identifying periods in which there were substantial changes 
in the rate of transmission of Ct infection in the population.
Results
We recruited participants of all ages from LRR (n = 1028, 41.9% male) and URR (n = 840, 42.5% male). Ten 
participants were excluded from the study because they either declined to provide a blood sample (n = 1) or had 
incomplete examination data (n = 9). The median participant age was 13 years in LRR (range: 1–88, IQR 6–34) 
and 11 years in URR (range: 0–90, IQR 5–40). The proportion of participants by age group is shown in Table 1. 
There were significantly more females than males overall (X2 = 45.332, p < 0.0001), which held true in both LRR 
(Χ2 = 26.483, p < 0.0001) and URR (X2 = 18.601, p < 0.0001) and is representative of Gambian demographics24. 
Age distributions were approximately equal between the two regions, as seen in Table 1 (Χ2 = 27.703, p = 0.14).
Both Regions Lower River Region Upper River Region
N % N % N %
Overall 1832 1010 55.1 822 44.9
Gender
Female 1056 57.7 584 58.0 472 57.0
Male 776 42.2 426 42.0 350 43.0
Age group (years)
1–9 742 39.7 383 37.3 359 42.7
10–19 412 22.1 231 22.5 181 21.5
20-29 191 10.2 101 9.8 90 10.7
30-39 152 8.1 79 7.7 73 8.7
40+ 335 17.9 216 21.0 119 14.2
Table 1. Age distribution of study participants, Lower River Region and Upper River Region, The Gambia, 
2014.
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Clinical signs. Thirty cases of TF were found in total (1.6%, 95% CI = 1.1–2.3%), of which 25 were in children 
aged 1–9 years (3.4%, 95% CI = 2.2–4.9, Table 2). There were 78 cases of trachomatous conjunctival scarring (TS), 
of which 70 were in participants aged 15 years and above (8.3%, 95%CI = 6.6–10.5); eight cases of TT, all of which 
were in those aged 40 years and older (0.9%, 95% CI = 0.4–1.8); and one case of corneal opacity (CO), in a par-
ticipant over 40 years of age (0.1%, 95% CI = 0.0–0.6) (Table 2). The prevalence of TS was significantly different 
(Χ2 = 7.7932, p = 0.005) between LRR (5.4%, 95% CI = 4.1–7.1%) and URR (2.8%, 95% CI = 1.8–4.2%). The TF 
prevalence in children aged 1–9 years was not significantly different (Χ2 = 0.199, p = 0.66) between LRR (3.7%, 
95% CI = 2.1–6.2%) and URR (3.1%, 95%CI = 1.6–5.6%). The prevalence of TI, TT and CO in this population 
was too low for further statistical analysis.
Data from this study show very low prevalence of active trachoma in these regions. In children aged 1–9 years, 
only 4.2% had detectable antibodies against Pgp3. In both regions, the prevalence of TF in 1–9-year-olds was 
below the 5% threshold for elimination as a public health problem as specified by the WHO.
Antibody responses in the populations. The threshold for seropositivity was set using a finite mix-
ture model25 to classify the samples as seropositive or seronegative based on maximum likelihood methods. The 
threshold was set at the mean of the Gaussian distribution of the seronegative population plus four standard devi-
ations, 0.810 OD450nm to ensure high specificity. Previous studies using the Pgp3 ELISA have commonly used a 
threshold set as three standard deviations above the mean of the negative population (the 97.5% confidence inter-
val)21,26. Using that lower threshold resulted in the same qualitative conclusions being drawn (See Supplementary 
Information).
The seroprevalence of antibodies against Pgp3 for each region, by age and gender, is summarised in Table 3. 
The overall seroprevalence in LRR and URR was 26.2% (95% CI = 23.5–29.0) and 17.1% (95% CI = 14.7–19.9%), 
respectively. Adjusting for multiple comparisons, there was a significant difference in overall seropreva-
lence between the two regions (Χ2 = 20.72, p < 0.0001). Figure 1 shows the seroprevalence by age group and 
region. In children 1–9 years old, seroprevalence was 4.4% in LRR and 3.9% in URR. As expected, the prev-
alence of anti-Pgp3 antibodies increased with age using the non-parametric test for trend (z-score = 23.35, 
p < 0.0001; alpha = 0.01). The seroprevalence doubled between 10–19-year-olds and the next oldest age group, 
20–29-year-olds, both in the two regions combined, and in each region. Across both regions, in study participants 
who had no signs of trachoma, seroprevalence was 21% (95% CI = 19–23). Of those who had active trachoma (TF 
and/or TI) (n = 30), 3% were seropositive (95% CI = 0.1–17) and of those who had scarring trachoma (TS and/or 
TT and/or CO in either eye; n = 122) 56% were seropositive (95% CI = 44–67).
The prevalence of antibodies was significantly higher in females than in males (z-score = 6.384, p < 0.0001). 
The same was true in each region (LRR: z-score = 4.881, p < 0.0001; URR: z-score = 4.114, p < 0.0001). When 
data were considered for each age group, the seropositivity difference between males and females was only sig-
nificant for 10–19-year-olds (z-score = 2.667, p = 0.0077) and 30–39-year-olds (z-score = 0.2551, p = 0.0107). 
Seroprevalence by gender and age group is shown in Fig. 2.
Frequency of signs (%)
N TF TI TS TT CO
Overall 1832 30 (1.6) 4 (0.2) 78 (4.3) 8 (0.4) 1 (0.1)
Region
LRR 1010 18 (1.8) 4 (0.4) 55 (5.4) 7 (0.7) 1 (0.1)
URR 822 12 (1.4) 0 23 (2.8) 1 (0.1) 0
Gender
Female 1056 10 (0.9) 3 (0.3) 52 (4.9) 5 (0.5) 1 (0.1)
Male 776 20 (2.5) 1 (0.1) 26 (3.4) 3 (0.4) 0
Age group (years)
1–9 742 25 (3.4) 2 (0.3) 7 (1.1) 0 0
10–19 412 4 (1.0) 1 (0.2) 2 (0.5) 0 0
20–29 191 0 0 1 (0.5) 0 0
30–39 152 1 (0.7) 1 (0.7) 5 (3.3) 0 0
40+ 335 0 0 63 (18.8) 8 (2.4) 1 (0.3)
1–9 year olds -LRR 383 14 (3.7) 2 (0.5) 1 (0.3) 0 0
1–9 year olds -URR 359 11 (3.1) 0 6 (1.7) 0 0
≥10 year olds-LRR 645 4 (0.6) 2 (0.3) 54 (8.4) 7 (1.1) 1 (0.2)
≥10 year olds-URR 481 1 (0.2) 0 17 (3.5) 1 (0.2) 0
Table 2. Frequency of signs of trachoma in study participants, Lower River Region and Upper River Region, 
The Gambia, 2014. TF = trachomatous inflammation—follicular; TI = trachomatous inflammation—intense; 
TS = trachomatous conjunctival scarring; TT = trachomatous trichiasis; CO = corneal opacity LRR = Lower 
River Region; URR = Upper River Region.
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Reduction in seroconversion rates over time. We used a reversible catalytic model together with the 
profile likelihood method to identify reductions in seroconversion rates (SCR) in both LRR and URR. The revers-
ible catalytic model is based on the premise that individuals transit between seropositive and seronegative states 
with specific average rates27. We compared three different models under which transmission dynamics might 
have changed across time. Our first model used the assumption that there had been a constant transmission, the 
second that there had at some point been an abrupt change in force of infection and the third that there had been 
a constant FOI to a point, after which it had decayed in a log-linear manner. We found that the model of abrupt 
change was most likely to explain the data we had observed in The Gambia. Abrupt reductions in SCRs were 
identified in both LRR and URR (Table 4 and Fig. 3) and these changes in SCR are estimated to have occurred 
respectively 23 and 16 years before data collection took place (Fig. 3). For LRR, the SCR would appear to have 
dropped from an incidence of 0.062 yearly events per person, to 0.010 yearly events per person. These estimates 
implied a putative 6.3-fold decrease in transmission intensity. In URR, the estimate of the past SCR dropped from 
Both Lower River Region Upper River Region
N n % 95% CI N n % 95% CI N n % 95% CI
Overall 1832 412 22.5 20.2–24.0 1010 268 26.5 23.5–29.0 822 144 17.5 14.7–19.9
Gender
Female 1056 295 27.9 24.8–30.2 584 190 32.5 28.8–36.5 472 105 22.2 18.6–26.3
Male 776 117 15.1 12.4–17.5 426 78 18.3 14.8–22.4 350 39 11.1 8.1–15.0
Age group (years)
1–9 742 31 4.2 2.9–5.9 383 17 4.4 2.6–7.0 359 14 3.9 2.1–6.5
10–19 412 48 11.7 8.7–15.1 231 29 12.6 8.6–17.5 181 19 10.5 6.4–16.0
20–29 191 48 25.1 19.1–31.9 101 28 27.7 19.3–37.5 90 20 22.2 14.1–32.2
30–39 152 73 48.0 39.9–56.3 79 41 51.9 40.4–63.3 73 32 43.8 32.2–55.9
40+ 335 212 63.3 57.9–68.5 216 153 70.8 64.3–76.8 119 59 49.6 40.3–58.9
Table 3. Seroprevalence of anti-Pgp3 antibodies by region, gender and age, Lower River Region and Upper 
River Region, The Gambia, 2014.
Figure 1. Proportion of participants who were seropositive for anti-Pgp3 antibodies by age group and region, 
Lower River Region (LRR) and Upper River Region (URR), The Gambia, 2014. Vertical bars indicate 95% CIs.
Figure 2. Proportion of participants who were seropositive for anti-Pgp3 antibodies, by age group and gender, 
Lower River Region and Upper River Region, The Gambia, 2014. Vertical bars indicate 95% confidence 
intervals.
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0.050 yearly events per person to 0.008 yearly events per person, a 3.2-fold decrease (Table 4). Figure 4 shows the 
expected seroprevalence curves as function of age assuming a change in transmission intensity.
Discussion
The Gambian government is currently compiling evidence for validation of trachoma elimination, following com-
pletion of its three-year TF/TT surveillance plan, which began in 201128,29. Previous studies have demonstrated 
declines in the prevalence of active trachoma in The Gambia both prior to8,30 and in response to the implemen-
tation of specific trachoma-control interventions31–33. Increased access to water, education and healthcare in The 
Gambia during recent decades are thought to have had an impact34, manifesting in a secular decline. Regardless 
of cause, the prevalence of active trachoma in 0–14-year-olds fell from 10.4% in 19866 to less than 5% in 19965 
and has subsequently remained low. Prevalence data from historical studies is presented in Table 5. More recently, 
six years before the survey reported here, communities in LRR received azithromycin to treat ocular Ct infection, 
further reducing the prevalence of trachoma in this region7,29, while communities in URR did not. Although not 
measured in our study, previous work has shown that there has been a reduction in the prevalence of ocular Ct 
infection in two villages in LRR35,36 with the most recent measurements showing 0.5% infection prevalence in 
PRET villages, a portion of which are in LRR7. In line with the findings of those previous studies, we provide a 
further data point showing TF prevalence <5% for each region. The prevalence of clinical signs strongly supports 
The Gambia’s claim to have eliminated trachoma as a public health problem from these areas. The seroprevalence 
estimates and FoI modelling of trachoma transmission intensity offer further support that transmission is greatly 
reduced and that trachoma is no longer a public health problem in the areas studied. Seroprevalence data pre-
sented here are very similar to those seen in a recent study in Tanzania, where ocular Ct infection was eliminated 
in 200537 and serology shows an equally low prevalence of antibodies against Ct in children15.
We used three SCR models to estimate the change in SCR: the first model assumed no change in SCR and 
serves as a baseline for the second and third models, both of which did assume a change in SCR. The best model 
allowed for an acute change in SCR (Table 4, Fig. 3).
Our analysis of age-specific seroprevalence suggests that the FOI is currently very low, with a substantial 
decrease in SCR in children having occurred approximately 20 years ago (compared to the children that grew up 
before then). This change is too acute to reflect secular decline in the FoI of trachoma and may indicate the effects 
of interventions.
Region SCRpast SCRcurrent SRR Fold change
Lower River Region 0.095 (0.051–0.176) 0.015 (0.012–0.019) 0.008 (0.004–0.015) 6.3
Upper River Region 0.038 (0.018–0.082) 0.012 (0.009–0.016) 0.011 (0.003–0.039) 3.2
Table 4. Maximum likelihood estimates for the past and current seroconversion and seroreversion rates (SCR 
and SRR, respectively) associated with data collected from participants in Lower River Region and Upper River 
Region, The Gambia, 2014 where the respective 95% confidence intervals are shown in brackets.
Figure 3. Akaike’s information criterion (AIC) using the profile likelihood method for estimating the change-
point for the models assuming an abrupt reduction in transmission intensity or annual log-linear decay 
of transmission intensity from the change-point to the present. In this analysis, the best model as function 
of change point is the one that leads to the minimum estimate of the AIC. Note that a change point of 0 is 
equivalent to the simple model assuming a constant transmission intensity over time. The results suggest abrupt 
reductions of transmission intensity 23 and 16 years before sampling for respectively the lower and upper river 
regions.
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One confounding factor in this analysis is that the serological test we used was not specific to ocular Ct infec-
tions; rather it indicates whether the individual being tested has antibodies against Ct that might originate from 
historical ocular or urogenital infections. Whilst the acute change in SCR that we identified would be consist-
ent with a significant drop in the transmission intensity of ocular Ct in the mid to late 1990s, it could also be 
explained by a confounding signal from contemporary seroconversion events that relate to sexual activity of 
people in their late teens to mid-twenties. It is arguably most likely that the data reflect both things, but without 
current data describing the population prevalence of urogenital and ocular infections, the proportional contribu-
tions of STIs and trachoma to the change in SCR cannot be fully assessed.
No currently available serological test distinguishes between exposure to ocular and urogenital CT infection. 
It is interesting to note that the seroprevalence among 10–19-year-old Gambian females in our study was almost 
double that of their male counterparts of the same age. In the Gambia, the median age at which females first have 
sex is 18.6 years, with 52% of women aged 20–24 years surveyed as part of the Demographic and Health Survey 
(2013) having had sexual intercourse by age 20. In males the median age is 23.1 years, with 48% of men aged 
25–29 years surveyed having had sexual intercourse by age 2238. This could in part explain why we observed a 
gender difference in seroprevalence in the 10–19-year-old age range, as those with earlier sexual debut would be 
expected to be more likely to acquire STIs39–41 and to seroconvert.
In a population in which the urogenital Ct infection prevalence has been consistently low, it might be expected 
that anti-Pgp3 serological data would more accurately reflect longitudinal trends in ocular Ct transmission. 
Whilst data suggest that the prevalence of urogenital Ct infections has historically been very low in rural areas 
of The Gambia42,43, there are no recent data, nor data based on modern molecular testing methods. A 2003 study 
from Malicounda in Thiès Region of neighbouring Senegal estimated that the prevalence of urogenital Ct infec-
tion there was just 0.3% (n = 73)44. A systematic review of global estimates of incidence and prevalence of sex-
ually transmitted infections (STI), including urogenital chlamydia, estimated that the prevalence of urogenital 
chlamydia was 2.9% in low-income countries45, although it is noted that this study did not include data from The 
Gambia.
Figure 4. Expected seroprevalence curves as function of age (solid lines) according to the maximum likelihood 
estimates and the respective 95% confidence intervals (dashed lines) according to the best models selected 
in Fig. 3. The dots represent the observed seroprevalence when the age distribution was broken down in the 
respective deciles and the vertical pointed line refers to the change point estimated by the profile likelihood 
method.
Region
Prevalence of signs of trachoma
19866 19966
TT (≥30 year-olds)
201329
TT (≥15 year-olds)TF/TI (0–14 year-olds) TF/TI (0–9 year-olds) TF (0–9 year-olds)
Lower River Region 12.3% 11.5% 4.6% 1.8% 1.0%
Upper River Region 5.0% 1.3% 1.3% 0.4% 0.07%
Table 5. Previously published data on the prevalence active trachoma and trachomatous trichiasis, Lower 
River Region and Upper River Region, The Gambia, 1986–2013. Data from the 1986 survey was not available 
for 0–9 year olds, thus we have used the data for 0–14 year olds. TF = trachomatous inflammation - follicular, 
TI = trachomatous inflammation - intense, TT = trachomatous trichiasis.
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The cross-specificity of serological tests for antibodies emerging in response to ocular and urogenital Ct infec-
tions is a substantial hurdle that will need to be overcome if serological tests are to be widely deployed for tra-
choma monitoring.
The confidence intervals associated with SCRs seen in Fig. 4 are very broad (which in part reflects the uncer-
tainty of modelling approaches) and comparison between the charts for LRR and URR is indicative but not 
conclusive of a difference in SCR between the two regions. Although a larger sample size would reduce the uncer-
tainty, interpretation of the model depends to a large extent on the magnitude of the change as well as the timing 
between the change in SCR and sample collection, as seen in malaria modelling work25. The very large sample 
sizes required of studies that could delineate SCR changes with high precision could be prohibitive. The analysis 
is further limited by the fact that the model assumes a memoryless property over time and the SCR models are 
defined as a function of the seroreversion rate, which not easily estimated from a single cross-sectional survey.
A recent serological study using samples from Tanzania15 examined the age-specific seroprevalence of 
anti-Pgp3 antibodies in a trachoma-endemic community that had received two rounds of high coverage azithro-
mycin MDA. The all-ages prevalence of ocular Ct infection had fallen from 9.5% to 0.1% two years after MDA46, 
and to 0% five years after MDA37, with a corresponding 11-fold decrease in SCR15. This change in infection 
prevalence occurred in a more defined (and probably narrower) timeframe than the one we have studied in The 
Gambia. This resulted in a more acute change in SCR, as has been demonstrated in malaria modelling exer-
cises26,47. Previous trachoma modelling studies suggest that an individual may require upwards of 100 lifetime 
ocular Ct infections in order to develop TT48, so even a modest reduction in transmission may have significant 
public health implications and reduce the future incidence of TT.
Research is ongoing to address remaining challenges in interpreting trachoma seroprevalence. It is unclear 
how many infections are required for seroconversion to occur. Studies involving urogenital Ct infection suggest 
that just 68% of infected women produce IgG antibodies against Ct49. The intensity of the inflammatory response, 
and the surface area of inflamed mucosa, however, are both likely to differ between the infected conjunctiva and 
infected female urogenital tract. Additionally, further work is needed to determine the half-life of Pgp3 antibod-
ies and seroreversion rates. A previous study that examined a high-prevalence community before and after one 
round of azithromycin suggested that individual anti-Pgp3 antibody levels decreased slightly six months after 
drug treatment, but not enough to be considered seroreversion50. This is similar to results seen for urogenital 
Ct infection, where anti-Pgp3 antibody titres decreased over 4–7 years, but patients were still in the seropositive 
range51. Although we have estimated SRR in this study (Table 4), a more accurate estimate could be obtained 
from a longitudinal study collecting serum samples over a period of years. In low transmission settings, such as 
post-MDA communities, the SRR may be under-estimated if the assumption of a balance between total number 
of seropositive and seronegative individuals does not hold true. Further studies to determine SRR are currently 
underway.
Dichotomising antibody levels to a simple seropositive/seronegative classification provides a straightforward 
estimation of seroprevalence, but SCR estimates could potentially be improved by using a model based on anti-
body levels and multiple sampling time points, as suggested by Yman et al.52. Such models might assume that 
antibody levels increase with age, as exposure is age-dependent and that transmission intensity can be calculated 
by measuring the boost in antibody levels. The use of age group-specific geometric mean antibody levels could be 
explored52 in addition to SCR.
Approximately 4% of 1–9-year-olds were positive for antibodies to Pgp3, which may be due to previously 
acquired ocular Ct infections and/or to ocular or respiratory Ct infections acquired at birth from mothers with 
urogenital Ct infections53. This seroprevalence is within the range of prevalence values previously estimated in 
post-MDA surveys in Tanzania and Nepal14,15. There was also no observed increase in anti-Pgp3 antibody pos-
itivity with age in 1–9-year-olds (Supplementary Table 2), in contrast to what is observed in trachoma-endemic 
settings, whether treatment-naive18 or after 3 rounds of MDA17,21 and is in stark contrast to communities with a 
high prevalence of ocular infection16. Focusing on age-specific changes in seropositivity as a measure of cumula-
tive exposure to ocular Ct infection might offset antibody responses from peri-natal infection, as the latter would 
be expected to be consistent across all ages, or even to decline with increasing age. The data from The Gambia 
presented here, combined with those from a variety of pre- and post-MDA settings, contribute to an understand-
ing of the potential use of antibody-based surveillance of children to ensure a lack of infection recrudescence.
Data from paired pre- and post-MDA surveys, or longitudinal data from MDA surveys, would substantially 
improve parameters and modeling efforts. A detailed series of surveys in one population would help to develop 
generalized models for use elsewhere. The inclusion of infection data for both ocular and urogenital Ct infection 
is needed to further clarify how urogenital Ct contributes to observed seropositivity rates.
Methods
Ethical Review. This study was conducted in accordance with the Declaration of Helsinki. It received 
approval from the London School of Hygiene & Tropical Medicine Ethics Committee (LSHTM; reference 7059) 
and The Gambia Government/Medical Research Council Joint Ethics Committee (SCC1408v2). CDC investiga-
tors did not engage with study participants.
Survey methodology. We conducted a population-based, cluster-random-sampled survey was conducted 
in February-March 2014. The Gambia is divided into geographically-defined census Enumeration Areas (EAs) of 
approximately 600–800 people each. Sampling by EA is equivalent to sampling settlements with probability pro-
portional to their size54. Twenty EAs in each of URR and LRR were randomly selected for participation. Trained 
field workers sensitised villagers and obtained verbal community-consent from each village chief (alkalo). Field 
workers and alkalos compiled a list of households for each EA, from which households were randomly selected 
for census and recruitment. The study and consent form were explained to the head of each selected household 
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and prospective participants. All members of selected households were invited to participate, regardless of age. 
Written (thumbprint or signature) consent was obtained from each participant aged ≥18 years, while a parent or 
guardian provided written consent for each participating child aged under 18 years. Children aged 12–17 years 
provided assent before participating.
The trachoma graders were experienced in field grading for active trachoma and had received regular training 
according to PRET7 and Global Trachoma Mapping Project (GTMP) protocols55,56. After informed consent was 
received, the grader examined both eyes of the subject using a binocular loupe (2.5×) and a torch. The grader 
changed gloves between each participant to minimise the risk of carry-over infection. In accordance with the 
Gambian NEHP policy, antibiotics were provided to individuals with evidence of active trachoma and to residents 
of their household.
Each participant had a finger-prick blood sample collected onto filter paper (Trop-Bio, Townsville, Australia) 
using a sterile single-use lancet (BD Microtrainer, Dublin, Ireland). Each filter paper had six extensions, cali-
brated to absorb 10 µL of blood each. Samples were air-dried for approximately five hours and then placed in indi-
vidual Whirl-Pak plastic bags (Nasco, Modesto, California) which were stored with desiccant sachets (Whatman, 
Little Chalfont, UK) at −20 °C. All samples were shipped to LSHTM for testing.
ELISA Assay. Dried blood spots (DBS) were tested for antibodies against Pgp3 according to the method 
previously described21. Briefly, serum was eluted from dried blots spots then applied to a plate coated with Pgp3 
protein17; known standards were included and assayed in triplicate on each plate. Following incubation, bound 
antibody was detected with HRP-labelled mouse anti-human IgG(Fc)-HRP (Southern Biotech, Birmingham, 
USA). Plates were incubated and washed, and then TMB (KPL, Gaithersburg, USA) was added to develop the 
plates. The reaction was stopped with 1 N H2SO4 and optical density was read at 450 nm (OD450) on a Spectramax 
M3 plate reader (Molecular Devices, Wokingham UK). Readings were corrected for background by subtract-
ing the average absorbance of three blank wells containing no serum, using Softmax Pro5 software (Molecular 
Devices).
Statistical Methods. Blanked OD450 values for samples were normalised against the 200 U standard included 
on each plate21. Laboratory work was undertaken masked to demographic and clinical information. Statistical 
analyses were carried out using R57. Using the “survey” package and assuming a design effect of 2.6555, the 95% 
confidence intervals (CI) were calculated using the Clopper-Pearson interval58. Wilcoxon-Mann-Whitney 
z-scores59 were calculated to compare the proportion seropositive between different regions, ages, and genders. 
The non-parametric test for trend was used to measure the increase in prevalence of anti-Pgp3 antibodies with age.
A finite mixture model25 was used to classify the samples as seropositive or seronegative based on normalised 
OD450 values. The data were fitted using maximum likelihood methods, estimating the distribution parameters for 
each classification group (assumed seropositive or assumed seronegative) as well as the proportion of samples in 
each category to fit the overall distribution of results60. To ensure that the assay had high specificity, the threshold 
for seropositivity was set using the mean of the Gaussian distribution of the seronegative population plus four 
standard deviations (the quantile inclusive of 99.994%) of the seronegative population25,60.
Population age groups were categorized according to known time points of changes in disease prevalence. 
The youngest age group was 1–9-year-olds, who in LRR are likely to have been born during or after MDA with 
azithromycin. The oldest group included people aged 40 years and above, who experienced secular declines in tra-
choma prevalence prior to 1986, the year of the first National Survey of Blindness and Low Vision6. Participants 
aged between 10 and 39 years were grouped into 10-year categories.
Different reversible catalytic models were applied to the analysis of the data from each region. These models 
are described as function of seroconversion and seroreversion rates (SCR and SRR, respectively). SCR is defined 
as the annual mean rate by which seronegative individuals become seropositive upon disease exposure and is 
usually considered as a proxy of the transmission intensity of the population. SRR describes the annual mean rate 
by which seropositive individuals revert to a seronegative status in the absence of re-infection. Three reversible 
catalytic models were fit to the serological data of each region: (i) a simple model that assumes a constant SCR 
(i.e., transmission intensity) over time and people are born seronegative27; (ii) a model with a constant historical 
SCR until a certain change point in the past where SCR changes abruptly to a new value (current SCR); (iii) a 
model that also assumes a historical seroconversion rate until a certain change point followed by a time period 
where SCR decays log-linearly every year. The respective parameter estimation was done using maximum likeli-
hood principles. In particular, the models assuming a change point were estimated via profile likelihood method, 
as described elsewhere25. Model comparison for the data of each region was based on the Akaike’s information 
criterion where the best model (and change point) is the one that provides the minimum estimate of this statistics.
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SUPPLEMENTARY INFORMATION 
 
We provide a more detailed description of the prevalence of clinical signs by age and gender in 
Supplementary Table 1, including prevalence in one-year increments for children 9 years and under, 
as well as extending the age groups up to 60+ years of age. 
Supplementary Table 5.1. Clinical signs assessed in participants in The Gambia 
 Prevalence of clinical signs (%) 
 N TF TI TS TT CO 
Overall 1832 30 (1.6) 4 (0.2) 78 (4.3) 8 (0.4) 1 (0.1)  
LRR 1010 18 (1.8) 4 (0.4) 55 (5.4)  7 (0.7) 1 (0.1) 
URR 822 12 (1.5) 0 23 (2.8) 1 (0.1) 0 
Female 1057 10 (0.9) 3 (0.3) 52 (4.9) 5 (0.5) 1 (0.1) 
Male 776 20 (2.6) 1 (0.1) 26 (3.4) 3 (0.4) 0 
1 year old 65 1 (1.5) 0 0 0 0 
2 years old 88 3 (3.4) 0 2 (2.3) 0 0 
3 years old 101 8 (7.9) 0 1 (1.0) 0 0 
4 years old 96 5 (5.2) 0 1 (1.0) 0 0 
5 years old 96 3 (3.1) 0 1 (1.0) 0 0 
6 years old 89 0 0 2 (2.2) 0 0 
7 years old 77 2 (2.6) 1 (1.3) 0 0 0 
8 years old 78 1 (1.3) 0 0 0 0 
9 years old 52 2 (3.8) 1 (1.9) 0 0 0 
10-19 412 4 (1.0) 1 (0.2) 2 (0.5) 0 0 
20-29 191 0 0 1 (0.5) 0 0 
30-39 152 1 (0.7) 1 (0.7) 5 (3.3) 0 0 
40-49 99 0 0 5 (5.1) 0 0 
50-59 95 0 0 15 (15.8) 2 (2.1) 0 
60+ 141 0 0 43 (30.5) 6 (4.3) 1 (0.7) 
1-9 year olds -LRR 383 14 (3.7) 2 (0.5) 1 (0.3) 0 0 
1-9 year olds -URR 359 11 (3.1) 0 6 (1.7) 0 0 
≥10 year olds-LRR 627 4 (0.6) 2 (0.3) 54 (8.6) 7 (1.1) 1 (0.2) 
≥10 year olds-URR 463 1 (0.2) 0 17 (3.7) 1 (0.2) 0 
TF = trachomatous inflammation, follicular; TI = trachomatous inflammation-intense; TS = 
trachomatous scarring; TT = trachomatous trichiasis; CO = corneal opacity 
LRR = Lower River Region; URR = Upper River Region 
Similarly, we provide a more detailed description of the seroprevalence of anti-Pgp3 antibodies in 
LRR and URR by region, gender and age in Supplementary Table 2. We again provide the 
seroprevalence in one-year increments for children 9 years and under, to facilitate comparison with 
other seroprevalence studies. 
 
 
 
174 
 
Supplementary Table 5.2. Seroprevalence of anti-Pgp3 antibodies in The Gambia by 
region, gender and age 
 % seropositive (95% confidence interval) 
 Overall Lower River Region Upper River Region 
 N n % 95%CI N n % 95%CI N n % 95% CI 
Overall 1868 489 26.18% (24.2-28.2) 1028 313 30.45% (27.7-33.4) 840 176 20.95% (18.3-23.9) 
Female 1080 341 31.57% (28.8-34.5) 597 215 36.01% (32.2-40.0) 483 126 26.09% (22.2-30.2) 
Male 788 148 18.78% (16.1-21.7) 431 98 22.74% (18.9-27.0) 357 50 14.01% (10.7-18.1) 
1 year old 65 2 3.08% (0.5-11.6) 29 0 0 (0-1.9) 36 2 5.56% (1.0-20.0) 
2 years old 88 2 2.27% (0.4-8.7) 33 2 6.06% (1.1-21.6) 55 0 0 (0-8.1) 
3 years old 101 6 5.94% (2.4-13.0) 59 2 3.39% (0.6-12.7) 42 4 9.52% (3.1-23.5) 
4 years old 96 7 7.29% (3.2-14.90 46 3 6.50% (1.7-18.9) 50 4 8.00% (2.6-20.1) 
5 years old 96 6 6.25% (2.6-13.6) 58 4 6.90% (2.2-17.5) 38 2 5.26% (1.0-19.1) 
6 years old 89 4 4.49% (1.4-11.7) 40 2 5.00% (0.9-18.2) 49 2 4.08% (0.7-15.1) 
7 years old 77 6 7.79% (3.2-16.8) 42 2 4.80% (0.8-17.4) 35 4 11.43% (3.7-27.7) 
8 years old 78 6 7.69% (3.2-16.6) 41 3 7.30% (1.9-21.0) 37 3 8.11% (2.1-23.0) 
9 years old 52 8 15.38% (7.3-28.6) 35 7 20.00% (9.1-37.5) 17 1 5.88% (0.3-30.8) 
1-9 742 47 6.33% (4.5-8.0) 383 25 6.53% (3.9-8.9) 359 22 6.13% (3.8-8.8) 
10-19 412 65 15.78% (12.2-19.5) 231 40 17.32% (12.8-23.0) 181 24 13.26% (8.8-19.3) 
20-29 191 60 31.41% (25.0-38.6) 101 35 34.65% (25.6-44.8) 90 25 27.78% (19.1-38.4) 
30-39 152 79 51.97% (43.8-60.1) 79 44 55.70% (44.1-66.7) 73 35 47.95% (36.2-59.9) 
40-49 99 65 65.66% (55.4-74.7) 62 47 75.81% (63.0-85.4) 37 18 48.65% (32.2-65.3) 
50-59 95 69 72.63% (62.4-81.0) 59 46 77.97% (64.9-87.3) 36 23 63.89% (46.2-78.7) 
60+ 141 104 73.76% (65.6-80.6) 95 75 78.95% (69.1-86.4) 46 29 63.04% (47.5-76.4) 
 
 
In our paper, we set the threshold for positivity at the mean of the Gaussian distribution of the 
seronegative population plus four standard deviations, 0.810 OD450nm. Previous studies using the 
Pgp3 ELISA have commonly used a threshold set as three standard deviations above the mean of the 
negative population (the 97.5% confidence interval) 15,20,21. Supplementary Figure 1 shows the 
positive and negative populations with both thresholds. 
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Supplementary Figure 5.1. Assumed seronegative (red) and assumed seropositive 
(green) populations as estimated using Finite Mixture Modelling.  
 
The dashed line shows the threshold set using the mean of the negative population plus three 
standard deviations, while the solid line shows the more specific threshold set using the mean of the 
negative population plus four standard deviations. 
Below we present the results had we used the typical threshold set using the mean of the Gaussian 
distribution of the seronegative population plus three standard deviations, 0.673 OD450nm. Note that 
the estimated time change in seroconversion rates does not change. 
Supplementary Table 5.3. Seroprevalence of anti-Pgp3 antibodies by region, gender and 
age, Lower River Region and Upper River Region, The Gambia, 2014. 
 Both regions combined Lower River Region Upper River Region 
  Prevalence  Prevalence  Prevalence 
 N % 95%CI N % 95%CI N % 95% CI 
Overall 1868 26.2 (24.2-28.2) 1028 30.5 (27.7-33.4) 840 20.9 (18.3-23.9) 
Gender          
Female 1080 31.6 (28.8-34.5) 597 36.0 (32.2-40.0) 483 26.1 (22.2-30.2) 
Male 788 18.8 (16.1-21.7) 431 22.7 (18.9-27.0) 357 14.0 (10.7-18.1) 
Age (years)          
1-9 742 6.3 (4.5-8.0) 383 6.5 (3.9-8.9) 359 6.1 (3.8-8.8) 
10-19 412 15.8 (12.2-19.5) 231 17.3 (12.8-23.0) 181 13.3 (8.8-19.3) 
20-29 191 31.4 (25.0-38.6) 101 34.6 (25.6-44.8) 90 27.8 (19.1-38.4) 
30-39 152 51.9 (43.8-60.1) 79 55.7 (44.1-66.7) 73 47.9 (36.2-59.9) 
40+ 335 71.0 (65.8-75.8) 216 77.8 (71.5-83.0) 119 35.2 (28.6-42.3) 
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Supplementary Figure 5.2. Proportion of participants who were seropositive for anti-
Pgp3 antibodies using a threshold set at 0.673 OD450nm, by age group and region, 
Lower River Region (LRR) and Upper River Region (URR), The Gambia, 2014.  
 
Vertical bars indicate 95% CIs.  
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Supplementary Figure 5.3. Proportion of participants who were seropositive for anti-
Pgp3 antibodies using a threshold set at 0.673 OD450nm, by age group and gender, 
Lower River Region and Upper River Region, The Gambia, 2014.  
Vertical bars indicate 95% confidence intervals. 
 
Supplementary Table 5.4. Maximum likelihood parameter estimates and the respective 
95% confidence intervals (in brackets) for the seroconversion and seroreversion rates 
(SCR and SRR, respectively); data collected from participants in Lower River Region and 
Upper River Region, The Gambia, 2014. 
 P-values <0.05 are indicative of a change in transmission intensity when comparing two reversible 
catalytic models, one assuming constant and stable transmission over and another assuming a 
sudden reduction in transmission intensity somewhere in the past. 
 SCRpast SCRcurrent SRR Fold change p-value 
Region      
Lower River 
Region 
0.062  
(0.038, 0.100) 
0.014  
(0.011, 0.018) 
0.006  
(0.003,0.014) 
4.4 <0.001 
Upper River 
Region 
0.038  
(0.017, 0.082) 
0.011  
(0.009, 0.016) 
0.011  
(0.003, 0.039) 
3.5 <0.001 
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Chapter 6- Analysis of age-dependent mean antibody levels is more 
informative than qualitative sero-status analysis for studies on 
elimination of trachoma. 
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Summary 
The previous chapters have explored setting seropositivity thresholds and estimating changes in 
seroprevalence. These analyses have relied on dichotomising the continuous data generated from 
ELISA and MBA assays. 
This chapter explores the use of antibody levels, rather than seroprevalence, to monitor effects of 
MDA for trachoma elimination and to compare levels between populations, including those where 
trachoma has been eliminated as a public health problem and where MDA is ongoing. 
In the following analyses, semi-quantitative antibody levels were used to create age-dependent 
geometric mean antibody level curves. This secondary analysis of antibody level data used a novel R 
package, ‘tmleAb’, which uses an ensemble machine learning approach to generate age-dependent 
antibody curves. These were compared between pre- and post-MDA communities of all ages in 
Nepal and a post-MDA community in Tanzania. Additionally, curves were compared for the two 
Gambian populations of all ages previously described in this thesis. Part of the analysis examined 
age-dependent curves for children from four countries between the ages of 1-9 years as this is the 
age range of interest in measuring the prevalence of clinical signs of trachoma. The final comparison 
was between the Gambian population, where there is a low prevalence of both ocular and genital Ct 
infection, and the Solomon Islands, where the prevalence of genital Ct infection is much higher 
which has affected the level of antibodies in the youngest children of the population. 
Using antibody levels removes the need to establish the somewhat arbitrary thresholds between 
positive and negative samples and uses the ‘raw’ antibody level data directly. These analyses are 
more sensitive to changes in antibody levels and capture information as levels change that may not 
be otherwise captured if the change were too small to cross the positivity threshold. Additionally, 
the analysis in this chapter shows that at a population-level, wider confidence intervals are seen 
when a population is under the greatest force of Ct infection.  
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6.1 Abstract 
Background 
Detecting antibodies against Chlamydia trachomatis (Ct), the cause of trachoma, may be useful for 
surveillance following population-level interventions, which include antibiotic mass drug administration 
(MDA). More information may be generated by analysing antibody levels rather than simply estimating 
seroprevalence. 
Methodology 
We used the level of antibodies against Pgp3, a Ct-specific antigen, to examine the intensity of Ct 
transmission at population level, using R package ‘tmleAb’. Dried blood spot or serum samples from seven 
countries where trachoma is either currently or was previously endemic were employed. Levels of IgG 
against Pgp3 were measured using either a multiplex bead assay (MBA) or an ELISA. Semi-quantitative 
antibody levels were used to create age-dependent geometric mean antibody level curves.  
The following comparisons were made: 1) pre- and post-MDA antibody levels from individuals of all ages in 
Nepal were compared with post-MDA data from Tanzania; 2) antibody levels from individuals of all ages in 
two regions of The Gambia, one of which had previously received MDA; 3) antibody levels in children aged 
1–9 years from peri-elimination populations in The Gambia, Uganda, and Laos were compared with those 
from children in Kiribati, a country with ongoing transmission of ocular Ct; and 4) antibody levels from 
individuals of all ages in The Gambia were compared with those from residents of the Solomon Islands, a 
country with a high prevalence of urogenital Ct infection. 
Significance 
In children from populations in which trachoma has been, or is close to being, eliminated as a public health 
problem, there is little or no increase in mean antibody levels with increasing age. In populations with a high 
prevalence of urogenital Ct infection, there is a rapid increase in signal at the age of sexual debut. Wide 
confidence intervals around age-standardised means suggest increased exposure to antibody-inducing Ct 
infections.  
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6.2 Introduction 
Ocular infection with Chlamydia trachomatis (Ct) causes trachoma, the leading infectious cause of blindness 
[1]. Trachoma is targeted for global elimination as a public health problem by 2020 [2]. Elimination requires 
the district-level prevalence of the active trachoma sign trachomatous inflammation—follicular (TF) to be 
<5% in 1–9-year-olds, and the district-level prevalence of trachomatous trichiasis (TT) unknown to the health 
system to be <0.2% in ≥15-year olds [3]. Any district in which the prevalence of TF and/or TT remains above 
the elimination threshold is targeted for some or all of the four components of the “SAFE” strategy: Surgery 
for TT, Antibiotics to clear infection, Facial cleanliness and Environmental improvement, particularly better 
access to water and sanitation. The A, F and E components of SAFE are intended to reduce the transmission 
of ocular Ct infection [1]. 
Recent evidence has shown that high prevalence of TF in 1–9-year-olds does not always correlate with high 
prevalence of ocular Ct infection [4], that TF can occur in the absence of any bacterial infection [5] and that a 
follicular conjunctivitis resembling TF may be common among people who have never had an ocular 
infection with Ct [6]. In light of this there are some concerns that antibiotic mass drug administration (MDA) 
might be administered in populations where there is no (or very limited) ongoing transmission of ocular Ct. 
There have been calls for the use of assessment methods that more directly measure the extent to which Ct 
is prevalent within a community [7,8]. Serological tests that could be used to measure the prevalence of 
antibodies against Ct have been proposed as alternative or additional measures for post-MDA surveillance 
surveys [9], which the World Health Organization (WHO) recommends should take place at least two and a 
half years after the last round of MDA [10].  
Pgp3 is a highly specific and immunogenic Ct antigen [11,12] and has been used extensively in serological 
studies of both ocular [9,13–24] and genital Ct infections [12,25–36]. Previous studies have evaluated the 
use of the age-specific prevalence of serum antibodies against Ct (classifying individuals either as 
seropositive or seronegative) as a potential marker of the intensity of transmission of ocular Ct infection 
[8,19,21,22,24]. Additional studies have used the prevalence of antibodies against Ct to estimate the 
seroconversion and seroreversion rates following ocular Ct infection [17,18]. Studies to date have measured 
seroprevalence by using thresholds to dichotomise semi-quantitative antibody measurements as 
positive/negative results, but resulting prevalence estimates can vary widely depending on the reference 
population and method used [17,37].  
Other approaches to serological analysis have proved useful elsewhere. For instance, the use of antibody 
acquisition models has been of benefit in malaria studies in populations with declining transmission. These 
models produce more precise estimates of transmission patterns than seroprevalence and may better 
estimate transmission intensity, particularly in low prevalence settings [38]. Ensemble machine learning has 
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meanwhile been used to fit age-dependent antibody curves for diverse pathogens that may be included in 
multiplex bead assays (MBA) [39]. Such analytical methods use semi-quantitative antibody results, such as 
those from ELISA or MBA, and remove the need to define a threshold between seropositive and 
seronegative samples. This may provide more detailed and, crucially, more consistent findings between 
studies, especially in settings with very low transmission intensity which would otherwise require a very 
large sample size [40]. Semi-quantitative data are also of intrinsic value where transmission is in decline, as 
in such an environment the average age of first infection is likely to increase, and the frequency of repeat 
infections to diminish. Both of these factors would contribute to a slower increase in population-level 
antibody levels with age [39]. Antibody acquisition models therefore have the potential to reflect 
transmission more appropriately than do analyses using proportions of individuals who demonstrate 
responses above investigator-defined thresholds.  
We used a new ensemble machine learning approach to antibody acquisition modelling to compare age-
dependent antibody curves from a series of cross-sectional population-based trachoma studies. This novel 
analysis using  R package ‘Targeted maximum likelihood estimation for antibody measurements’ (tmleAb) 
[39] includes an ensemble machine learning approach to antibody acquisition modelling which is 
computationally advanced but straightforward to implement with the open-source statistical analysis 
software R [41]. The populations studied include pre-, peri-, and post-elimination communities, with 
antibody levels measured using both ELISA and MBA. Age-specific seroprevalence data from these studies, 
using various methods to determine the cut-off between seronegative and seropositive, have been 
previously published [17,18,20,21,23,42]. We hypothesise that the age-antibody level curve in populations in 
which trachoma has been eliminated as a public health problem will have a characteristic profile, differing 
significantly from that derived from populations in which Ct infection remains a problem. 
 
6.3 Methods 
6.3.1 Ethics 
This study was a secondary analysis of de-identified data. All of the antecedent studies [17,18,20,21,23,42] 
from which data were sourced had received approval from the relevant ethics committees or review boards. 
Ethical approval for secondary analysis of the data was received from London School of Hygiene & Tropical 
Medicine (Ref 16187). All studies were conducted in accordance with the Declaration of Helsinki.  
 
6.3.2 Datasets 
Table 6.1 summarizes the datasets used in the antibody acquisition analysis, including the population 
demographics, assay used, seroprevalence, and disease and infection prevalence for each study. 
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6.3.3 Measuring effects of MDA on antibody levels 
Serological data were compared between pre- and post-MDA populations in 4 villages in Kapilvastu District 
of southwest Nepal [23]. In 2000–2002, serum samples were collected from participants of all ages and 
stored at -20°C. The prevalence of TF in children aged 1–9 years was 17.6% (95% Confidence Interval: 9.4–
29.7). Three annual rounds of MDA were administered (2007–2009) and in 2014, blood samples were 
collected from the population. For children under 15 years of age, dried blood spots (DBS) were collected 
while serum samples were collected from participants aged 15 years and older. Disease prevalence was 
measured again in 2014: the prevalence of TF had declined to 0% (95CI: 0-5.6) in 1–9-year olds (who had not 
yet been born at the time of the previous survey) [23]. Serum samples from 2000–2002 and serum and DBS 
from 2014 were analysed. The prevalence of antibodies against Pgp3 was 59.6% (95CI: 46.1–71.8) in the first 
sample collection: the prevalence of antibodies was 3% in the samples collected in 2014 [23]. 
Antibody levels from Nepal were compared to those from a Tanzanian village in which ocular Ct infection 
was eliminated in 2005, following two rounds of high-coverage (>90%) MDA [18]. This study saw the 
prevalence of ocular Ct infection decline from 9.5% (95CI: 7.8-11.6) prior to the first round of MDA in 2000 
[43] to 0% (95CI: 0-0.01) in 2005, three years after the second round of MDA [44].   
 
6.3.4 Evaluating antibody levels in a peri-elimination setting 
In The Gambia, despite a secular decline in trachoma prevalence from 1986–2006 associated with improved 
access to water and sanitation [45–50], the TF prevalence remained above the elimination threshold in some 
areas. Antibiotic MDA was therefore required in several regions of the country in 2007–2010 [46,48,51], 
including Lower River Region (LRR) but not Upper River Region (URR). The Gambia was subsequently 
considered to be in the peri-elimination phase. The most recent study, which examined samples of residents 
of all ages across LRR and URR in 2014, showed low prevalence of TF (3.4%), and a seroprevalence across the 
study population ranging from 4% in 1–9-year-olds to 63% in those aged 40 years and older [20,52]. 
Antibody levels were compared between the two regions. 
 
6.3.5 Comparing Ct exposure in children  
DBS were collected from children aged 1–9 years in Laos, Uganda and Kiribati [17,21]. In Laos, samples were 
collected from in three provinces considered to be potential trachoma “hot spots” [53]. Specific trachoma 
elimination interventions, including antibiotic MDA, have never been undertaken in Laos; the country was 
recently validated as having eliminated trachoma as a public health problem [54]. Samples from Uganda 
were collected as part of an impact survey, following three years (2010–2012) of implementation of the A, F 
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and E components of the SAFE strategy. DBS were collected from children in Kiribati in work coupled to 
surveys supported by the Global Trachoma Mapping Project [55], which was designed to determine the need 
for interventions against trachoma. Antibody levels from children in these three countries were compared to 
those from children aged 1–9 years in The Gambia, as described above. 
 
6.3.6 Visualising the relative impact of urogenital and ocular Ct infections on antibody levels  
DBS were collected from participants of all ages in the Solomon Islands, where there is a low prevalence of 
ocular Ct infection (1% in children aged 1–9 years) [4] but high prevalence of urogenital Ct infection [56,57]. 
The prevalence of urogenital Ct infection has been estimated to be as high as 28% in women under the age 
of 30 years in Honiara, the capital city [56], although this may have declined following azithromycin MDA 
given as part of trachoma elimination efforts [57]. Antibody levels were compared to those from individuals 
of all ages in The Gambia, where there is a low prevalence of ocular [48] and genital Ct infection [58,59]. 
 
6.3.7 Specimen handling 
Sample management has previously been described for each dataset, but in brief: specimens from The 
Gambia, Laos, Uganda, Solomon Islands and Kiribati were shipped to the London School of Hygiene & 
Tropical Medicine, London, UK, for testing. They were stored at -20°C before being assayed using a Pgp3-
specific ELISA [17]. Samples from Nepal and Tanzania were shipped to the US Centers for Disease Control 
and Prevention, Atlanta, USA, at ambient temperature (for DBS) or on cold packs (for sera), and stored at -
20°C before being assayed for antibodies against Pgp3 using MBA [24]. 
 
6.3.8 Serological analysis of anti-Ct-antibodies 
Specimens from The Gambia, Laos, Uganda, Solomon Islands and Kiribati were assayed using a Pgp3-specific 
ELISA as previously described [17]. In brief, serum was eluted from DBS then applied to a plate coated with 
Pgp3 protein; known standards were included on each plate and assayed in triplicate. Following incubation, 
bound antibody was detected using HRP-labelled mouse anti-human IgG(Fc) (Southern Biotech, Birmingham, 
USA). Plates were incubated and washed and then developed using 3,3′,5,5′-tetramethylbenzidine (TMB, 
KPL, Gaithersburg, USA). The reaction was stopped with 1 N H2SO4 and optical density was read at 450 nm 
(OD450) on a Spectramax M3 plate reader (Molecular Devices, Wokingham UK). Readings were corrected for 
background by subtracting the average absorbance of three blank wells containing no serum using Softmax 
Pro5 software (Molecular Devices, Wokingham, UK).  
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Specimens from Tanzania and Nepal were assayed using an MBA as previously described [24]. Briefly, Pgp3-
coupled beads were added to each well of a filter plate (Millipore) and washed. Control sera and serum 
eluted from DBS were added in duplicate then incubated. Following incubation, antibodies were detected 
with biotinylated mouse anti-human total IgG (Southern Biotech, Birmingham, AL) and biotinylated mouse 
antihuman IgG4 (Invitrogen, South San Francisco, CA). Plates were incubated and washed then developed 
with R-phycoerythrin-labelled streptavidin and a solution of bovine serum albumin, Tween 20 and sodium 
azide in PBS. Beads were suspended in PBS, shaken, and immediately read on a BioPlex 200 instrument (Bio-
Rad, Hercules, CA) equipped with Bio-Plex Manager 6.0 software (Bio-Rad). The median fluorescence 
intensity (MFI) for each sample was recorded and background from the blank well subtracted out (MFI-BG).  
 
6.3.9 Statistical analysis 
Statistical analyses were carried out using R [60]. Each cross-sectional survey captured age, gender, signs of 
trachoma, community of residence and other characteristics. These data were combined with laboratory 
results which in some instances included results from nucleic acid amplification tests for ocular Ct infection 
(Table 6.1). A nominal value was added to zero data: 0.001 for ELISA data, 1 for MBA data.  
The R package ‘tmleAb’ [39] was used to fit age-dependent antibody curves. This package uses  data 
adaptive ensemble learning  [61] based on multiple models to create an algorithm which is used to minimise 
the variance in the distribution of data. In this case, the algorithm was based on the ‘SuperLearner’ 
ensemble [61], and included a generalised additive model, generalised linear model, geometric mean, local 
regression (loess) and Yman [38], for targeted maximum likelihood estimation [62] of antibodies by age 
group [63].  
Because the range of possible values varied between ELISA (which measures absorption in units of optical 
density) and MBA (which measures fluorescent intensity in units of median fluorescent intensity [MIF-
background]) data, the tmleAb script was modified to exponentiate the ELISA data, adjusting for the reduced 
range of possible values. Also for this reason, datasets generated using the MBA platform (Nepal and 
Tanzania) could not be compared to those generated using ELISA (The Gambia, Uganda, Laos, Kiribati and 
the Solomon Islands). 
Data between studies were compared using age ranges that were common between studies. The parameter 
of interest was the marginal difference between age groups in geometric mean antibody levels. P-values for 
the geometric mean antibody level by age group were calculated accounting for stratified data (within age 
bands) and adjusted using a Bonferroni correction [39]. 
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6.3.10 Seroprevalence estimation 
Seroprevalence data obtained in each of the data sets were previously published [17,18,20,21,23,42]. 
Thresholds used to establish seropositivity were determined either by using finite mixture modelling [17] or 
by receiver operator characteristics (ROC) curves [24]. 
 
6.4 Results 
6.4.1 Effect of MDA on antibody levels 
In Nepal, pre-MDA data show a sharp increase in antibody levels with age in the youngest age groups, 
reaching a plateau around age 10 years then remaining high in older age groups. In contrast, there was a 
much slower rise in levels of antibodies in younger participants post-MDA (Figure 6.1A). The post-MDA 
antibody curves did not reach a plateau until around age 50 years. Until age ~20 years there was at least a 
log10 difference in geometric mean antibody levels between age-equivalent participants in the two surveys: 
for example the average 10-year-old in post-MDA Nepal had 100 times lower antibody levels against Ct than 
the average 10-year-old in the pre-MDA population. The antibody acquisition model shows lower levels of 
antibodies in the youngest participants, with a sustained and significant difference between the pre- and 
post-MDA populations. The confidence intervals (CI) surrounding the mean estimates (Figure 6.1B) provide 
additional information, suggesting that not only were average antibody levels higher in children in 2002, but 
also that the absolute majority of children aged 6–10 years  in 2002 had high levels of antibodies whilst the 
majority in 2014 had negligible levels. There are wide CI associated with the geometric mean antibody level 
among 1–5-year-olds in pre-MDA Nepal; CI are narrower for other age groups in the pre-MDA population 
and for all ages they are wider than the CI for the corresponding age group in post-MDA Nepal. In 2014 there 
was no period in which the geometric mean antibody level varied to this extent, suggesting that no age 
group was (compared to others) at particularly increased risk of seroconverting (Figure 6.1B). 
Figure 6.2 compares Nepal’s pre- and post-MDA data to data from a community in Tanzania where 
transmission of ocular Ct was interrupted with MDA. The post-MDA data from Nepal follow the same curve 
as the data from Tanzania (Figure 6.2A), providing some empirical indication that the 2014 Nepal survey was 
conducted in a district in which ocular Ct transmission was low or negligible. The confidence intervals are 
wide amongst 21–30-year-olds in both Tanzania and post-MDA Nepal (Figure 6.2B), while in pre-MDA Nepal, 
confidence intervals are widest in the youngest age group. 
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Table 6.1. Datasets used in the antibody acquisition analysis 
Samples analysed using Pgp3-specific ELISA 
Country  Survey 
pre- or 
post-
MDA 
Age 
range 
(years) 
N Antigen Threshold 
(OD450) 
Seroprevalence 
% (95CI) 
TF prevalence in 
 1–9-year-olds % 
(95CI) 
Infection 
prevalence 
%(95CI) 
The Gambia 
[17,20] 
post 1–90 1868 Pgp3 0.672 26.2 (24.3-28.3) NA 0.5 (0-0.9) [48]  
1–9 738 Pgp3 0.672 6.4 (4.8-8.4) 1.6 (0.9-2.8)  
Uganda [17] post 1–9 2700 Pgp3 0.5537 17.1 (15.7-18.6) 3.4 (2.8-4.8) 0.3 (0.1-0.6) [9] 
Laos [17] post 1–9 952 Pgp3 0.696 15.6 (13.5-18.1) 1.6 (1.0-2.6) Not measured 
Kiribati [21] pre 1–9 397 Pgp3 0.245 53.0 (48.0-57.8) 28.0 (23.8-32.6) 24.0 (20.0-28.4) 
Solomon 
Islands [4] 
post 1–90 1511 Pgp3 0.7997 42.2 (39.8-44.7) NA Not measured 
1–9 458 Pgp3 0.7997 18.0 (14.7-21.7) 14.2 (11.3-17.7) 9.8 (4.6-19.9)* 
 
Samples analysed using Pgp3-specific MBA assay 
Country Survey 
pre- or 
post-
MDA 
Age 
range 
(years) 
N Antigen Threshold 
(MFI-Bkgd) 
Seroprevalence 
% (95CI) 
TF prevalence in 
 1–9-year-olds % 
(95CI) 
Infection 
prevalence % 
(95CI) 
Nepal [23] pre 2–80  659 Pgp3 801 77.1 (73.7-80.1) 17.6 (14.9-20.7) Not measured 
post 3–90 646 Pgp3 801 34.9 (31.3-38.6) 0 (0-0.6) Not measured 
Tanzania 
[18] 
post 1–87 557 Pgp3 1024 31.1 (27.4-35.0) 6.5 (4.7-8.8) 0 (0-0.7) [44] 
MDA=mass drug administration; TF=trachomatous inflammation—follicular; 95CI= 95% Confidence Interval; NA=not applicable. MFI-
Bkgd=Median fluorescence intensity with background subtracted. OD450 = optical density at 450 nm. ELISA = enzyme-linked 
immunosorbent assay. MBA = multiplex bead assay. 
* Swabs for infection testing were only collected from the 61 children in whom TF was present. 
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Figure 6.1. A shift in the C. trachomatis Pgp3 age-antibody level curves demonstrates a reduction in transmission following antibiotic mass drug 
administration (MDA) in Kapilvastu District, Nepal. IgG antibody responses to Pgp3 measured in serum sampled both prior to mass drug administration 
(MDA) in 2002 (n=659, orange) and after MDA in 2014 (n=646, blue). MDA was performed in three annual rounds (2007, 2008 and 2009). 1A shows age-
specific geometric means are shown as curves. Shaded bands show 95% confidence intervals. 1B shows age-adjusted geometric mean antibody response 
(ages 1-20) and 95% confidence intervals for the same both before (2002, orange) and after (2014, blue) azithromycin MDA. Age is limited to individuals 20 
years and younger to demonstrate the width of the confidence intervals in the youngest age group. Differences between means are significant (Bonferroni 
corrected p<2e-16) except for the 1–5-year-olds age group. Data are stratified into 5–year age categories. 
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Figure 6.2. C. trachomatis Pgp3 age-antibody level curves from Kapilvastu District, Nepal, compared to a population in Rombo, Tanzania, where 
ocular Ct infection was eliminated in 2005 [44]. 2A shows the geometric mean antibody levels by age and survey. Data from the pre-mass drug 
administration (MDA) Nepal population (2002, orange) is compared to the post-MDA Nepal population (blue, 2014) as well as a population from 
Rombo, Tanzania (pink) where ocular Ct infection was eliminated following antibiotic MDA. Shaded bands show 95% confidence intervals. 2B shows 
age-adjusted geometric mean antibody responses in individuals aged 10–50 years and 95% confidence intervals for the two sets of samples from Nepal 
before (2002, orange) and after (2014, blue) azithromycin MDA and the post-MDA population in Rombo (pink). Differences between Nepal pre-MDA 
and Rombo means are significant (Bonferroni corrected p<0.002) for the 1–10 and 11–20 years age categories, and (Bonferroni corrected p<0.2e-16) for 
the 21–30 years age category. Data are stratified into 10–year age categories.  
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6.4.2 Antibody levels in the peri-elimination setting 
Figure 6.3 shows the age-dependent geometric mean of anti-Pgp3 antibodies in the two Gambian regions 
studied: LRR and URR. Age-dependent means are equal between the two regions in the youngest 
participants and there is only a difference in the adult population (Figure 6.3A). Closer examination of the 
age-adjusted mean shows consistently low antibody levels across the youngest age groups, with narrow 
confidence intervals for the adjusted geometric mean antibody levels for participants aged 1–9 years; the 
width of the confidence intervals is slightly wider amongst 10–12-year-olds and 13–15-year-olds than in the 
younger age categories, while still overlapping with those of other age groups (Figure 6.3B). 
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Figure 6.3. Variation in the C. trachomatis Pgp3 age-antibody level curves between populations in two regions of The Gambia. Communities in Lower 
River Region (LRR, N=1,010, orange) received three annual rounds of antibiotic mass drug administration (MDA), while those in Upper River Region (URR, 
n=822, blue) received none. 3A shows the age-dependent geometric means. Shaded bands show 95% confidence intervals. 3B shows the age-adjusted 
geometric mean antibody response for children aged 1–15 years with 95% confidence intervals for the two regions. Differences between means are not 
significant (Bonferroni corrected p=0.619). Data are stratified into 3-year age categories.
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6.4.3 Comparing Ct exposure in children  
Figure 6.4 shows the combined age-adjusted geometric means of children aged 1–9 years from four 
countries: Laos, Uganda, The Gambia and Kiribati. Disease and infection prevalence estimates in each setting 
are provided in Table 6.1. 
The geometric mean anti-Pgp3 levels for Laos, Uganda and The Gambia are all similarly low: under 0.5 OD450, 
and nearly horizontal. In contrast, the mean antibody level for Kiribati increases steeply with increasing age, 
and at all ages is higher than those for the other three countries, suggesting ongoing intense transmission of 
Ct. The confidence intervals are wider for every age group in Kiribati than in any other population included 
here. 
 
Figure 6.4. C. trachomatis Pgp3 age-antibody level curves between children aged 1–9 years in The Gambia, 
Uganda, Laos and Kiribati. The age-adjusted geometric mean antibody levels, including 95% confidence 
intervals, for Kiribati (green) compared to those from Laos (blue), Uganda (orange) and The Gambia (pink); 
data are stratified into 3-year age categories. The geometric means of age groups in Kiribati were compared 
to those from Laos, where trachoma has been certified as being eliminated. Differences between means are 
significant (Bonferroni corrected p<0.01) for 1–3 years age group and (Bonferroni corrected p>0.002) for 4–6 
years age group and 7–9 years age group. 95% confidence intervals are shown. Data are stratified into 3-year 
age categories. 
 
6.4.4 Relative impact of genital and ocular infections on antibody levels  
Figure 6.5A shows the age-dependent geometric mean of anti-Pgp3 antibodies populations in The Gambia 
and the Solomon Islands across all ages. The summary curves from The Gambia shows a change in slope, 
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increasing around 20 years, while the summary curve for the Solomon Islands increases sharply from 15 to 
30 years, then drops from 30 to 70 years of age before increasing again. For all ages, the summary curve in 
the Solomon Islands is higher than that of The Gambia. Figure 6.5B shows the geometric mean antibody level 
stratified in age groups with the geometric mean values from the Solomon Islands and The Gambia.  
In both Figures 6.5A and 6.5B, the age-dependent mean antibody levels are higher in the Solomon Islands 
than in The Gambia. In the Solomon Islands the age-dependent antibody level begins to increase around 15 
years, while in The Gambia, mean antibody levels increase at a lower rate after 20 years. Confidence 
intervals are wider in the Solomon Islands beginning in age group 21–30 and remain wide thereafter. 
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Figure 6.5. Variation in the C. trachomatis Pgp3 age-antibody level curves between The Gambia and the Solomon Islands. 5A shows the age-dependent 
geometric mean in the Solomon Island samples (n= 1,499, orange) and The Gambia (n=1,805, blue). Shaded bands show 95% confidence intervals. 5B shows 
the age-adjusted geometric mean antibody response by age category. Differences between means are significant (Bonferroni corrected p<0.01) for 1-10 
years and 50+ age groups and (Bonferroni corrected p<0.002) for all other age groups, although optical densities measured at an intensity >2.0 are 
associated with higher levels of error. Data are stratified into 10-year age categories. 
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6.5 Discussion 
We have evaluated age-dependent antibody response to infection with Ct in seven different populations 
using an ensemble machine learning approach. Previous serological studies have assigned 
seropositive/seronegative status to samples, however determining thresholds for estimation of prevalence 
can be problematic [17]. This novel analysis, using R package ‘tmleAb’, removes the need to dichotomise 
continuous ELISA or MBA data and produces age-dependent mean antibody levels. 
These age-dependent geometric mean antibody levels produce characteristic curves based on Ct 
transmission intensity at different ages. Samples collected from trachoma-endemic populations show a rapid 
increase in antibody levels with age in 1–9-year-olds, as seen in Kiribati (Figure 6.4), and continuing to rise 
steeply before plateauing around 50 years of age, as seen in the pre-MDA population in Nepal (Figure 6.1A 
and 6.2A). In post-MDA and peri-elimination communities, antibody levels increase much more slowly, as 
seen in the samples from post-MDA Nepal and Tanzania (Figure 6.2A) and The Gambia (Figure 6.3A). In 
children aged 1–9 years, the antibody acquisition curve is virtually horizontal in peri- and post-elimination 
populations (Figure 6.4), suggesting there is a characteristic shape to age-dependent mean antibody 
acquisition curves in populations where trachoma is no longer a public health concern. This could be used to 
support, or as an alternative indicator to, the clinical findings of TF. As decisions regarding implementation 
and cessation of MDA are based on the prevalence of TF in children aged 1–9 years, there may be no need to 
extend serological surveys to older age groups. Extending the survey to include adults may provide 
information about the prevalence of genital Ct infections, which can contribute to the prevalence of 
antibodies in the youngest participants through vertical transmission of Ct during birth. 
Interestingly, the relative width of confidence intervals around age-stratified means may indicate when a 
population is under the greatest force of Ct infection, either ocular or genital. The confidence interval 
around the mean is impacted by the variability (as standard deviation) in the sampled population, the 
specified confidence level (95% in this analysis) and the sample size (all relatively similar in this analysis) [64]. 
Prior to infection with Ct, mean antibody levels are low, with narrow confidence intervals. When infection 
occurs within an age group, it is likely to occur asynchronously amongst different individuals in that group, 
thus producing a stimulus towards variability in the level of antibodies between individuals. In pre-MDA 
Nepal, when the prevalence of TF in 1–9 year olds was 17.6% (95CI 14.9-20.7), the widest confidence 
intervals were seen in the youngest population, children aged 1–5 years (Figures 6.1B and 6.2B). Similarly, in 
Kiribati, where TF prevalence in children aged 1–9 was 28.0% (95CI 23.8-32.6), confidence intervals are wide, 
particularly in comparison to children of the same age from Laos, Uganda and The Gambia, where TF 
prevalence was estimated to be 1.6% (95CI 1.0-2.6), 3.4% (95CI 2.8-4.2) and 1.6% (95CI 0.9-2.8), respectively 
(Figure 6.4), suggesting children in these population have only limited Ct infection. It would be useful to 
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examine age-dependent antibody level data from populations with higher estimations of seroprevalence to 
determine if our findings regarding wide confidence intervals hold true when seroprevalence rises greatly in 
a small age range, such as the population described by Goodhew and colleagues where 97% (95CI 93.9-98.7) 
of study participants were seropositive by the age of 6 years [15]. 
In populations with low levels of active trachoma in children, wide confidence intervals are seen in young 
adults around the age of sexual debut. The post-MDA populations in Nepal and Tanzania both had the 
widest confidence intervals in 21–30 year olds (Figures 6.1B and 6.2B).Confidence intervals were particularly 
wide for this age group in the Solomon Islands (Figure 6.5B), a country known to have a high prevalence of 
urogenital Ct infection [56,57]; The Gambia, in contrast, is thought to have a low prevalence of urogenital Ct 
infection [58,59].  
This analysis has some limitations. The use of serology to monitor transmission of ocular Ct infection is not 
yet standardised. There are two assays commonly used for trachoma serological studies: a Pgp3-specific 
ELISA [17] and an MBA [24], which also detects antibodies against Pgp3. Data from the two assays are not 
directly comparable due to the distinct nature of each assay’s output. Additionally, we were not able to 
compare all age ranges as some studies included only include children between 1–9 years of age as this is 
the age range of interest in measuring the prevalence of TF. This may be relatively unimportant as our 
analysis shows a distinct difference between communities with on-going ocular Ct infection and those with 
low levels, and this difference is obvious even in the limited age range of 1–9 years. 
Using mean antibody levels removes the challenges of setting an appropriate threshold between 
seropositive and seronegative samples. By comparing antibody data from several studies, we have shown: a) 
a clearly significant separation between pre- and post-MDA populations; b) which ages of a population are 
under transmission pressure and acquiring Ct infections, either ocular or genital; c) the characteristic 
baseline and slope of a population in which elimination has been achieved; d) that it may be possible to 
segregate effects of ocular and genital Ct, at least in populations with low prevalence of ocular Ct infection 
and high levels of genital Ct infection. 
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Chapter 7- Discussion
208 
 
Summary 
In this final chapter, each research objective is summarised. Limitations to the work and to serology 
in general are discussed. Finally, practical considerations are presented, placing the work in this 
thesis in the greater context of NTD control and elimination, as well as future research possibilities 
which would apply to both genital and ocular infection with Ct
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7.1 Summary of Research Findings 
This section provides a brief overview of the findings of this thesis work in relation to the objectives 
set out in in Chapter 1. For each objective, the research paper in which a detailed description of the 
findings is reported, is highlighted. 
 
7.1.1 Objective 1 
Collect demographic and clinical information and fingerprick blood samples to determine the 
prevalence of trachoma and antibodies against Pgp3 in Lower and Upper River Regions of The 
Gambia (Chapters 4 and 5) 
 
A population-based prevalence survey was undertaken in Lower River Region (LRR) and Upper River 
Region (URR) The Gambia, using a two-stage sampling strategy with villages selected by probability 
proportional to size and households randomly selected a household list. LRR had previously 
undergone three rounds (2007-2009) of MDA of azithromycin for trachoma, while URR has never 
had specific trachoma elimination activities because trachoma has not been of a sufficiently high 
prevalence to justify intervention activities. 
A total of 1,868 people of all ages participated in the study. The overall prevalence of TF was 1.6% 
(95CI 1.1-2.3%). Amongst 1-9 year olds, the prevalence of TF was 3.7% (95CI 2.2-6.1%) in LRR and 
3.1% (95CI 1.7-5.4%) in URR [1], a non-significant difference (Χ2 = 0.1343, p = 0.714) and in both 
regions the prevalence of TF in 1-9 year-olds was below the 5% threshold for elimination as a public 
health problem, as specified by the WHO [2]. Additionally, examiners found 78 cases of TS (71 cases 
in those >15 years), eight cases of TT and one case of CO (all in >15 years). There was a significant 
difference in TS prevalence between the URR (2.7%; 95CI 1.8-4.2%)) and LRR (5.4%; 95CI 4.1-6.9%)) 
(Χ2 = 7.2435, p = 0.007116). 
The prevalence of TF in children aged 1-9 years is below the 5% threshold for elimination as a public 
health problem [3]. 
 
Seroprevalence estimates suggest there is very little Ct circulating in the regions studied, as 
evidenced by the low seroprevalence in the youngest participants (Chapter 5) and corresponds to 
virtually non-existent levels of ocular Ct infection, demonstrated following the PRET study [4].  
 
7.1.2 Objective 2 
Develop a Pgp3-specific ELISA to measure antibodies against Ct using fingerprick dried blood spots 
(Chapters 3 and 4) 
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Previous work using serological assays to measure antibodies against Ct in trachoma-endemic 
populations was performed using a multiplex bead assay (MBA) and measured antibodies against 
Pgp3 and CT694 [5–7]. This assay was financially unviable for this thesis research thus with 
collaborators from the CDC, I optimised the protocol for a Pgp3-specific ELISA [1]. Serum standards 
were provided by the CDC and are described in detail in Chapter 3 and 4. Standards were tested in 
triplicate and standard deviations (SD) and coefficients of variations (CoV) were calculated based on 
the blanked OD450 value. 
For ongoing quality control, the mean OD450 values, SD and CoV for the five serum standards were 
tracked across sample sets. Inter-plate variation was less than 15% across all plates in each set. This 
ELISA has been used by other researchers in surveys of the South Pacific, Malawi and Ghana [8–10] 
with similar results.  
 
7.1.3 Objective 3 
Determine appropriate thresholds to distinguish between seropositive and seronegative 
individuals in populations from The Gambia, Laos and Uganda (Chapter 4) 
Both ELISA and MBA produce continuous numerical data as outputs which are typically converted 
into a simple binary positive/negative response. The thresholds used to determine positive/negative 
are based on reference standards. Mis-classification in the reference standards may introduce errors 
in the threshold between seropositive and seronegative samples. To overcome the need for 
reference standards, we explored alternative methods to establish thresholds, based only on the 
data generated during the study. These internally calibrated methods specified thresholds at 
approximately the same OD450 value for each of the samples sets from the three countries in the 
study (Laos, Uganda and The Gambia). The finite mixture model (FMM) and expectation-
maximisation algorithm (EM) are replicable and can allow for increasing sensitivity or specificity by 
changing the number of SD used by the algorithm to determine the threshold. 
From a programmatic point of view, the absolute value and accuracy of the estimated 
seroprevalence is less relevant than the changes in population seroprevalence over time, particularly 
between pre- and post-MDA sampling of populations. Trachoma elimination programmes should 
consider collecting DBS as MDA is initiated. The fieldwork in this thesis has shown that DBS can be 
easily incorporated into trachoma surveys, following ocular examination.  
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7.1.4 Objective 4 
Use seroprevalence data to estimate changes in transmission in The Gambia and estimate 
seroconversion and seroreversion rates (Chapter 5) 
A large amount of effort and international funding has gone into the trachoma elimination efforts 
and it is important to monitor and evaluate the effectiveness of these efforts. Detecting a 
significantly reduced transmission of infection is a key indicator that elimination is likely to have 
been achieved. 
Using the  seroprevalence estimates from LRR and URR [1], estimates of seroconversion (SCR) and 
seroreversion (SRR) were used to explore the dynamics of Ct transmission in these two regions. The 
seroconversion and seroreversion rates were estimated under different epidemiological conditions 
using a reversible catalytic model [11]. Using catalytic models for trachoma research is not a new 
concept, as it has previously been used to model disease prevalence [12,13], and combining 
modelling with serological data can help determine the force of infection (FoI) by using SCR as a 
proxy [14]. 
Our model compared three possible situations: i) a constant SCR, ii) an abrupt change in SCR at some 
point prior to sample collection, or iii) a constant SCR followed by a log-linear decay in SCR. The 
model allowing for an abrupt change in SCR showed the best fit, suggesting a change in SCR in LRR 
approximately 23 years before sample collection and in URR approximately 16 years before sample 
collection. This interpretation may be confounded by considering an alternative scenario, wherein 
participants are exposed to a genital chlamydial infection at some more contemporaneous time.  
Detecting a change in SCR additionally depends on both the sample size as well as the scale of 
change in SCR, with smaller changes in SCR requiring larger sample sizes.  
 
7.1.5 Objective 5 
Use antibody level data as an alternative to seroprevalence data to measure changes in Ct 
transmission (Chapter 6) 
 
Antibody-level data was used to generate age-dependent antibody curves for comparison using a 
recently developed statistical package, ‘tmleAb’ [15]. I compared: countries pre- and post-
intervention, regions with different scales of intervention activities, and countries with varying 
prevalence of ocular and genital Ct infections. My analysis showed that there is a characteristic 
shape to the curve in communities where trachoma is no longer a public health problem, with a 
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nearly horizontal curve in the youngest age groups, which increases slowly with age. In populations 
with low prevalence of ocular Ct infection but where genital Ct infection is prevalent, the slope 
increases rapidly around the age of sexual debut, then stays elevated. When comparing pre- and 
post-MDA populations, there is a statistically significant difference in the age-dependent mean 
antibody levels, shown by comparing pre-MDA data from Nepal to post-MDA data from the same 
population [16]. The post-MDA data was statistically similar to data from a post-MDA community in 
Tanzania [17,18]. Similarly, children (1-9 year olds) in Kiribati [19] had statistically higher mean 
antibody levels than their peers of the same age in Laos, Uganda and The Gambia, all regions that 
are post-MDA [1] or have been declared to have eliminated trachoma as a public health problem 
[20].  
Confidence intervals around the age group-dependent means are widest in the age groups that are 
experiencing the force of Ct infection, whether ocular or genital. The 95% CI are wider in young 
children in trachoma-endemic regions- pre-MDA Nepal and Kiribati- while in regions in which 
trachoma is no longer considered a public health problem, wider confidence intervals are often 
present at the age when sexual debut occurs. This is most obvious in the Solomon Islands, where 
there is a high prevalence of genital Ct infection [21,22], but can also be seen in post-MDA 
populations in Nepal and the Solomon Islands. 
Based on the above, age-dependent antibody levels are a practical means of monitoring Ct infections 
in a population, eliminating the need to set a threshold between seropositive and seronegative 
samples.  
7.2 Limitations 
There are limitations to the analyses presented in this thesis. Some are due to practical restrictions, 
while others require a reconsideration of trachoma elimination programmes 
7.2.1 Study design 
 
Most studies are cross-sectional, covering a single point in time; few studies collect serological 
samples at two or more time points [6,16,23]. An ideal study would collect samples from 
communities prior to the implementation of any interventions, then again during and following 
completion of the SAFE strategy. However, this thesis included one study with pre- and post-MDA 
samples [16], which showed a significant reduction in age-dependent antibody levels from pre- to 
post-MDA population and produced a similar age-dependent antibody profile to a population in 
Rombo, Tanzania where trachoma and ocular Ct infection were eliminated following MDA [17,18]. 
This thesis also compared three populations with low prevalence of both trachoma and ocular Ct 
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infection [1], two of which had previously undergone MDA with azithromycin, to a population with 
high prevalence of trachoma that had yet to undergo MDA [19]. The antibody levels in the pre-MDA 
population were significantly higher than those of the three low prevalence populations, which all 
had similar levels of antibodies.  
 
7.2.2 Population to be sampled 
 
There is no consensus on which age range should be surveyed for serological studies. Thresholds for 
the initiation or cessation of programmatic MDA are based on the prevalence of TF in children aged 
1-9 years and many studies have focused on these children for serology as well [6,23,25–28]. In 
principle, the serological history of individuals born before the reduction in FoI (older) consists of a 
time period at a high SCR which is then followed by a second period at lower SCR. Those born after 
the change in SCR (younger) will have experienced a constant SCR [29]. DBS were collected from 
participants of all ages in The Gambia; datasets from Nepal and Tanzania also comprised samples 
from participants of all ages. All modelling performed as part of this thesis was applied to data from 
either a wide age range (1-90 years) or a more limited age range focusing only on children. 
Increasing the age range of participants involved in a study to include adults may result in 
confounding if levels of genital Ct are high, however data from Chapter 6 suggests it may be 
possible, at population-level, to use confidence intervals to estimate when Ct infections are being 
acquired. Using age-based confidence intervals may allow for researchers to ascertain whether Ct-
specific antibodies are being produced as a result of ocular or genital Ct infections. 
 
7.2.3 Seroconversion 
 
Secondly, most of the analyses assume persistent antibody levels and that both seroprevalence and 
antibody levels in participants have not declined significantly since they were initially infected with 
Ct. In Chapter 5, the SRR was estimated to be 0.008 and 0.010 in two Gambian populations. These 
calculations could be made more robust by examining a population at multiple time points following 
elimination, as has recently been demonstrated [24].   
A study conducted in Tanzania showed no seroreversion in 1-6 year-old children six months 
following MDA [16], however  a study in which children aged 1-9 years were followed up one year 
after baseline showed that seroreversion did occur, primarily in participants with antibody levels 
close to the threshold between seropositive and seronegative [23]. Following up a large population 
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of all ages may show that once antibodies are established above a certain level, for example 
following multiple ocular Ct infections in hyper-endemic populations, or multiple genital Ct 
infections, antibody levels remain fixed. This would support data in Chapter 6, where high antibody 
levels can be seen in the oldest population groups in Nepal, Tanzania, The Gambia and the Solomon 
Islands. The ability to detect a change using catalytic modelling assumes that an abrupt reduction in 
the Ct transmission intensity will translate into a similar change in SCR.  
 
7.2.4 Assay Limitations 
 
The Pgp3 antigen used in this ELISA was derived from serovar D, a urogenital strain of Ct. Another 
Pgp3-specific ELISA existed when this research was carried out [30] which was based on serovar L1, 
associated with LGV. Other Pgp3-specific ELISAs have been since been developed, one based on 
serovar E [31], as well a double antigen sandwich ELISA based on serovar L1 [32,33]; these other 
ELISAs have been used to study the prevalence of antibodies due to genital Ct infection. Only the 
double antigen ELISA has been compared to the original, indirect Pgp3 ELISA [32], however the other 
ELISAs, including the one used in this study, have not undergone head-to-head comparison.  
Finally, there remains no gold standard references for antibodies resulting from Ct infection. 
Previous studies have used serum samples from children in non-endemic populations as negative 
controls, however these have shown to include samples that are considered seropositive based on 
their antibody levels. Similarly, positive samples have included infection-positive samples that would 
be classified as seronegative based on the antibody levels measured.  
 
7.3 Practical Considerations 
The research presented in this thesis can be considered translational in its nature, extending beyond 
the standard ‘bench-to-bedside’ [34] to ‘bush-to-beside’. As such, application to practical public 
health outcomes is dependent on a variety of factors. 
7.3.1 Sampling frame 
 
Estimates of seroprevalence depend on the population sampled. As shown in Chapters 5 and 6, it is 
important to consider the age of people sampled and whether they are likely to have been exposed 
genital Ct infections through sexual activity, in addition to ocular Ct infection. 
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The size of the population to be sampled must be considered: the WHO recommends that trachoma 
(disease) prevalence estimates should be collected at the district level, with population sizes 
between 100,000 and 250,000, as this is the normal administrative unit for SAFE implementation [2]. 
It is likely district-level estimates of age-specific seroprevalence would also be sufficient, provided 
probability-proportional-to-size sampling rather than convenience sampling is followed. This also 
assumes in post-MDA districts, a low seroprevalence in young people is associated with a decline in 
the transmission of ocular Ct infection. The sample size required will depend on the population 
structure and a priori knowledge or estimation of disease and infection prevalence in the population 
to be sampled. Depending on the shape of the population pyramid within a country, it may be 
necessary to over-sample the youngest proportion of the population to achieve the power necessary 
to confidently measure changes in seroprevalence [35]. A second consideration is the time between 
the change in SCR and sample collection [29], such that there is a sufficiently large proportion of the 
population born after the change in SCR to compare to the older proportion. In areas with a high 
prevalence of genital Ct infection, oversampling around the age of sexual debut may elucidate 
additional patterns of infection [36]. Sampling frames should be guided by local knowledge of the 
epidemiology and prevalence of genital Ct infection. 
7.3.2 Assays and data 
 
Few studies to date have assayed samples in-country; the samples analysed as part of this thesis 
were assayed at either LSHTM or the CDC. With the exception of the lateral flow assay [28,37,38], 
assays to measure antibodies against Pgp3 are based on ELISA or MBA technology and require 
expensive reagents, many of which must be kept cold or frozen prior to use, and a continuous source 
of electricity. This may not be practical in trachoma-endemic countries and may require 
collaboration with a research or academic institute elsewhere.  
Interpretation of ELISA or MBA data is straightforward when presented as seroprevalence data, can 
be easily understood and has been well-published using datasets from around the world. The 
interpretation of antibody level data is more complex and still a relatively new concept, not only for 
trachoma but for neglected tropical diseases in general [15]. This thesis contributes to the reservoir 
of knowledge about Ct serology and analysis and interpretation of antibody levels. 
 
7.3.3 Following successful MDA 
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As more countries work towards the elimination of trachoma as a public health programme, MDA 
strategies may result in over-administration of antibiotics. This could potentially lead to 
antimicrobial resistance in Ct and commensal or opportunistic bacteria. A recent study has shown no 
antimicrobial resistance in Mycoplasma genitalium following one round of MDA [39], though there is 
concern that Salmonella typhi could easily develop resistance to azithromycin [40]. One possible 
solution to prevent over-administration is household targeted treatment, wherein households with 
one of more members presenting with active trachoma are treated, as is the current policy in The 
Gambia [36]. Because trachoma clusters by household [41–43], targeted treatment with a high level 
of coverage has been modelled to be cost-effective and to reduce the prevalence of ocular Ct 
infection [44].  
MDA of azithromycin has been shown to reduce the prevalence of genital Ct infection [22] as well as 
reducing childhood mortality [45], and there may be other trade-offs to discontinuing MDA of 
azithromycin for trachoma elimination. This will need to be considered by policymakers in affected 
countries and NGOs involved with trachoma elimination programmers. 
7.3.4 Symbiosis with other NTD programmes 
 
The Expanded Special Project for the Elimination of Neglected Tropical Diseases (ESPEN) was 
established to accelerate elimination of NTDs for which preventive chemotherapy and transmission 
control (PCT) exist and to implement large-scale MDA. Along with trachoma, lymphatic filariasis, 
onchocerciasis, loiasis, schistosomiasis and soil-transmitted helminths are often co-endemic and 
therefore may benefit from collaborative efforts to accelerate treatment and prevention of these 
diseases [46]. As treatment for NTDs is expanded across all endemic regions, the incidence and 
prevalence of these disease will decrease, meaning case detection will become increasingly difficult 
and expensive [47–50]. Combining efforts for surveying, treatment and monitoring of intervention 
efforts across multiple endemic diseases may be one way in which to maximise resources. For 
example, the use of MBA to measure antibodies against a variety of NTDs would also allow for field 
surveys to collect information about a multiple diseases from a single DBS [51]. NTD programmes 
should consider combining efforts to maximise results, while reducing the demands of those 
affected by these diseases, donors and healthcare workers.  
 
7.3.5 Future Research 
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Leading from this thesis, there are many areas for future research. A head-to-head comparison of 
ELISA and MBA results has not yet been published and doing so would allow for a direct comparison 
of the two techniques using the same research samples and standards. This would help inform assay 
choices in-country and the purpose for which each assay could be used. The development of serum 
reference standards would greatly facilitate this. 
There is a need to further explore what level of antibodies may be associated with scarring sequelae, 
such that antibody level could be used to determine the risk of a person developing long-term 
sequelae. This would be relevant for both ocular and genital Ct infections, and in terms of intensified 
disease management, would help trachoma programmes follow up individuals at risk of progressing 
to trichiasis. For genital Ct infections, antibody levels could help determine the risk of infertility and 
the need for further medical intervention (I. Toskin, WHO, personal communication.) 
Importantly, the research in this thesis was only able to compare one region for pre- and post-MDA 
antibody levels. With the increase in MDA for trachoma elimination that has occurred in the past 
decade [52] before the recent renaissance in Ct serology, it will not be possible to collect blood 
samples from pre-MDA populations. Serology should be incorporated in future MDA efforts to allow 
for monitoring changes in seroprevalence and antibody levels in communities. Combining efforts 
with other NTD programmes working in co-endemic regions could allow for on-going monitoring 
even once MDA for trachoma has been successful, and could be used to estimate more accurate 
seroreversion rates [24] once the FoI for trachoma reaches a non-significant level. 
Finally, on-going studies have hypothesized that follicles on the upper tarsal may not solely be due 
to Ct, as seen in populations in the Solomon Islands [8]. Follicles may be due to a variety of non-
chlamydial bacteria [53–55]; further consideration of the ocular microbiome and the role of 
commensal bacteria in good eye health should be explored. 
 
7.4 Conclusions 
The clinical results from my field work supports The Gambia’s milestone of eliminating trachoma as a 
public health problem. Additionally, the analyses presented here support elimination in Laos and in 
the two regions studied in Uganda. 
The data presented within this thesis substantiates the use of serology as an additional measure to 
monitor the prevalence of Ct infections and to support the decision-making process in trachoma 
elimination efforts. This is particularly demonstrated by the antibody prevalence data, which showed 
a consistent horizontal curve in children from post-MDA communities and regions where trachoma 
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has been eliminated as a public health problem.  Ultimately, it may not be an exact seroprevalence 
or antibody level that is used as a metric for elimination, but the changes in seroprevalence or 
antibody levels over time.  
In contrast to clinical indicators like follicles of the conjunctiva, which can be caused by other 
infectious agents, are not always correlated to Ct ocular infection and are subject to inter-grader 
variation, antibodies persist, can be (semi) quantitatively measured and those against Pgp3 are 
considered highly specific for infection with Ct.  
A considered analysis of serological data may offer a complementary method to assess efforts to 
eliminate trachoma as a public health problem. Combined serological assays could gather 
information about multiple NTDs and infections, thereby maximising impact in resource-limited 
settings. 
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Eye Exam and Dried Blood Spot (DBS) sample collection 
Standard Operating Procedure (SOP) 
 
V 19.11.2014 
By Stephanie Migchelsen 
 
Overview 
This pilot project aims to measure the levels of anti-C. trachomatis antibodies in two populations: one 
where is it hoped that trachoma has been controlled through the recent mass administration of 
azithromycin and one where trachoma and the sequelae have been under control for many years. 
Photographs will be taken of everted eyelids and blood samples, preserved on filter paper, will be 
collected from participants. 
 
This project is designed to collect the following information from participants: 
• Demographic information of participant 
• Clinical phenotype according to the Simplified WHO trachoma grading system (Presence or 
absence of each of TF, TI, TS, TT, CO) 
• Four dried blood spots from participants (at least 100 from each EA) 
• Photographs of the conjunctiva (using predefined SLR photography protocol) 
 
Written consent is required to take part in the follow-up project.  
Blood spots must be dried before being stored in envelopes. 
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Staff and materials (per cluster) 
 
Staff Materials  
2x MRC trachoma staff (grading 
and photography) 
Information sheets  
2 x Community Ophthalmic Nurses 
(CON) (blood and consent) 
Inkpad for thumbprints 
1 x field recorder  Pen(s) for signatures 
1x driver  Consent forms 
 Ocular Examination forms  
 Census print-outs 
 Binder to store forms 
 Filter papers  
 Lancets 
 Alcohol swabs (EtOH+cotton) 
 Storage bags 
 Desiccant 
 Sample storage box 
 Drying sticks 
 Printed labels 
 Gloves 
 Waste bag 
 Nikon SLR camera 
 Truck 
 Fuel 
 Table 
 Chairs 
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Phase 1: Informed Consent 
 
Step  Task 
1 (Informed consent) 1.1 Read information sheet to household decision maker 
 1.2 Invite decision maker to participate in study. Written consent required. 
 1.3 If consent granted, a consent form must be signed for each member of the 
household who will take part in the survey. 
  NOTE: Children below the age of 18 must have consent granted on their 
behalf by a parent or guardian. Children between 12 and 17 must provide 
their own assent. 
  NOTE: Adults aged 18 or above must provide their own consent 
 1.4 If consent is granted, proceed to step 2 
2 2.1 Record ID number on Ocular Examination Form 
 2.2 Ask demographic questions: Sex, Date of Birth/Age, and General Observations 
   
 
Phase 2: Examination 
 
2 (Examination) 2.1 Examine household head and any other adults who have consented to 
examination first 
 2.2 Assistant calls ID to recorder for recording  
 2.3 Grader uses 2.5x binocular loupes to examine eye in normal position. 
 2.4  Grader examines for signs of TT and CO and calls verdict to recorder 
 2.5 Grader everts right eyelid  
 2.6 Grader examines for signs of TF and calls verdict to recorder 
 2.7 Grader examines for signs of TI and calls verdict to recorder 
 2.8 Grader examines for signs of TS and calls verdict to recorder 
 2.9 Photographer takes photo of label 
 2.10 Photographer takes photograph of everted right lid with SLR camera 
 2.11 Photographer calls photo frame number to recorder 
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  NOTE: If lid eversion is too painful due to signs of trichiasis, the lid will not be 
everted and a photograph will be taken of the lid in normal position 
 2.12 The right lid is returned to its normal position 
 2.13 Steps 2.3-2.12 are repeated with the left eyelid 
 2.14 Nurse collects one filter paper disk and one alcohol swab (cotton and 
ethanol)  
 2.15 Nurse wipes participant’s fingertip with alcohol swab, then pierces skin with 
the lancet 
 2.16 Wipe the first drop of blood from the finger using the alcohol wipe 
 2.17 Gently squeezing the fingertip, and holding the filter wheel by the label, use 
the filter wheel to collect at least four drops of blood, one on each of four 
outer circles. Both sides of the paper must be saturated with blood. 
 2.18 Pass the filter paper to the assistant, who then places the wheel on a drying 
stick in the sample collection box. 
  NOTE: Approximately 6 filter wheels can be placed on one drying stick. One 
finger-width must be kept between each wheel to ensure proper drying. 
 2.19 Grader/Nurse thanks the examinee for their participation 
 2.20 Grader changes gloves  
  NOTE: Nurse to change gloves when (s)he thinks the gloves may be 
contaminated 
   
 
Phase 3: Between clusters (end of the day) 
 
Step  Task 
3 (Storage) 3.1 Before the end of each day, the filter wheels must be removed 
from the storage box and placed individually in resealable plastic 
bags with a small amount of desiccant 
 3.2 Data from Ocular Forms must be entered into database; 
photographs must be uploaded to Eyescores 
4 (Charging) 4.1 Recorder must return to electricity source to enter data 
 4.2 Assistants must charge photographic equipment each night 
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Appendix 3- Participant Information Sheet (Child) 
 
 
 
 
  
Identification code: SOP-CTS-015, Attachment 2d (Child)  
Version : 2.0 – 15 April 2013 
 
 
 
PARTICIPANT INFORMATION SHEET (CHILD) 
Version 1.0 Date 21/10/2014 
 
Study Title: Age-specific seroprevalence of anti-Chlamydia trachomatis antibodies and the 
historical prevalence of trachoma 
SCC:  Protocol:  
 
Sponsor: Wellcome Trust 
What is informed consent?  
You are invited to let your child take part in a research study. Before you decide you need to 
understand why the research study is being done and what it will involve. Please take time 
to read the following information or get the information explained to you in your language. 
Listen carefully and feel free to ask if there is anything that is not clear or you do not 
understand. You may also wish to consult your spouse, family members, friends or others 
before deciding to let your child take part in the study. 
 
If you decide to allow your child to join the study, you will need to sign or put a thumbprint 
on a consent form saying you agree for your child to be in the study. If your child is between 
the ages of 12-17, we will ask for his/her assent as a signature or thumbprint. 
Why is this study being done?  
One reason many people go blind in The Gambia is because of trachoma. Trachoma is an 
eye disease that is easily passed from person to person. If you get the infection many times 
it can lead to scarring in your eyelid, which causes the eyelashes to rub on the eyeball. This 
is painful and can eventually lead to blindness. When a person is infected with trachoma, 
they will produce antibodies to help fight this infection. These antibodies can stay in a 
person’s blood for a very long time. 
The National Eye Health Programme has recorded that over time, the amount of trachoma in 
many communities has gone down. We think this is because there is better access to latrines 
and water, as well as community screening for eye health, and giving antibiotics for 
infection. 
A few years ago, some communities in The Gambia were given antibiotics against trachoma. 
We would like to compare communities that did receive antibiotics with communities that did 
not receive antibiotics because they did not need them.  
We would like to check your child’s eyes for signs of trachoma and test his/her blood to see 
if he/she has antibodies against trachoma. 
The results of the study will be made available to your community. 
What does this study involve? 
We will ask 100 people of all ages in your community to have their eyes examined. We will 
examine the eye by gently turning over the eyelid. We will also take a small sample of 
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Version  Date  
Page 2 of 4 
blood. This will be done using a new, clean lancet to prick the fingertip. We will collect a few 
drops of blood onto a piece of paper. 
 
If we discover your child’s eyes cannot be examined because of an eye disease, we will refer 
him/her to the nearest eye health unit for appropriate care.  
 
In case the investigator discovers your child is sick and decides that he/she cannot 
participate in the study because of that, he/she will receive immediate care at the study site 
and then be referred to the appropriate health facility.  
 
If the research study needs to be stopped, you will be informed and your child will have the 
normal medical care. 
What will happen to the samples taken in this study? 
The samples will be taken back to the MRC laboratory in Fajara for testing to see if there are 
antibodies against trachoma. We will also send some of the samples to a lab in England to 
verify the results. 
What harm or discomfort can you expect in the study? 
We will prick your child’s finger with a sharp pin to collect the blood. This can cause some 
discomfort to your child but the discomfort is not expected to last more than a day. 
 
What benefits can you expect in the study?  
While there are no direct benefits to you or your child, the information we get from this 
study will help us determine if the trachoma has been successfully eliminated from your 
community. This will help researchers make decisions that will help other communities 
around the world in their efforts to eliminate trachoma. 
Will you be compensated for your child’s/ward’s participation in the study? 
You will not get paid for participation of your child in the study. 
What happens if you refuse to participate in the study or change your mind later? 
You are free to let your child participate or not in the study and you have the right to stop 
his/her participating at anytime without giving a reason. This will not affect the medical care 
that your child would normally receive. 
In case you decide to withdraw your child’s participation during the study, we will not work 
on your child’s samples without your permission, but any information already generated 
from the samples will be kept. The study doctor may also ask for tests for your child’s 
safety.  
Should any new information become available during the study that may affect your child’s 
participation, you will be informed as soon as possible. 
What compensation will be available if your child is injured during the study?  
We will be responsible to provide for treatment caused by procedures of the research study.  
If medical treatment is required as an emergency, please refer to your health centre or clinic 
and contact the field worker who gave his/her telephone number to you or contact 
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Stephanie Migchelsen on [Phone number] or Mr Sarjo Kanyi on 9901716, 3011349, 6651344 
or 7510996.  
How will your child’s information be kept and who will be allowed to see it?  
All information that is collected about your child in the course of the study will be kept 
strictly confidential. Your child’s personal information will only be available to the study team 
members and might be seen by some rightful persons from the Ethics Committee, 
Government authorities and sponsor. 
Who should you contact if you have questions? 
If you have any queries or concerns you can contact Stephanie Migchelsen on [Phone 
number] or Mr Sarjo Kanyi on 9901716, 3011349, 6651344 or 7510996 and you can always 
call the personal numbers of the study staff given to you.  
Please feel free to ask any question you might have about the research study. 
Who has reviewed this study?  
This study has been reviewed and approved by a panel of scientists at the Medical Research 
Council and the Gambia Government/MRC Joint Ethics Committee, which consists of 
scientists and lay persons to protect your rights and wellbeing. 
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CONSENT / ASSENT FORM 
Participant’s Name    
Participant’s Identification Number: |__|__|__|__|__|__|__|__|__|__| 
   OR   
 (Printed name of parent) (Printed name of guardian) 
 I have read the written information OR 
 I have had the information explained to me by study personnel in a language that I 
understand,  
and I 
 confirm that my choice to let my child participate is entirely voluntarily, 
 confirm that I have had the opportunity to ask questions about this study and I am 
satisfied with the answers and explanations that have been provided, 
 understand that I grant access to data about my child to authorised persons described 
in the information sheet, 
 have received time to consider to let my child take part in this study, 
 agree to allow my child take part in this study.  
Tick as appropriate 
I agree to further research on my child’s samples as described in 
the information sheet 
Yes  No  
Participant’s signature/ 
thumbprint* for assent 
(child aged 12-17 years) 
    
   Date (dd/mmm/yyyy) Time (24hr) 
Participant’s 
parent/guardian 
signature/thumbprint* 
     
   Date (dd/mmm/yyyy) Time (24hr) 
Printed name of witness*  
 
Printed Name of Person 
obtaining consent 
 
 
I attest that I have explained the study information accurately in _______________________ 
to, and was understood to the best of my knowledge by, the participant/parent/guardian. 
He/she has freely given consent to participate *in the presence of the above named witness 
(where applicable). 
Signature of Person 
obtaining consent    
   Date (dd/mmm/yyyy) Time (24hr) 
* Only required if the participant is unable to read or write. 
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Identification code: SOP-CTS-015, Attachment 2b (Adult)  
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PARTICIPANT INFORMATION SHEET (ADULT) 
Version 1.0 Date 21/10/2014 
 
Study Title: Age-specific seroprevalence of anti-Chlamydia trachomatis antibodies and the 
historical prevalence of trachoma 
SCC:  Protocol:  
 
Sponsor: Wellcome Trust 
What is informed consent?  
You are invited to take part in a research study. Participating in a research study is not the 
same as getting regular medical care. The purpose of regular medical care is to improve 
one’s health. The purpose of a research study is to gather information. It is your choice to 
take part and you can stop any time. 
Before you decide you need to understand all information about this study and what it will 
involve. Please take time to read the following information or get the information explained 
to you in your language. Listen carefully and feel free to ask if there is anything that you do 
not understand. Ask for it to be explained until you are satisfied. You may also wish to 
consult your spouse, family members or others before deciding to take part in the study. 
 
If you decide to join the study, you will need to sign or thumbprint a consent form saying 
you agree to be in the study.  
Why is this study being done?  
One reason many people go blind in The Gambia is because of trachoma. Trachoma is an 
eye disease that is easily passed from person to person. If you get the infection many times 
it can lead to scarring in your eyelid, which causes the eyelashes to rub on the eyeball. This 
is painful and can eventually lead to blindness. When a person is infected with trachoma, 
they will produce antibodies to help fight this infection. These antibodies can stay in a 
person’s blood for a very long time. 
The National Eye Health Programme has recorded that over time, the amount of trachoma in 
many communities has gone down. We think this is because there is better access to latrines 
and water, as well as community screening for eye health, and giving antibiotics for 
infection. 
A few years ago, some communities in The Gambia were given antibiotics against trachoma. 
We would like to compare communities that did receive antibiotics with communities that did 
not receive antibiotics because they didn’t need them.  
We would like to check your eyes for signs of trachoma and test your blood to see if you 
have antibodies against trachoma. 
The results of the study will be made available to your community. 
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What does this study involve? 
We will ask 100 people of all ages in your community to have their eyes examined. We will 
examine the eye by gently turning over the eyelid. We will also take a small sample of 
blood. This will be done using a new, clean lancet to prick the fingertip. We will collect a few 
drops of blood onto a piece of paper. 
 
If we discover your eyes cannot be examined because of an eye disease, we will refer you to 
the nearest eye health unit for appropriate care.  
 
In case the investigator discovers you are sick and decides that you cannot participate in the 
study because of that, you will receive immediate care at the study site and then be referred 
to the appropriate health facility.  
If the research study needs to be stopped, you will be informed and you will have your 
normal medical care. 
What will happen to the samples taken in this study? 
The samples will be taken back to the MRC laboratory in Fajara for testing to see if there are 
antibodies against trachoma. We will also send some of the samples to a lab in England to 
verify the results. 
What harm or discomfort can you expect in the study? 
We will prick your finger with a sharp pin to collect the blood. This can cause some 
discomfort but the discomfort is not expected to last more than a day. 
What benefits can you expect in the study?  
While there are no direct benefits to you, the information we get from this study will help us 
determine if the trachoma has been successfully eliminated from your community. This will 
help researchers make decisions that will help other communities around the world in their 
efforts to eliminate trachoma. 
Will you be compensated for participating in the study? 
You will not get paid for participation.  
What happens if you refuse to participate in the study or change your mind later? 
You are free to participate or not in the study and you have the right to stop participating at 
anytime without giving a reason. This will not affect the medical care that you would 
normally receive.  
In case you decide to withdraw your participation during the study, we will not work on your 
samples without your permission, but any information already generated from the samples 
will be kept. The study doctor may also ask for tests for your safety.  
Should any new information become available during the study that may affect your 
participation, you will be informed as soon as possible. 
If you are injured in the study what compensation will be available?  
We will be responsible to provide for treatment caused by procedures of the research study.  
If medical treatment is required as an emergency, please refer to your health centre or clinic 
and contact the field worker who gave his/her telephone number to you or contact 
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Stephanie Migchelsen on [Phone number] or Mr Sarjo Kanyi on 9901716, 3011349, 6651344 
or 7510996. 
How will personal records remain confidential and who will have access to it? 
All information that is collected about you in the course of the study will be kept strictly 
confidential. Your personal information will only be available to the study team members and 
might be seen by some rightful persons from the Ethics Committee, Government authorities 
and sponsor. 
Who should you contact if you have questions? 
If you have any queries or concerns you can contact Stephanie Migchelsen on [Phone 
number] or Mr Sarjo Kanyi on 9901716, 3011349, 6651344 or 7510996 and you can always 
call the personal numbers of the study staff given to you.  
Please feel free to ask any question you might have about the research study. 
Who has reviewed this study?  
This study has been reviewed and approved by a panel of scientists at the Medical Research 
Council and the Gambia Government/MRC Joint Ethics Committee, which consists of 
scientists and lay persons to protect your rights and wellbeing. 
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CONSENT FORM 
Participant Identification Number: |__|__|__|__|__|__|__|__|__|__|__|__| 
  
 (Printed name of participant) 
 I have read the written information OR 
 I have had the information explained to me by study personnel in a language that I 
understand, 
and I 
 confirm that my choice to participate is entirely voluntarily, 
 confirm that I have had the opportunity to ask questions about this study and I am 
satisfied with the answers and explanations that have been provided, 
 understand that I grant access to data about me to authorised persons described in the 
information sheet, 
 have received time to consider to take part in this study,  
 agree to take part in this study.  
 
Tick as appropriate 
I agree to further research on my samples as described in the 
information sheet 
Yes  No  
 
Participant’s signature/ 
thumbprint* 
    
   Date (dd/mmm/yyyy) Time (24hr) 
    
Printed name of witness*  
 
Printed name of person 
obtaining consent 
 
I attest that I have explained the study information accurately in ______________________ 
to, and was understood to the best of my knowledge by, the participant. He/she has freely 
given consent to participate *in the presence of the above named witness (where applicable).  
Signature of person 
obtaining consent    
   Date (dd/mmm/yyyy) Time (24hr) 
* Only required if the participant is unable to read or write. 
 
